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The FAM83 family of proteins are classified based on the presence of a  
conserved domain of unknown function 1669 (DUF1669) within their N-termini. 
Although structural and bioinformatic studies suggest that the DUF1669 domain adopts 
a phospholipase D-like motif, no phospholipase D activity has yet been demonstrated 
for FAM83 members experimentally. Thus, the role and function of FAM83 proteins 
remains elusive. This study provides evidence that FAM83 proteins bind to different 
isoforms of the casein kinase 1 (CK1) family of Ser/Thr protein kinases and direct them 
to the distinct cellular sites in which the FAM83 proteins reside. FAM83 members 
mediate CK1 binding through their conserved DUF1669. In this capacity, FAM83 proteins 
may act as the A Kinase Anchoring proteins (AKAPs) of the CK1 world, and act 
analogously to the way AKAPs serve to regulate protein kinase A. 
Regarded as constitutively-active, promiscuous protein kinases, the regulation 
of CK1 isoforms is critically important, yet poorly understood. This is particularly crucial 
when considering the reported participation of CK1 kinases in many, diverse signalling 
processes, from Wnt signalling to the regulation of Circadian rhythm. Mechanisms 
regulating CK1 isoforms, through controlling their cellular localisation and therefore 
substrate accessibility, are thus attractive regulatory targets to facilitate the study into 
specific CK1 functions, which rely on the recruitment of CK1 isoforms to the relevant 
cellular sites. As FAM83 proteins have the potential to act in such a manner, 
investigation was focussed on specific FAM83-CK1 interactions in order to further define 
this emerging regulatory role of FAM83 members. 
FAM83D is unique amongst the FAM83 proteins, in that it is the only FAM83 
member known to localise to the mitotic spindle. RNA interference approaches 
targeting FAM83D have been reported to impact chromosome alignment and cause a 
 xv 
delay in the timings of cell division. Whilst all FAM83 proteins appear to associate 
robustly with the CK1 alpha isoforms (CK1α), interestingly, the interaction between 
FAM83D and CK1α in asynchronous cell extracts was weak. Armed with the knowledge 
that FAM83D localises to the spindle apparatus in mitosis, a hypothesis that the 
FAM83D-CK1α interaction might only occur during cell division was developed. This 
study provides evidence that FAM83D binds and recruits CK1α to the mitotic spindle, 
and that the FAM83D-CK1α interaction is critical for correct and efficient spindle 
positioning. Cells devoid of FAM83D, or those harbouring a FAM83D CK1-binding-
deficient knockin point mutation, fail to localise CK1α to mitotic spindles, and present 
with spindle orientation defects, and a concurrent delay in the metaphase-to-anaphase 
transition. As the spindle position determines the axis of cell division, correctly-
orientated spindle positioning is critically important in both development and in the 
maintenance of healthy adult tissues.  
When one thinks of mitotic kinases regulating spindle positioning, prominent 
players such as cyclin-dependent kinases, aurora kinases, and polo-like kinases tend to 
dominate the cell division limelight. However, these kinase families alone cannot 
account for the extent of protein phosphorylation reported over a cell division cycle, 
implying roles for other protein kinases in this process. Thus, implicating CK1α as a 
mitotic kinase provides further mechanistic insights into the regulation of mitosis, and 
the phosphorylation-mediated control of cell division. 
As FAM83 proteins are an emerging family of proteins, tools to study them are 
scarce, yet warranted. In this vein, part of this study was devoted to developing unique 
approaches and technologies to aid in the investigation of FAM83 biology, and beyond. 
In this context, two nanobody-based strategies to either promote the phosphorylation 
of the target protein, or mark it for proteasomal degradation are described. These novel 
 xvi 
tools have been employed here to explore the role of the FAM83D-CK1α interaction in 
cells, and I provide evidence that they are applicable for research into diverse biological 

























β-TRCP   Beta-transducin repeat containing protein 
ACN   Acetonitrile 
AdPROM  Affinity-directed PROtein Missile 
aGFP   anti-green fluorescent protein nanobody 
aGFP.16  anti-green fluorescent protein nanobody 16 
AID   IAA17 degron sequence 
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1. Introduction: 
1.1: Casein kinase 1: 
 CK1 kinases are a major focus of this thesis. Thus, an appreciation for the roles 
and regulation of CK1 kinases is required to aid the understanding of this thesis. The 
current knowledge on CK1 will be discussed in the following sections. 
 
1.1.1: Overview of CK1 isoforms: 
Protein kinases, which are enzymes that catalyse the phosphorylation of 
primarily Ser, Thr, and Tyr residues on protein substrates (Cohen, 2002a, Pawson & 
Scott, 2005), not only play central roles in controlling many diverse signal transduction 
pathways, but also represent important therapeutic targets (Cohen, 1999, Cohen, 
2002b, Cohen, 2009). By phosphorylating their protein substrates, kinases are able to 
impart critical regulation on virtually every conceivable aspect of that substrate’s 
function, such as its activity, stability, altering its binding to other effectors, or 
promoting a change in subcellular distribution (Pawson & Scott, 2005). Thus, protein 
kinases play essential roles within biological systems. 
The human genome encodes over 500 protein kinases, which are classified into 
several families based on the sequence similarities of their kinase domains (Manning, 
Whyte et al., 2002). A dendrogram encapsulating all human protein kinases is commonly 
referred to as the kinome tree, where each specific branch represents a family of similar 
kinases (Manning et al., 2002). The serine/threonine (Ser/Thr) protein kinase CK1 family 
forms its own distinct branch of the kinome tree (Manning et al., 2002) (Figure 1-1), and 
constitute one of the first Ser/Thr protein kinase families to be discovered (Kumar & 












Figure 1-1: Phylogenetic schematic of the CK1 family of protein kinases: Phylogenetic 
tree depicting the human CK1 family members, adapted from Manning et al, 2002. 
 
 
related kinases (VRKs), and tau tubulin kinase 1 (TTBK1) members (Ikezu & Ikezu, 2014, 
Manning et al., 2002) (Figure 1-1). Originally named casein kinases for their ability to 
phosphorylate casein in vitro, it should be noted that CK1 kinases are not the 
physiological casein kinases (Ishikawa, Xu et al., 2012, Venerando, Ruzzene et al., 2014). 
The bona fide casein kinase was recently identified as FAM20C, a Golgi-localised protein 
kinase that is capable of phosphorylating many secreted proteins, including casein 
(Ishikawa et al., 2012). 
To date, six mammalian CK1 isoforms and their associated splice variants have 
been reported. These include the α, γ1, γ2, γ3, δ and ɛ CK1 isoforms, which have been 
grouped together based on their high degree of homology within their kinase domains 
located at their N-termini (Gross & Anderson, 1998, Knippschild, Gocht et al., 2005a, 

















Figure 1-2: Multiple sequence alignment of the human CK1 proteins: The alignment 
was performed using Clustal Omega and visualised in boxshade. Shading indicates the 
% sequence similarity (black = identical, grey = similar; in more than 50% of sequences). 





CSNK1G1    1 MDHPS----REKDERQRTTKPMAQRSAHCSRPSGSSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEP 
CSNK1G2    1 MDFDKKGGKGETEEGRRMSKAGGGRSSHGIRS--SGTSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEP 
CSNK1G3    1 MENKK---KDKDKSDDRMARP-SGRSGHNTRG-TGSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEP 
CSNK1A1    1 -------------------------------MASSSGSKAEFIVGGKYKLVRKIGSGSFGDIYLAINITNGEEVAVKLES 
CSNK1AL    1 -------------------------------MTNNSGSKAELVVGGKYKLVRKIGSGSFGDVYLGITTTNGEDVAVKLES 
CSNK1D     1 ---------------------------------------MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLEC 
CSNK1E     1 ---------------------------------------MELRVGNKYRLGRKIGSGSFGDIYLGANIASGEEVAIKLEC 
 
 
CSNK1G1   77 IKSRAPQLHLEYRFYKQLGSAGEGLPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLLSRMEYVH 
CSNK1G2   79 IKSRAPQLHLEYRFYKQLSA-TEGVPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLITRMEYVH 
CSNK1G3   76 MKSRAPQLHLEYRFYKQLGS-GDGIPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFSLKTVLMIAIQLISRMEYVH 
CSNK1A1   50 QKARHPQLLYESKLYKILQG-GVGIPHIRWYGQEKDYNVLVMDLLGPSLEDLFNFCSRRFTMKTVLMLADQMISRIEYVH 
CSNK1AL   50 QKVKHPQLLYESKLYTILQG-GVGIPHMHWYGQEKDNNVLVMDLLGPSLEDLFNFCSRRFTMKTVLMLADQMISRIEYVH 
CSNK1D    42 VKTKHPQLHIESKIYKMMQG-GVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIH 
CSNK1E    42 VKTKHPQLHIESKFYKMMQG-GVGIPSIKWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIH 
 
 
CSNK1G1  157 SKNLIYRDVKPENFLIGRQGNKKEHVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEA 
CSNK1G2  158 TKSLIYRDVKPENFLVGRPGTKRQHAIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEA 
CSNK1G3  155 SKNLIYRDVKPENFLIGRPGNKTQQVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEA 
CSNK1A1  129 TKNFIHRDIKPDNFLMGIG--RHCNKLFLIDFGLAKKYRDNRTRQHIPYREDKNLTGTARYASINAHLGIEQSRRDDMES 
CSNK1AL  129 TKNFLHRDIKPDNFLMGTG--RHCNKLFLIDFGLAKKYRDNRTRQHIPYREDKHLIGTVRYASINAHLGIEQSRRDDMES 
CSNK1D   121 SKNFIHRDVKPDNFLMGLG--KKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLES 
CSNK1E   121 SKNFIHRDVKPDNFLMGLG--KKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLES 
 
 
CSNK1G1  237 LGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRNTPIEALCENFPEEMATYLRYVRRLDFFEKPDYEYLRTLFTDLFE 
CSNK1G2  238 LGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFD 
CSNK1G3  235 LGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPE-MATYLRYVRRLDFFEKPDYDYLRKLFTDLFD 
CSNK1A1  207 LGYVLMYFNRTSLPWQGLKAATKKQKYEKISEKKMSTPVEVLCKGFPAEFAMYLNYCRGLRFEEAPDYMYLRQLFRILFR 
CSNK1AL  207 LGYVFMYFNRTSLPWQGLRAMTKKQKYEKISEKKMSTPVEVLCKGFPAEFAMYLNYCRGLRFEEVPDYMYLRQLFRILFR 
CSNK1D   199 LGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFH 
CSNK1E   199 LGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFSTYLNFCRSLRFDDKPDYSYLRQLFRNLFH 
 
 
CSNK1G1  317 KKGYTFDYAYDWVGRPIPTPVGSVHVDSGASAITRESHTHRDRPSQ-----------------------------QQPLR 
CSNK1G2  318 RSGFVFDYEYDWAGKPLPTPIGTVHTDLPSQP-Q-----LRDKT-------------------------------QPHSK 
CSNK1G3  314 RKGYMFDYEYDWIGKQLPTPVGAVQQDPALSS-NREAHQHRDKMQQSKNQSADHRAAWDSQQANPHHLRAHLAADRHGGS 
CSNK1A1  287 TLNHQYDYTFDWTMLKQKAAQQAASSSG-----QGQQA---------------QTPTGKQTDKTKSNMK---------GF 
CSNK1AL  287 TLNHQYDYTFDWTMLKQKAAQQAASSSG-----QGQQA---------------QTQTGKQTEKNKNNVK---------DN 
CSNK1D   279 RQGFSYDYVFDWNMLKFGASRAADDAER-----ERRDR--EERLRHSRNPATRGLPSTA-----SGRLR---------GT 
CSNK1E   279 RQGFSYDYVFDWNMLKFGAARNPEDVDR-----ERREHEREERMGQLRGSATRALPPGPPTGATANRLR---------SA 
 
 
CSNK1G1  368 NQVVSSTNGELNVDDPTGAHSNAPITAHAEVEVVEEAKCCCFFKRKRKKTAQRHK------------------------- 
CSNK1G2  361 NQALNSTNGELNADDPTAGHSNAPITAPAEVEVADETKCCCFFKRRKRKSLQRHK------------------------- 
CSNK1G3  393 VQVVSSTNGELNTDDPTAGRSNAPITAPTEVEVMDETKCCCFFKRRKRKTIQRHK------------------------- 
CSNK1A1  338 -------------------------------------------------------------------------------- 
CSNK1AL  338 -------------------------------------------------------------------------------- 
CSNK1D   338 Q--------EVAPPTPLTPTSHTANTSPRPVSGME---------RERKVSMRLHRGAPVNISSSDLTGRQDTSRMSTSQI 
CSNK1E   345 A--------EPVASTPASRIQPAGNTSPRAISRVD---------RERKVSMRLHRGAPANVSSSDLTGRQEVSRIPASQT 
 
 
CSNK1G1      --------------- 
CSNK1G2      --------------- 
CSNK1G3      --------------- 
CSNK1A1      --------------- 
CSNK1AL      --------------- 
CSNK1D   401 PGRVASSGLQSVVHR 






identified in cows, conclusive evidence for its existence and function in cows or other 
mammalian species remains elusive.  
All CK1 isoforms have been reported to act as monomeric, constitutively-active 
enzymes (Gross & Anderson, 1998, Knippschild et al., 2005a, Schittek & Sinnberg, 2014). 
As ubiquitously-expressed and constitutively-active Ser/Thr protein kinases, CK1 
isoforms have been reported to be involved in numerous, varied signalling pathways, 
and many proteins have been reported to be phosphorylated by CK1 isoforms (Cheong 
& Virshup, 2011, Gross & Anderson, 1998, Knippschild et al., 2005a, Schittek & Sinnberg, 
2014). The CK1 family of kinases are conserved throughout evolution, and several CK1 
orthologues have been identified in yeast (Hoekstra, DeMaggio et al., 1991, Wang, 
Vancura et al., 1992). Outside of the kinase domains, the non-catalytic C-termini of CK1 
isoforms vary significantly and are not conserved between isoforms (Figure 1-2). 
However, the C-termini have been shown to play crucial roles in regulating substrate 
recognition, and in the modulation of kinase activity for some CK1 isoforms (Carmel, 
Leichus et al., 1994, Cegielska, Gietzen et al., 1998). That said, it should be noted that 
the C-termini are very small compared to other kinases, thereby suggesting that CK1 
kinases may require functional interacting partners, or regulatory subunits, for their 
regulation. 
 
1.1.2: Mode of CK1 action: 
CK1 family members catalyse the transfer of phosphate on to Ser/Thr residues 
of their substrate proteins by utilising ATP exclusively as the source of the phosphate 
donor (Flotow, Graves et al., 1990, Tuazon & Traugh, 1991). Early attempts aimed at 
elucidating the substrate specificity of CK1 identified the requirement for a priming 
phosphorylation event in the -3 position, within the consensus sequence pS/pT-X-X-
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S*/T*, where X is any amino acid and S*/T* denote CK1-phosphorylation residues 
(Flotow et al., 1990, Meggio, Perich et al., 1992, Meggio, Perich et al., 1991). This 
sequence is often referred to as the canonical CK1 consensus motif. Given this 
requirement for a priming phosphorylation event, CK1 isoforms were thought to act 
downstream of other kinases, and as such, this restricted their contribution within 
signalling cascades to one of a hierarchical manner. However, since the discovery of the 
canonical consensus motif, it has come to light that a cluster of acidic residues N-
terminal to the target Ser/Thr phosphorylation sites, with an acidic amino acid at the n-
3 position, can effectively substitute for the priming phosphorylation event (Agostinis, 
Pinna et al., 1989, Flotow & Roach, 1991, Graves, Haas et al., 1993, Marin, Meggio et al., 
1994, Pulgar, Marin et al., 1999). Furthermore, a non-canonical S-L-S motif with a 
concurrent cluster of C-terminal acidic residues has also been shown to be 
phosphorylated by CK1 isoforms, albeit less efficiently than the canonical phospho-
primed sequence (Knippschild et al., 2005a, Marin, Bustos et al., 2003). Such 
phosphorylation of S-L-S motifs are best showcased in two of the most robustly 
established CK1 substrates – nuclear factor of activated T-cells (NFAT) and β-catenin 
(Knippschild et al., 2005a, Marin et al., 2003).  
 
1.1.3: Regulation of CK1 in cells: 
Absence of selective CK1 inhibitors has led to confusion regarding exactly which 
CK1 isoform is the physiological kinase for each of the identified substrates. The kinase 
domains (sequence-wise and structurally) are very similar between CK1 isoforms (Figure 
1-2), and all CK1 isoforms are constitutively active in vitro, and can phosphorylate 
substrate residues with identical motifs (Gross & Anderson, 1998, Knippschild et al., 
2005a, Schittek & Sinnberg, 2014). Due to most cellular proteins harbouring at least one 
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CK1 consensus motif, it is not surprising that hundreds of CK1 substrates have been 
reported thus far. Added complexity arises when considering the cellular environment. 
Indeed, the substrate specificity of CK1 isoforms in vitro is thought to be largely different 
from that observed in vivo, and different isoforms are known to impact distinct 
biological processes, suggesting tight regulation of distinct isoforms in cells (Gross & 
Anderson, 1998, Knippschild et al., 2005a, Schittek & Sinnberg, 2014). This difference in 
the in vitro versus in vivo substrate specificity is attributed to intracellular regulatory 
mechanisms involved in modulating CK1 isoforms, such as functional binding partners 
and post-translational modifications. Furthermore, as the kinase domain of CK1 
isoforms constitutes the vast majority of the protein sequence, regulatory domains that 
are prevalent in many other kinases are very small, if not completely absent in CK1 
isoforms, adding further merit to the existence of regulatory CK1-binding partners in 
cells. These attributes have prompted researchers to ascertain the precise molecular 
mechanisms by which the activities of specific CK1 isoforms towards their cellular 
substrates are governed. 
One such mode of regulation known to modulate CK1 function in cells involves 
the use of scaffold proteins, that act to direct and/or coordinate the correct positioning 
of protein complexes. Scaffolds can also act as signalosome assembly platforms, that act 
to bring functional enzymes, such as kinases, in close proximity to their substrate 
proteins, thereby increasing reaction efficiency through spatial control (Good, Zalatan 
et al., 2011). In some cases, scaffold/anchoring proteins have also been shown to 
allosterically activate their catalytic binding partners (Bayliss, Sardon et al., 2003, Good 
et al., 2011). In regard to the CK1 family of kinases, such scaffolds could be envisaged to 
regulate the constitutively-active CK1 members through multiple avenues. For example, 
scaffolds could bind and sequester CK1 isoforms at discreet cellular locations, either to 
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take CK1 isoforms towards or away from their substrates, or act as a physical bridge 
between CK1 isoforms and their substrates. Furthermore, CK1 scaffolds may act to 
promote optimal CK1 activation through direct allosteric activation. Indeed, several 
protein scaffolds have been found to exert regulation towards some of the CK1 family 
members. For example, the centrosomal and Golgi N-kinase anchoring protein (CG-NAP, 
aka AKAP450) was shown to interact with CK1δ and ɛ and recruit them to centrosomes 
(Sillibourne, Milne et al., 2002). Furthermore, the DEAD-box RNA helicase DDX3 has 
been shown to directly interact with CK1ɛ in a Wnt-dependent manner, to promote the 
phosphorylation of the Wnt receptor-associated protein Dishevelled (Dvl) (Cruciat, 
Dolde et al., 2013). Interestingly, in the case of some CK1 substrates such as NFAT and 
the circadian clock protein period 1 (PER1), a F-X-X-X-F motif on the substrate was found 
to mediate the interaction with CK1 (Okamura, Garcia-Rodriguez et al., 2004). Whether 
this interaction mechanism is universally applicable to every CK1-binding partner 
remains to be determined. 
Additionally, post-translational modifications are known to be involved in the 
regulation of CK1 activity. These are largely thought to occur through reversible 
phosphorylation, either by CK1 itself through autophosphorylation, or by other kinases 
(Carmel et al., 1994, DeMaggio, Lindberg et al., 1992, Fish, Cegielska et al., 1995). In both 
cases, phosphorylation of CK1 was shown to be inhibitory towards intrinsic catalytic 
activity. How then the CK1 family kinases retain their constitutive activity remains 
unclear, although phosphatase involvement has been inferred (Gietzen & Virshup, 
1999). Interestingly, NEDDylation of CK1α was also shown to occur (Huart, MacLaine et 




1.1.4: The roles of CK1 in biology: 
Given the reported phosphorylation of numerous substrates by CK1 family 
isoforms, it is perhaps unsurprising that CK1 kinases have been implicated in many, 
diverse biological processes (Gross & Anderson, 1998, Knippschild et al., 2005a, Schittek 
& Sinnberg, 2014). The most evident of these processes will each be briefly summarised 
in the following sections: 
 
1.1.4.1: Wnt signalling:  
To date, the canonical Wnt signalling pathway is perhaps the best characterised 
CK1-regulated process. In short, stimulation of the cognate Wnt receptors with Wnt 
ligands lead to the nuclear translocation of the transcription factor β-Catenin, ultimately 
resulting in transcription of Wnt-dependent target genes (MacDonald, Tamai et al., 
2009) (Figure 1-3). In the absence of Wnt ligands, β-Catenin is maintained within the so-
called β-Catenin destruction complex, which is comprised of the scaffold proteins Axin 
and adenomatous polyposis coli (APC), the SKP1-Cul1-F-Box protein E3 ubiquitin ligase 
(SCF) substrate receptor β-TRCP, and the kinases glycogen synthase kinase 3 (GSK3) and 
CK1 (MacDonald et al., 2009, Stamos & Weis, 2013) (Figure 1-3). Within this destruction 
complex, the current model proposes that β-Catenin is first phosphorylated by CK1 on 
Ser45, thereby priming β-Catenin for subsequent, sequential phosphorylation on Thr41, 
Ser37, and Ser33 by GSK3 (Amit, Hatzubai et al., 2002, Gao, Seeling et al., 2002, Liu, Li 
et al., 2002, Marin et al., 2003, Yost, Torres et al., 1996). Next, this phosphorylated β-
Catenin species is ubiquitinated by the β-TRCP-SCF complex, priming it for degradation 
via the proteasome (Cruciat, 2014). In the presence of Wnt ligands, however, Axin is 
expelled from the destruction complex through as yet unidentified mechanisms, and 
phosphorylated β-Catenin is thought to accumulate and saturate the destruction  
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Figure 1-3: Schematic representation detailing the involvement of CK1 in Wnt 
signalling: In the absence of Wnt ligands, β-catenin is held by the so-called destruction 
complex composed of Axin, APC, the SCF E3 ubiquitin ligase substrate receptor β-TRCP, 
and the kinases CK1 and GSK3. Sequential phosphorylation of β-Catenin by CK1 and 
GSK3 triggers β-catenin ubiquitination by the β-TRCP-complex, and its subsequent 
proteasomal degradation. In the nucleus, Groucho binds TCF to block the transcription 
of Wnt target genes. Following binding of Wnt ligands to the receptors, LRP5/6 becomes 
phosphorylated, and triggers the formation of the Wnt signalosome, largely composed 
of Axin and Dvl. This recruits the destruction complex to the membrane. β-catenin is 
stabilised in the cytosol and is free to enter the nucleus where it displaces Groucho from 
TCF, and together with LEF activates transcription of Wnt target genes. CK1 has been 
reported to phosphorylate LRP5/6 and Dvl in the presence of Wnt ligands. 
 
 
complex (Cruciat, 2014, Stamos & Weis, 2013, Teo & Kahn, 2010) (Figure 1-3). 
Subsequently, the newly translated β-Catenin is free to translocate to the nucleus and 
initiate transcription of Wnt target genes (Cruciat, 2014, Stamos & Weis, 2013, Teo & 
















































Despite this seemingly conclusive model, the exact CK1 isoform that mediates 
phosphorylation of β-Catenin on Ser45 has not been irrefutably identified. This is largely 
due to the non-selective nature of CK1 inhibitors, and the fact that CK1 isoforms are 
largely essential for cell viability, thereby making genetic ablation experiments very 
challenging, if not impossible. Indeed, virtually all CK1 isoforms have been implicated in 
Wnt signalling (Cruciat, 2014, Del Valle-Perez, Arques et al., 2011, Gao & Chen, 2010), 
thereby making it extremely difficult to decipher the function of individual CK1 members 
within the Wnt pathway. Further complexity to the regulation of Wnt signalling by CK1 
stems from the reported phosphorylation of the Wnt receptor-associated protein Dvl by 
CK1ɛ, which is thought to increase the affinity between Dvl and the Wnt receptor 
complex (Bryja, Schulte et al., 2007, Cheong & Virshup, 2011, Del Valle-Perez et al., 
2011). Thus, in this context, CK1-mediated phosphorylation acts to promote Wnt 
signalling, in stark contrast to its inhibitory role within the destruction complex. Thus, 
exactly how CK1 isoforms can act to both positively and negatively regulate the same 
signalling pathway presents an intriguing paradox, yet adds further credence to the 
influence that CK1 regulating proteins and modifications are likely to have in 
coordinating these constitutively-active protein kinases.  
 
1.1.4.2: p53 signalling: 
The tumour suppressor protein p53 functions as a key regulator of many aspects 
of biology, including the cell cycle, apoptosis and DNA damage responses (Bieging, Mello 
et al., 2014). Both p53 and its inhibitory interacting proteins mouse double minute 
homologue 2 and 4 (MDM2 and MDM4) are substrates of CK1 isoforms (Dumaz, Milne 
et al., 1999, Knippschild, Milne et al., 1997, Winter, Milne et al., 2004). MDM2 and 
MDM4 are E3 ubiquitin ligases responsible for regulating p53 stability. CK1α, δ and ɛ 
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have all been shown to be capable of phosphorylating p53 at Ser9 in vitro, with 
phosphorylation by CK1α only occurring at high CK1α concentrations (Milne, Palmer et 
al., 1992). Additionally, CK1δ and ɛ were shown to phosphorylate p53 in cultured cells 
(Knippschild et al., 1997). CK1δ-mediated phosphorylation of MDM2 was shown to 
result in reduced affinity between p53 and MDM2, thereby resulting in stabilisation and 
subsequent activation of p53 (Dumaz et al., 1999, Knippschild et al., 1997, Winter et al., 
2004). Thus, the data would suggest that CK1 activity is important in p53 activation.  
However, and as seen in Wnt signalling, different CK1 isoforms can have 
contrasting effects on p53 signalling, depending on the experimental conditions used 
and the cell type being investigated. Indeed, knockdown of CK1α has been shown to 
activate p53 (Elyada, Pribluda et al., 2011, Jaras, Miller et al., 2014, Sarasqueta, Forte et 
al., 2013). In agreement, one study showed that CK1α associates with MDM2 to 
inactivate p53, through increasing MDM2-p53 binding affinity (Wu, Chen et al., 2012). 
This was further cemented through independent observations where CK1α knockdown 
led to a reduction in the MDM2-p53 interaction, thereby increasing p53 activity (Huart, 
MacLaine et al., 2009). Interestingly, in agreement with CK1α regulating p53 stability, a 
recent publication reported that ablation of CK1α in keratinocytes induced p53-
dependent, sunburn-protective skin hyperpigmentation (Chang, Kuo et al., 2017). In 
addition, p53 activity leads to upregulation of CK1δ, but not CK1ɛ, thereby suggesting 
an autoregulatory feedback mechanism between CK1δ and p53 (Knippschild et al., 
1997). Indeed, CK1δ kinase activity is reduced in p53-deficient primary lymphocytes, 
compared to wild-type controls (Maritzen, Lohler et al., 2003). Thus, at least in the case 
of p53 signalling, the role of CK1 phosphorylation appears more complex than a mere 
kinase-substrate relationship.  
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1.1.4.3: Hippo signalling: 
During development, Hippo signalling contributes to correct organ maturation, 
through the regulation of cell proliferation and apoptosis (Zhao, Li et al., 2010). As such, 
dysfunctional Hippo signalling can lead to tumorigenesis and cancer. In mammals, the 
Hippo pathway begins through stimulation by growth-suppressive signals, such as 
cellular stresses and contact inhibition (Figure 1-4). Within the Hippo pathway, the 
upstream kinases mammalian STE20-like protein kinase 1/2 (MST1/2) act to 
phosphorylate the large tumour suppressor 1 and 2 (LATS1/2), and LATS1/2 
subsequently phosphorylate the transcriptional co-activator yes-associated protein 
(YAP) and its paralog transcriptional co-activator with PDZ-binding domain (TAZ) (Zhao 
et al., 2010) (Figure 1-4). Phosphorylation of YAP/TAZ leads to their inhibition through 
phosphodegron-mediated proteolysis, in addition to promoting their separation from 
their cognate nuclear-localised transcription factor targets, such as SMAD (Zhao et al., 
2010) (Figure 1-4). Effectively, YAP/TAZ phosphorylation leads to Hippo pathway 
inhibition.  
CK1 isoforms have been suggested to regulate Hippo signalling. Indeed, CK1δ or 
ɛ have been proposed to phosphorylate YAP after priming phosphorylation from 
LATS1/2 (Zhao et al., 2010). This phosphorylation event was proposed to act as a 
phosphodegron signal, and mediate recruitment of the SCF E3 ubiquitin ligase complex 
containing β-TrCP (Zhao et al., 2010). Similarly, CK1ɛ has been reported to 
phosphorylate TAZ to promote TAZ degradation through a phosphodegron signal, again 
following priming phosphorylation from LATS1/2 (Liu, Zha et al., 2010). Interestingly, 
cross-talk between the Wnt and Hippo pathways has been suggested to be mediated 
through CK1ɛ (Xu, Wang et al., 2014). Following MST1 binding to CK1ɛ, CK1ɛ is 
sequestered and unable to phosphorylate Dvl, thereby leading to inhibition of the Wnt  
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Figure 1-4: Schematic representation detailing the involvement of CK1 in Hippo 
signalling: Under conditions of low cell density, the YAP/TAZ transcriptional coactivator 
complex cycles between the cytosol and nucleus, and in the nucleus YAP/TAZ bind to 
their cognate transcription factor targets such as SMAD to trigger transcription of Hippo 
target genes to promote cell growth and differentiation. CK1 phosphorylates Dvl to 
promote Wnt signalling under these conditions. Under conditions of cell stress, such as 
contact inhibition, the kinase MST1/2 becomes activated and phosphorylates LATS1/2, 
which promotes LATS1/2-mediated phosphorylation of YAP/TAZ. YAP/TAZ 
phosphorylation acts as phosphodegron signal to promote YAP/TAZ ubiquitination by β-
TrCP, and subsequent YAP/TAZ proteolysis. As YAP/TAZ cannot enter the nucleus, Hippo 
target gene transcription is suppressed and cells cease to grow. CK1 has been reported 
to phosphorylate YAP/TAZ after priming phosphorylation from LATS1/2, and following 




signalling pathway (Xu et al., 2014). Thus, in this context, MST1 can act as key regulator 
of CK1ɛ, by promoting a change in its subcellular localisation and restricting access 


































1.1.4.4: Cell division: 
The cell cycle in eukaryotes is divided into two main phases: interphase, in which 
the cell replicates its DNA and duplicates its organelles in preparation for division; and 
M phase, in which cell division takes places, creating two genetically identical daughter 
cells in the process (Nigg, 2001). Throughout the cell division cycle, checkpoint 
mechanisms are in place to ensure the correct and efficient replication and distribution 
of both the DNA, and the cytoplasm (Macurek, Lindqvist et al., 2008, Nigg, 2001). The 
yeast orthologue of CK1 was among the first kinases identified to have a role in the 
regulation of cell cycle progression (Hoekstra, Liskay et al., 1991). In mammals, however, 
where there are multiple CK1 isoforms present, the precise contribution of each isoform 
to the regulation of the cell division cycle is not well understood. CK1δ has been found 
to localise to centrosomes, and displays high affinity towards microtubules in response 
to DNA damage, suggesting a checkpoint role for CK1δ in cell division (Behrend, Milne 
et al., 2000, Stoter, Bamberger et al., 2005). Furthermore, inhibition of CK1δ/ɛ using 
IC261 is accompanied with cell cycle arrest (Behrend et al., 2000). 
In addition to CK1δ, CK1α has long been suggested to have a role in mitosis. Early 
immunostaining efforts identified CK1α on mitotic spindles (Brockman, Gross et al., 
1992), and CK1α morpholinos triggered mitotic arrest and chromosomal alignment 
defects in mouse oocytes (Wang, Lu et al., 2013).  
 
1.1.4.5: Circadian rhythm: 
Circadian rhythms are biological processes that oscillate in a predictable, 
entrainable manner, that are regulated by an endogenous time keeper, or circadian 
clock (Takahashi, 2017).  CK1 was the first kinase found to regulate the circadian clock. 
In Drosophila, the CK1 orthologue doubletime (dbt) phosphorylates the transcription 
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factor PERIOD (PER), which acts to modulate the oscillatory circadian cycle (Kloss, Price 
et al., 1998). In mammals, in the brain and periphery, oscillatory transcriptional 
feedback encompasses the positive regulatory CLOCK-BMAL (Brain and muscle ARNT-
like 1) complex, which acts to activate transcription of the mammalian PER orthologues 
PER1-3, as well as cryptochrome proteins termed CRY1-2 (King & Takahashi, 2000, 
Reppert & Weaver, 2002) (Figure 1-5). Following their transcription, the newly-
synthesised PER and CRY proteins dimerise and translocate to the nucleus where they 
bind and inhibit the CLOCK-BMAL complex, thereby preventing their own transcription 
(King & Takahashi, 2000, Reppert & Weaver, 2002) (Figure 1-5). In doing so, one 
circadian cycle is thus completed. Subsequently, CK1-dependent phosphorylation of PER 
proteins induces PER degradation by the proteasome, thereby initiating a new circadian 
cycle, and the process repeats (Akashi, Tsuchiya et al., 2002, Takano, Uchiyama et al., 
2004, Vielhaber, Eide et al., 2000) (Figure 1-5). CK1ɛ has also been shown to 
phosphorylate BMAL and CRY proteins (Eide, Vielhaber et al., 2002), although the 
relevance of these phosphorylation events are yet to be determined. 
The exact physiological CK1 isoform(s) responsible for PER1/2 phosphorylation 
is a subject of debate, but CK1δ and ɛ have both been implicated, and the vast majority 
of data support roles for both isoforms in the regulation of circadian rhythm. Perhaps 
the most striking evidence for the involvement of CK1 in the regulation of circadian 
rhythm stems from evidence gathered in CSNK1E-deficient mice (Etchegaray, Machida 
et al., 2009). In these mice, which lack expression of CK1ɛ, the length of circadian 
rhythms were significantly longer compared to wild-type littermates (Etchegaray et al., 
2009). Similarly, mice heterozygous for CSNK1D deletion present with longer circadian 
rhythms, whereas homozygous CSNK1D knockout mice died in the perinatal period 
(Etchegaray et al., 2009). Furthermore, a mutation in the Syrian hamster CSNK1E1 gene  
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Figure 1-5: Schematic representation detailing the involvement of CK1 in the 
regulation of circadian rhythm: The circadian cycle begins with the CLOCK-BMAL 
complex, which acts to activate the transcription of PER and CRY. Following their 
translation, PER and CRY proteins heterodimerise and translocate to the nucleus where 
they act to inhibit CLOCK-BMAL, thereby preventing their own transcription. 
Subsequently, CK1 phosphorylates PER to trigger PER proteolysis and relieve CLOCK-
BMAL inhibition. The cycle then begins again. CK1 has also been reported to 
phosphorylate CRY and BMAL, but the relevance of these phosphorylation events 
remains to be elucidated. 
 
 
(T178C) increases catalytic activity towards PER proteins, resulting in reduced PER 
stability and shorter circadian rhythms (Meng, Logunova et al., 2008). Collectively, there 
is strong evidence supporting roles for both CK1δ and ɛ in circadian rhythm regulation, 














































As CK1δ and ɛ are very closely related proteins (Figure 1-2), it is feasible that they 
may act redundantly in some contexts. The fact that CSNK1E-deficient mice are 
surprisingly viable, whereas CSNK1D-deficient mice are not (Etchegaray et al., 2009), 
perhaps suggests that the non-circadian rhythm functions of CK1δ are indispensable for 
viability, whereas those of CK1ɛ are not. Thus, there seems to be a limit to CK1δ and ɛ 
redundancy, likely dependent on the biological process in question. 
 
1.1.4.6: Hedgehog signalling: 
Hedgehog (Hh) signalling is critical for both correct development and 
maintenance of healthy adult cells, although the activity of the Hh signalling pathway is 
vastly reduced in adulthood (Ingham & McMahon, 2001). Hh signalling contributes to 
the maintenance of epithelia and tissue regeneration, thus, unsurprisingly, 
dysfunctional Hh signalling can lead to tumorigenesis and cancer (Beachy, Karhadkar et 
al., 2004, Wicking, Smyth et al., 1999). Within the mammalian Hh pathway, ligands such 
as sonic hedgehog (Shh) bind to the negative regulator of the pathway, the 
transmembrane receptor protein patch homologue (PTCH), which is in complex with the 
positive Hh regulator smoothened homologue precursor (SMO) (Varjosalo & Taipale, 
2008) (Figure 1-6). Upon PTCH stimulation, SMO is released from PTCH, and is free to 
mediate activation and release of GLI transcription factors from a cilia-localised, GLI-
inhibitory multiprotein complex containing the kinases CK1, GSK3 and protein kinase A 
(PKA) (Varjosalo & Taipale, 2008) (Figure 1-6). Once free, the GLI transcription factors 
are free to translocate to the nucleus and induce transcription of Hh-dependent target 
genes (Figure 1-6). Conversely, in the absence of PTCH stimulation by Hh ligands, SMO 




Figure 1-6: Schematic representation detailing the involvement of CK1 in hedgehog 
signalling: In the absence of hedgehog (Hh) ligands, the Hh receptor PTCH associates 
with SMO to inhibit SMO function. The GLI2/3 transcription factors are held in complex 
by a primary cilium-localised inhibitory complex consisting of the kinases CK1, GSK3 and 
PKA. Following GLI2/3 phosphorylation by CK1, GSK3 and PKA, GLI2/3 is marked for 
proteasomal degradation. In the presence of Hh ligands, SMO is released from PTCH and 
is free to mediate the release of GLI2/3 from the inhibitory kinase complex. GLI2/3 can 
now translocate to the nucleus and induce Hh target gene transcription. CK1 and GRK2 
have been reported to phosphorylate SMO to promote full SMO activation and maximal 
release of GLI2/3 from the inhibitory complex. 
 
 
GSK3 and PKA to trigger their proteasomal degradation (Denef, Neubuser et al., 2000, 
Taipale, Cooper et al., 2002, Varjosalo & Taipale, 2008) (Figure 1-6).  
In addition to the role of CK1 in promoting GLI transcription factor proteolysis, 
CK1 was also shown to have a positive regulatory role within the Hh pathway. 
Mammalian SMO was shown to be phosphorylated by CK1α and G protein-coupled 
































factors from the inhibitory multiprotein complex (Chen, Sasai et al., 2011). Thus, as seen 
with the other signalling pathways reviewed above, CK1 isoforms appear to have both a 
positive and negative regulatory influence on the Hh signalling pathway.  
 
1.1.4.7: Apoptosis: 
Programmed cell death, or apoptosis, is an evolutionary conserved mechanism 
whereby cells act to terminate themselves in an effort to limit the proliferation of faulty 
and disease-prone cell populations (Elmore, 2007). In short, proteins called death 
receptors such as Fas, and tumour necrosis factor receptor 1 (TNFR1), act to transduce 
extrinsic apoptotic cues, ultimately leading to the formation of the intracellular death-
inducing-signalling-complex (DISC) (Elmore, 2007). DISC proteins go on to recruit 
caspases in order to propagate the apoptotic signal (Elmore, 2007). The involvement of 
CK1 in apoptosis has been well documented, and CK1 has been implicated in various 
programmed cell death molecular pathways. CK1 isoforms can phosphorylate the TNF 
receptor p75, thereby negatively regulating p75-mediated apoptosis (Beyaert, 
Vanhaesebroeck et al., 1995). Furthermore, inhibition of CK1 isoforms, or RNAi-
mediated silencing of CSNK1A1, sensitises tumour cells to TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis (Izeradjene, Douglas et al., 2004). Recently, 
IC261-mediated inhibition of CK1δ/ɛ was shown to result in decreased expression of 
anti-apoptotic proteins, with a concurrent heightened sensitivity to apoptosis, in 
pancreatic cancer cells (Brockschmidt, Hirner et al., 2008). 
Again, the exact contribution of each CK1 isoform in apoptosis is not well 
established, and more selective tools are required in order to ascertain which CK1 kinase 
acts where in the various apoptotic pathways.  
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1.1.5: CK1 in disease: 
Given the involvement of CK1 isoforms in many, key signalling pathways involved 
in regulating proliferation, cell growth and viability, it is unsurprising that dysfunctional 
CK1 activity has been linked to disease. Of note, neurodegeneration and cancer are 
particularly prominent diseases that CK1 isoforms have been implicated in (Knippschild 
et al., 2005a, Knippschild, Kruger et al., 2014, Knippschild, Wolff et al., 2005b). In 
addition to the obvious effects dysfunctional CK1 activity would have on p53-dependent 
genomic stability (see section 1.2.4.2), CK1ɛ mutations in breast cancer were found to 
cause loss-of-function in the canonical Wnt signalling pathway (Foldynova-Trantirkova, 
Sekyrova et al., 2010). CK1ɛ expression was also found to be elevated in a variety of 
adenoid cystic carcinomas, including those derived from ovarian, renal and prostatic 
cancers (Rodriguez, Yang et al., 2012, Yang & Stockwell, 2008). Additionally, CK1α was 
found to be essential for acute myeloid leukemia (AML) viability, and treatment with 
D4476 resulted in selective killing of the AML cells (Jaras et al., 2014). However, a 
common theme that has emerged whilst investigating the functions of CK1 isoforms, is 
that they can act in both a positive and negative manner within the same signalling 
pathways. As such, it is very difficult to call an individual CK1 isoform a tumour 
suppressor or an oncogene.  
The role of CK1 isoforms in neurodegenerative diseases is perhaps best 
showcased in Alzheimer’s disease (AD). CK1δ transcripts are up-regulated 30-fold in the 
hippocampus of AD brains (Ghoshal, Smiley et al., 1999), and it is thought that CK1δ 
phosphorylates the AD-related protein tau, leading to the formation of neurofibrillary 
tangles (Li, Yin et al., 2004). CK1ɛ has been proposed to regulate the processing of 
amyloid precursor protein (APP), and thus dysfunctional CK1ɛ activity has been linked 
to the formation of amyloid plaques (Flajolet, He et al., 2007). 
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Given such pleiotropy in the cellular roles of CK1 kinases, they have long been 
deemed undruggable kinases. Thus, methods to selectively inhibit CK1-specific 
functions, in a temporally and spatially controlled manner, are highly warranted, yet 
extremely challenging to generate. That said, recent years have seen increasing interest 
in CK1 isoforms as drug targets (Knippschild et al., 2014). However, due to high 
homology between their kinase domains (Figure 1-2), isoform-specific CK1 inhibitors 
have been next to impossible to develop. However, several small molecule CK1 
inhibitors have been generated and many have been used to aid research into CK1 
function (Table 1-1) (Knippschild et al., 2014). However, due to their non-isoform-
selective nature, data should be interpreted with caution, especially when assigning 
CK1-substrate relationships.  
As alternative approaches to kinase inhibition, the thalidomide-related drug 
lenalidomide was recently found to induce the degradation of CK1a through recruiting 
CK1a to the cereblon-containing Cullin 4 ubiquitin E3 ligase complex, for its subsequent 
ubiquitination and proteolytic degradation (Stahl & Zeidan, 2017). Such treatment with 
lenalidomide was shown to be effective in the treatment of pre-leukemic human 
myelodysplastic syndrome (MDS) (Stahl & Zeidan, 2017). As an alternative strategy, 
CK1α-derived peptides were successfully employed to block binding between CK1α and 
MDM2 (Huart et al., 2012). These blocked the CK1α-MDM2 interaction without 
inhibiting CK1α kinase activity, and led to a reduction in p53 proteolysis with concurrent 
heightened p53 stability (Huart et al., 2012). Such approaches are attractive as they 
provide a means to inhibit selective CK1-dependent processes, whilst rendering other, 
unrelated CK1-associated processes intact. Although, one can imagine that such 
peptides would impact the binding to other CK1-interacting proteins, and lenalidomide-
induced proteolysis is known to target many proteins other than CK1α for proteasomal  
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Table 1-1: Summary of CK1-inhibitory agents: Known CK1 inhibitors are listed, along 
with the respective CK1 isoform(s) that they target. Their in vitro IC50 values and known 
off-targets are provided, along with the appropriate reference(s). 
 
 
degradation (An, Ponthier et al., 2017). Interestingly, CK1-activating compounds, such 
as pyrvinium pamoate, have also been described (Kucherenko, Zelenak et al., 2012), 
although their mechanism of action remain contentious (Venerando, Girardi et al., 
2013). However, these are thought to be very non-selective drugs, and as such, their 





Inhibitor CK1 Isoform 
targeted
In vitro IC50 (µM) Known off-targets References
CKI-7 ⍺/δ/ε 6.00 ERK8/SGK1/MNK1/AMPK/PIM1/PIM3 Chijiwa et al, 1989, 
Bain et al, 2007
IC261 δ/ε 2.50 CK1⍺/PIM1/PIM3 Mashhoon et al, 
2000, Bain et al, 2007
D4476 δ 0.30 CK1⍺/ALK5/p38 Rena et al, 2004
DAA δ 0.30 CK2 Cozza et al, 2008
R-DRF053 δ/ε 0.01 CDKs Oumata et al, 2008
PF-670462 δ/ε 0.013/0.08 PKA/PKC/p38/GSK3 Walton et al, 2009
PF-4800567 δ/ε 0.032/0.70 EGFR Walton et al, 2009
CR8 δ/ε Not reported CDKs/GSK3 Bettayeb et al, 2008, 
Delehouze et al, 2014
Hua-1h γ 0.02 CK1⍺/δ Hua et al, 2012
Bischof-5 δ/ε 0.04/0.199 CK1⍺ Bischof et al, 2012
SR-653234 δ/ε 0.16/0.54 FLT3/CDKs Bibian et al, 2013
SR-1277 δ/ε 0.049/0.26 FLT3/CDKs Bibian et al, 2013
SR-3029 δ/ε 0.044/0.26 FLT3/CDKs Bibian et al, 2013
Richter-1 δ/ε 0.02/0.21 CK1⍺/CK1⍺L/FLT3 Richter et al, 2014
Richter-2 δ/ε 0.14/0.52 CK1⍺L/CK1γ/FLT3/CLK/DYRK1/DYRK2/MLCK Richter et al, 2014
Halekotte 11-b δ 0.04 CK1ε/CK1⍺/p38/JNK/RIPK/LCK Halekotte et al, 2017
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1.2: Post-translational control of cell division: 
 As mentioned in the previous subchapter, CK1 kinases are known to participate 
in the regulation of cell division. In this thesis, I present evidence supporting a role for 
CK1α in mitotic spindle positioning. Thus, an appreciation for the post-translational 
mechanisms regulating cell division, and in particular mitotic spindle positioning, is 
required to aid the understanding of this thesis, and will be discussed in the following 
sections. 
Accurate execution of the cell division cycle results in the precisely coordinated 
replication and subsequent separation of DNA and cytoplasm into two newly-formed 
daughter cells (Figure 1-7). The cell cycle is divided into two main phases: interphase 
and mitosis. Interphase is further divided into the Gap 1 phase (G1), where the cell 
synthesises mRNA and proteins in preparation for the subsequent stages of the cell 
cycle, Synthesis phase (S), where DNA replication occurs, and Gap 2 phase (G2), a period 
of rapid cell growth and protein synthesis where the cell prepares for mitosis. Multiple 
regulatory checkpoints exist in cells to ensure that the cell cycle occurs with precision 
and accuracy, and errors at any point can be detrimental to the cell and organism as a 
whole (Dephoure, Zhou et al., 2008, King, Deshaies et al., 1996, Kronja & Orr-Weaver, 
2011). Many disease states, most notably cancer, have been linked to aberrant cell cycle 
control (Dephoure et al., 2008, Massague, 2004, Williams & Stoeber, 2012). Deciphering 
the regulatory modes of the cell cycle is thus a topic of wide research interest, from both 
a basic science and therapeutic standpoint. Whilst many regulatory mechanisms exist in 
the G1, S and G2 phases, this sub-chapter will focus on the regulatory mechanisms 
coordinating M phase of the eukaryotic cell cycle, particularly those pertaining to 




Figure 1-7: Overview of the cell division cycle: The eukaryotic cell cycle is divided into 4 
main stages – G1, S, G2 and M. M phase is the shortest phase and can be further 
subdivided into prophase (where the chromatin condenses), prometaphase (where the 
mitotic spindle begins to be established and spindle microtubules start to capture the 
chromosomes), metaphase (where the chromosomes are lined up along the cell 
equator), anaphase (where sister chromatids separate and the cell begins to divide), 
telophase (where the sister chromatids reach opposite poles and the nuclear envelope 




1.2.1: Overview of mitotic kinases: 
 The entry into mitosis is accompanied by a profound increase in the level of 
protein phosphorylation throughout the cell (Dephoure et al., 2008, Ly, Whigham et al., 
2017, Nousiainen, Sillje et al., 2006). Many studies have determined the critical roles 
protein phosphorylation plays in key mitotic processes, such as chromosome 
condensation and mitotic spindle assembly (Nigg, 2001). Historically, the observation 












was a key cornerstone in the identification of M-phase promoting factor (MPF) (Masui 
& Markert, 1971, Rao & Johnson, 1970). MPF consists of a protein kinase termed cell 
division cycle 2 [Cdc2, aka cyclin-dependent kinase 1 (CDK1)], and its associated 
regulatory subunit called Cyclin B (Lohka, Hayes et al., 1988). Since then, several other 
protein kinases have been identified as having instrumental roles in eukaryotic cell 
division, and enormous effort has been devoted to understanding the roles of these 
protein kinases in mitosis, and to the identification of their physiological substrates. 
 The most-studied of these protein kinases will be individually explored in the 
subsequent sections. 
 
1.2.1.1: Cyclin-dependent kinases: 
 Cyclin-dependent kinases (CDKs) are Ser/Thr protein kinases, whose activity is 
dependent on a regulatory subunit termed cyclin. CDKs belong to the CMGC branch of 
the human kinome tree, along with the MAPKs, GSK3, CDK-like kinases, and members 
of the dual-specificity tyrosine-regulated kinases (DYRKs) (Manning et al., 2002). To 
date, 20 members of the CDK family have been identified, and these have been 
designated CDK1-CDK20 (Malumbres, Harlow et al., 2009). Like the other CMGC kinases, 
CDKs are proline-directed Ser/Thr kinases with a preference for the S/T-P-X-K/R 
consensus motif (Echalier, Endicott et al., 2010).  
 CDKs were first identified through genetic and biochemical studies in model 
organisms such as yeast and Xenopus (Malumbres & Barbacid, 2005). These experiments 
established CDKs as critical regulators of the cell cycle. The founding member, CDK1, 
was identified in genetic screens searching for yeast mutants with defects in cell division 
(Hartwell, 1974, Hartwell, Mortimer et al., 1973). CDK1, designated Cdc2 in 










Figure 1-8: Overview of cyclin expression during a mammalian cell cycle: Cyclin D levels 
remain constant during the cell cycle. Cyclin E levels rise dramatically at the G1/S 
transition. Cyclin A and Cyclin B levels rise in G2 and decline during M phase.  
 
 
essential for cell-cycle progression (Russell & Nurse, 1986), and soon after its discovery, 
a Cdc2 homologue was identified in human cells (Lee & Nurse, 1987). With the advent 
of cDNA libraries and polymerase chain reaction (PCR) technology, many other CDK 
family members were identified, and their role as crucial regulators of eukaryotic cell 
division began to be appreciated (Elledge & Spottswood, 1991, Matsushime, Ewen et 
al., 1992, Meyerson, Enders et al., 1992, Xiong, Zhang et al., 1992). 
 Independent studies in sea urchin oocytes led to the identification of some 
proteins that were synthesised and degraded at each cleavage division (Evans, 
Rosenthal et al., 1983). Due to this cyclical nature in their expression, these proteins 
were termed cyclins (Figure 1-8). Subsequently, cyclins were cloned from fertilised sea 
urchin and clam embryos, and their expression was demonstrated to promote meiosis 
in Xenopus embryos (Swenson, Farrell et al., 1986). In agreement with their reported 
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identified in S. pombe, S. cerevisiae and humans, respectively. The biochemical 
connection between CDKs and cyclins came in 1989 when researchers determined that 
CDK1 associates with Cyclin A and B in starfish, clam and Xenopus oocytes (Nurse, 1990). 
In mammals, subsequent studies identified the additional cyclins, Cyclin C, D and E. 
CDK1-Cyclin binding is required for CDK1 catalytic activity, and isolated CDKs present 
with minimal enzymatic output (Xiong & Beach, 1991).  
 Following completion of DNA synthesis, A-type cyclins bind CDK1 and CDK2 and 
these CDK-Cyclin A complexes act to resolve S phase and promote entry into the G2 
phase (Malumbres & Barbacid, 2005). During G2, A-type cyclins are degraded through 
ubiquitin-mediated proteolysis, and the B-type cyclins are actively synthesised. 
Consequently, CDK1 associates with the newly-formed Cyclin B and this active complex 
is thought to regulate several key steps during the G2/M transition (Malumbres & 
Barbacid, 2005, Nigg, 2001). Of note, CDK1-Cyclin B complexes have been shown to 
localise to centrosomes during prophase to phosphorylate the motor protein Eg5, in 
order to promote centrosome separation (Nigg, 2001). Many substrates have been 
reported for CDK1-Cyclin B during this transition. These include histones, whose 
phosphorylation by CDK1 promote chromosome condensation, and lamins, whose 
phosphorylation trigger nuclear envelope breakdown. CDK1 activity has also been 
shown to activate several other mitotic protein kinases (Malumbres & Barbacid, 2005, 
Nigg, 2001). 
 The inactivation of CDK1-Cyclin B complexes is required for proper mitotic exit. 
This inactivation is achieved through the proteasomal degradation of Cyclin B following 
ubiquitination by the anaphase-promoting complex E3 ligase (see section 1.3.2) (Chang, 
Xu et al., 2003, King et al., 1996). Although many CDK1-Cyclin B substrates have been 
identified (Enserink & Kolodner, 2010, Ly et al., 2017, Malumbres & Barbacid, 2005), 
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direct kinase-substrate relationships are challenging to demonstrate as inhibition of 
CDK1 leads to G2 arrest, and cells already in mitosis rapidly exit the cell cycle following 
CDK1 inhibition (Vassilev, 2006). Thus, many of the reported substrates may be 
indirectly dephosphorylated following mitotic exit. 
 
1.2.1.2: Polo-like kinases: 
 The discovery of CDKs prompted investigation into other protein kinase that may 
cooperate with CDKs in the regulation of cell division. One such kinase family identified 
in this vein was the polo-like kinase (PLK) family. PLKs are Ser/Thr protein kinases that 
were first described in lower eukaryotes (Llamazares, Moreira et al., 1991, Sunkel & 
Glover, 1988). In Drosophila melanogaster, a mutant of the protein polo was found to 
present with defects in mitosis (Sunkel & Glover, 1988), and subsequently, PLK 
homologues were identified in mammals (Barr, Sillje et al., 2004).  
 All PLKs have a similar architecture. PLKs present with an N-terminal kinase 
domain, and a C-terminal regulatory domain containing two signature motifs, termed 
polo boxes (Barr et al., 2004). Humans have 5 PLK enzymes, termed PLK1-5, however 
the exact role and contribution of each PLK isoform is not well understood (Barr et al., 
2004). As PLK1 is thought to mediate most of the functions attributed to the D. 
melanogaster polo, the focus will be on PLK1 in the subsequent sections. 
 Similar to many other protein kinases, human PLK1 is activated through 
phosphorylation within its T-loop (at Thr210), by an upstream protein kinase (Jang, Ma 
et al., 2002, Lee & Erikson, 1997, Qian, Erikson et al., 1999). Whilst still a topic of debate, 
Aurora kinase A has been reported to be the upstream PLK1 kinase in cells (Macurek et 
al., 2008), although other kinases have also been implicated (Ji, Hwang et al., 2010). 
Emerging as a key regulatory feature of PLK1 in cells, the polo boxes have been shown  
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Figure 1-9: Overview of PLK1 regulation: PLK1 is activated by phosphorylation at T210 
in its kinase domain by an upstream kinase (largely thought to be AURKA). Following 
phosphorylation of docking proteins, the newly-formed phosphoepitope acts as a 
receptor for the polo-box domain of PLK1 to bind, thereby facilitating PLK1 localisation 
to distinct cellular sites.  
 
 
to be instrumental in mediating PLK localisation (Jang, Lin et al., 2002, Lee, Grenfell et 
al., 1998, Reynolds & Ohkura, 2003, Song, Grenfell et al., 2000) (Figure 1-9). The polo-
box domain (PBD) of PLK1 acts as a phosphopeptide-binding motif, and in this capacity, 
the PBD facilitates the recruitment of PLK1 to phosphorylated docking proteins, 
following priming phosphorylation of the docking protein by a distinct kinase (Cheng, 
Lowe et al., 2003, Elia, Cantley et al., 2003, Elia, Rellos et al., 2003, Neef, Preisinger et 
al., 2003). In cases where the phosphorylated docking proteins are localised to cellular 
structures, such as kinetochores and centrosomes (where PLK1 is known to reside), PBD-
mediated targeting also imparts spatial control towards PLK1 (Arnaud, Pines et al., 1998, 
Golsteyn, Mundt et al., 1995, Lee, Yuan et al., 1995, Seong, Kamijo et al., 2002); and 
many PBD-binding proteins have been identified (Park, Soung et al., 2010). In the 













domain of PLK1, thereby impeding kinase activation and substrate binding (Marshall, 
1994). However, upon PBD-phosphopeptide association, the kinase domain is thought 
to be released from the PBD, and together with T-loop phosphorylation, acts to activate 
PLK1 (Marshall, 1994). 
 In both interphase and mitosis, PLK1 localises to centrosomes, and centrosome-
localised PLK1 in mitosis has been reported to be critical for spindle pole formation, and 
positioning of the mitotic spindle (see section 1.3.3) (Connell, Chen et al., 2017, 
Kiyomitsu & Cheeseman, 2012). Interestingly, following inhibition of PLK1, monopolar 
spindles form due to defective centrosome separation, and cells arrest in mitosis 
(Connell et al., 2017, Kiyomitsu & Cheeseman, 2012). Whilst the exact PLK1-dependent 
substrate landscape is not fully elucidated, many proteins involved in centrosome 
function and microtubule dynamics have been reported (Park et al., 2010, Santamaria, 
Wang et al., 2011). Recent attempts at defining the optimal PLK1 substrate motif have 
been made, with (E/D/Q)-X-(S/T)-Ø, where Ø denotes a hydrophobic amino acid, 
emerging as the putative consensus motif (Barr et al., 2004).  
 In mitotic cells, PLK1 also associates with kinetochores, the centromere-
associated protein complexes to which microtubules attach that are required for 
chromosome segregation, during the latter stages of cell division (Arnaud et al., 1998, 
Barr et al., 2004). Kinetochores can sense unattached chromosomes, and even one 
unattached chromosome can trigger a checkpoint mechanism known as the spindle 
assembly checkpoint (SAC) (Musacchio, 2015). The localisation of PLK1 to kinetochores 
thus suggests a role for PLK1 in kinetochore assembly, regulation of kinetochore-
microtubule connections, and/or modulation of the SAC. CDK1 has been suggested as a 
priming kinase for PBD-mediated PLK1 recruitment (Barr et al., 2004), but whether this 
holds true for the kinetochore-localised PLK1 remains unclear, as CDK1/Cyclin B activity 
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would be reduced at this stage of mitosis. Thus, other kinases may act in this capacity, 
and thereby promote localised PLK1 activity in mitosis. 
 
1.2.1.3: Aurora kinases: 
 The aurora gene was first identified in the late 1980s in a Drosophila screen 
aimed at identifying genes whose products control cell cycle progression (Glover, 1989, 
Glover, 1991, Glover, Leibowitz et al., 1995). Since the discovery of homologues in other 
species, the Aurora kinases (AURKs) have emerged as central players in cell division 
(Carmena, Ruchaud et al., 2009). AURKs are thus highly conserved, and present with 
similar domain architecture between homologues (Ke, Dou et al., 2003). AURKs possess 
an N-terminal domain, a Ser/Thr protein kinase domain, and a C-terminal domain 
(Bolanos-Garcia, 2005). The N- and C- terminal domains are thought to be important in 
regulating AURK stability, as well as in determining the interaction partners of distinct 
AURK members (Bolanos-Garcia, 2005). 
In humans there are three AURKs, designated AURKA, B and C, and they have 
different localisation profiles (Nigg, 2001). AURKA localises to the duplicated 
centrosomes at the start of S phase, and shifts to bipolar spindle microtubules during 
mitosis (Bischoff & Plowman, 1999, Giet & Prigent, 1999). AURKB, on the other hand, 
localises to chromosomes in prophase, the centromere in prometaphase and 
metaphase, before shifting to the central spindle in anaphase and the mid-body in 
cytokinesis (Bischoff & Plowman, 1999, Giet & Prigent, 1999). The least-studied family 
member, AURKC, is localised to chromosomes during mitosis, and, unlike AURKA and B, 
is principally expressed in the male and female germline of mammals (Carmena et al., 
2009, Wang, Jiang et al., 2014).   
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Interestingly, AURKs have distinct modes of regulation through binding different 
regulatory proteins. For example, following nuclear envelope breakdown, AURKA is 
recruited to spindle microtubules by binding the microtubule-associated protein 
targeting protein for Xklp2 (TPX2), where TPX2 serves the additional purpose of 
allosterically activating AURKA (Carmena et al., 2009, Chen, Mohan et al., 2014, Kufer, 
Sillje et al., 2002). At this time point, AURKA activity is required for spindle assembly and 
spindle microtubule dynamics. AURKB is a component of the chromosome passenger 
complex (CPC), which consists of three AURKB-regulatory proteins termed inner 
centromere protein (INCENP), borealin and survivin (Kelly, Sampath et al., 2007, Vader, 
Kauw et al., 2006a, Vader, Medema et al., 2006b). INCENP, borealin and survivin all act 
as both targeting and activating subunits of AURKB (Kelly et al., 2007, Vader et al., 2006a, 
Vader et al., 2006b). The CPC has been linked to correction of microtubule-chromosome 
attachment errors, and activation of the SAC (Vader et al., 2006b). Interestingly, a single 
amino acid change in human AURKA (G198N) renders the kinase AURKB-like, promoting 
localisation to chromosomes and interaction with INCENP and survivin. Curiously, this 
AURKA mutant was able to rescue mitotic defects resulting from AURKB knockdown (Fu, 
Bian et al., 2009, Hans, Skoufias et al., 2009).  
Additionally, centrosomal AURKA was shown to be activated and localised by the 
protein Bora, a highly-conserved AURKA-interacting protein originally identified due to 
its phenotypic similarity to AURKA (Hutterer, Berdnik et al., 2006). Bora-depleted cells 
frequently present with multipolar mitotic spindles, an effect reminiscent of TPX2 
knockdown. Thus, Bora is thought to be a key AURKA activator in cells (Hutterer et al., 
2006). The AURKA-Bora complex was suggested to be the upstream PLK1-activating 
kinase, thereby illustrating some of the crosstalk evident in mitotic kinase regulation 
(Macurek et al., 2008). 
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1.2.1.4: Kinetochore kinases: 
 Given the name kinetochore by Lester Sharp in the 1930s, kinetochores are the 
power-generating business ends of chromosomes during mitosis (Sharp, 1934). In their 
capacity to bridge spindle microtubules to chromosomes, kinetochores are key focal 
points of phosphorylation-mediated regulation, for both the SAC and cell cycle 
progression (London & Biggins, 2014, Sacristan & Kops, 2015). The kinases CDK1, PLK1 
and AURKB discussed above have all been implicated in the regulation of the SAC and 
subsequent attachment error-correction (Sacristan & Kops, 2015). However, two other 
kinases have critical roles in the SAC and their roles and regulation will be subsequently 
explored. 
 The transition to anaphase is triggered by the E3 ligase anaphase-promoting 
complex/cyclosome (APC/C), which acts to ubiquitinate inhibitors of mitotic exit (cyclin 
B) and of chromosome segregation (securin), thereby marking them for proteolysis 
(Chang et al., 2003, Pines, 2011). Thus, when an attachment error is created, the SAC 
acts to inhibit the APC/C, and in doing so, prevents the metaphase-to-anaphase 
transition. The kinetochore-localised multi-protein complex responsible for the 
inhibition of APC/C in response to attachment error is called the mitotic checkpoint 
complex (MCC) (Sacristan & Kops, 2015). The MCC assembles on unattached 
kinetochores, and following its assembly, is free to diffuse throughout the cell to inhibit 
the APC/C (Sacristan & Kops, 2015). MCC assembly is coordinated by the kinase 
monopolar spindle 1 (Mps1), and Mps1 activity drives the recruitment of SAC proteins 
such as the kinase budding uninhibited by benzimidazoles 1 (BUB1), the regulatory 
proteins BUB3, mitotic arrest-deficient 1 (Mad1), Mad2, the APC/C co-activator cdc20, 
and the pseudokinase BUB-related 1 (BUBR1) (Kemmler, Stach et al., 2009, Murray, 
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2011, Nijenhuis, von Castelmur et al., 2013, Vleugel, Hoogendoorn et al., 2012). Mps1 is 
thus the master regulator of the SAC. 
 Mps1 is activated by autophosphorylation upon its localisation to kinetochores, 
which is regulated by AURKB, again illustrating some of the cross-talk evident between 
mitotic kinases (Kang, Chen et al., 2007, Santaguida, Vernieri et al., 2011, Saurin, van der 
Waal et al., 2011). Mps1 is then in a position to efficiently recruit the MCC, including the 
BUB1 kinase. The importance of BUB1 is perhaps best showcased in yeast-centred 
experiments, where deletion of BUB1 in S. pombe increases the rate of chromosome 
missegregation, and deletion of BUB1 in S. cerevisiae causes slow growth and 
chromosome loss (Bernard, Hardwick et al., 1998, Warren, Brady et al., 2002). BUB1 is 
also required for the kinetochore localisation of MAD1, MAD2 and BUBR1, following its 
recruitment by Mps1 (Klebig, Korinth et al., 2009). BUB1 has been linked to the 
phosphorylation and subsequent inhibition of cdc20, thereby providing a mechanistic 
insight into how the SAC acts to inhibit the APC/C following chromosome attachment 
error (Reddy, Rape et al., 2007, Tang, Shu et al., 2004).  
 
1.2.1.5: Underappreciated mitotic kinases: 
 Whilst research has primarily focussed on the roles and regulation of the 
conventional mitotic kinase families mentioned above, it is beginning to be appreciated 
that these kinase families alone, cannot account for the full extent of protein 
phosphorylation that is evident during mitosis (Ly et al., 2017, Malik, Lenobel et al., 
2009, Malik, Nigg et al., 2008, Nousiainen et al., 2006). Interestingly, a recent proteomic 
study sought to identify and assign cell cycle-regulated phosphopeptides to known 
kinases, based on the optimal consensus motifs present within the phosphopeptides (Ly 
et al., 2017). In this manner, whilst CDKs and PLKs were identified within the top ten 
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kinase families, the vast majority of phosphopeptides conformed to the predicted motifs 
for CK1, CK2, PKA and GSK3 kinases (Ly et al., 2017). Indeed, mitotic roles for some of 
these kinases, and others such as protein kinase C (PKC) and NIMA-related kinases 
(NEKs), have also been reported (Fry, Bayliss et al., 2017, Martini, Soliman et al., 2018, 
O'Regan, Blot et al., 2007, Saurin, Durgan et al., 2008). 
 Like CK1 (see section 1.2.4.4), CK2 isoforms are highly conserved, and are 
thought to be constitutively-active Ser/Thr protein kinases (Litchfield & Luscher, 1993). 
CK2 has been implicated in the regulation of chromosome condensation through the 
phosphorylation of condensin 1 (Takemoto, Kimura et al., 2006). CK2-mediated 
condensin 1 phosphorylation is thought to inhibit the action of condensin 1 during 
interphase, until the G2/M transition (Takemoto et al., 2006). Additionally, ablation of 
CK2 in S. cerevisiae was shown to block cell cycle progression through inhibition of the 
G1/S and G2/M transitions (Glover, 1998, Lorenz, Pepperkok et al., 1993, Pepperkok, 
Lorenz et al., 1994, Pepperkok, Lorenz et al., 1991). Interestingly, a subset of CK2 was 
shown to localise to the mitotic spindle apparatus through association with the peptidyl-
prolyl isomerase Pin1 (St-Denis, Bailey et al., 2011).  
 The mitotic role of GSK3 is beginning to be unravelled, particularly in the context 
of spindle microtubule regulation. GSK3 activity was shown to be required for the SAC, 
as GSK3 inhibition or its knockdown with RNAi reduced mitotic arrest in the presence of 
the SAC-inducing microtubule-stabilising agent taxol (Rashid, Mazur et al., 2018). GSK3 
inhibition has also been linked to defects in chromosome alignment and spindle 
dynamics (Wakefield, Stephens et al., 2003).  
 The role of PKC in mitosis is well-documented. PKCɛ was shown to regulate the 
process of cytokinesis, and inhibition of PKCɛ blocked cells in the final stages of 
separation (Saurin et al., 2008). At the molecular level, PKCɛ is phosphorylated by p38 
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MAPK, GSK3, and PKCɛ itself, and these phosphorylation events were shown to promote 
the association between PKCɛ and 14-3-3 binding proteins (Saurin et al., 2008). The 
interaction between PKCɛ and 14-3-3 was determined to be important in regulating this 
cytokinetic function of PKCɛ. More recently, PKCɛ was reported to impact the earlier 
stages of mitosis, with PKCɛ activity being linked to the coordination of mitotic spindle 
assembly and centrosome migration, through modulating dynein motor protein 
function (Martini et al., 2018).  
 The NEKs are a curious group of mitotic kinases. The founding member of this 
family was identified in the filamentous fungus Aspergillus nidulans, as part of a screen 
aimed at identifying regulators of the cell cycle (Morris, 1975). This screen identified two 
types of mutant: those that became blocked in mitosis (bim), or those that became 
blocked in interphase, and were never in mitosis (nim) (Morris, 1975). The first of the 
latter class was found to encode a Ser/Thr protein kinase, and was called nimA (Oakley 
& Morris, 1983, Osmani, McGuire et al., 1991, Osmani, May et al., 1987). NIMA-related 
kinases have since been identified in higher eukaryotes, and different NEKs have been 
attributed to different functions within the cell cycle (Fry et al., 2017, O'Regan et al., 
2007). For example, NEK2 localises to the centrosome and been linked to the regulation 
of centrosome separation, and a complex containing NEK6, 7 and 9 has been shown to 
coordinate spindle assembly (Fry et al., 2017, O'Regan et al., 2007). Thus, despite the 
name, NEKs do participate in mitosis, and are emerging as key regulators of cell division. 
 Thus, whilst CDKs, PLKs and Aurora kinases have been the main focus of research 
in terms of kinases coordinating cell division, the contribution of other kinase families 
to the phosphorylation-mediated control of mitosis cannot be ignored, and is beginning 
to be unravelled and appreciated.  
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1.2.2: Proteolytic control of mitosis: 
 Central to the progression of mitosis is the proteasomal-mediated degradation 
of cell cycle-regulated proteins. This is particularly evident in the metaphase-to-
anaphase transition, where the targeted degradation of specific proteins is critical for 
the segregation of sister chromatids, and subsequent progression through the cell cycle 
(Chang et al., 2003, Pines, 2011). Two different ubiquitin E3 ligase complexes are 
thought to be the main players coordinating the proteolysis of cell cycle-regulated 
proteins: the Skp1/Cullin/F-box (SCF) E3 ligase complex, and the APC/C.  
 The SCF is functional throughout the cell cycle, but its activity is most profound 
at the G1/S and G2/M boundaries where SCF-mediated ubiquitylation and subsequent 
degradation of proteins triggers these cell cycle phase transitions (Pintard, Willems et 
al., 2004). The APC/C on the other hand is mainly required within M phase, and acts to 
regulate the progression through and exit from mitosis. The APC/C will now be explored 
in more detail in the next section. 
 
1.2.2.1: The APC/C: 
 The APC/C is a large multi-protein complex, harbouring 14 subunits (Brown, 
VanderLinden et al., 2015, Chang, Zhang et al., 2014, Dube, Herzog et al., 2005). No clues 
about the biochemical functions of most of these subunits can be inferred from their 
sequence composition. However, two subunits termed Apc2 and Apc11 have homology 
with proteins involved in other ubiquitination systems. Apc2 resembles a cullin, and 
Apc11 shares homology with a really interesting new gene (RING)-H2 protein (Deshaies, 
1999, Gmachl, Gieffers et al., 2000, Yu, Peters et al., 1998). Thus, the Apc2-11 complex 
is thought to comprise the catalytic core of the APC/C. Despite containing a cullin 
subunit, substrate recognition by the APC/C is mediated through a different mechanism 
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to other cullin RING E3 ligases (CRLs). Two distinct co-activating proteins, Cdc20 and 
Cdh1, act to coordinate APC/C activity and substrate recognition at different stages of 
the cell cycle (Fang, Yu et al., 1998, Kramer, Gieffers et al., 1998, Sigrist & Lehner, 1997, 
Visintin, Prinz et al., 1997).  
 Cdc20 was originally identified in Drosophila as fizzy, a gene required for normal 
metaphase-to-anaphase transition (Dawson, Roth et al., 1993). Subsequently, fizzy 
mutants were shown to block the mitotic degradation of cyclins A and B, thereby 
implicating fizzy as a key regulator of mitotic cyclin stability (Dawson, Roth et al., 1995). 
Subsequently, a distinct Drosophila protein was identified that shared significant 
homology to Fizzy, and was termed Fizzy-related. In contrast to Fizzy, Fizzy-related was 
required for cyclin removal during the G1 phase (Sigrist & Lehner, 1997). In higher 
eukaryotes, Fizzy-related is called Cdh1. Subsequent studies in yeast and humans 
determined that the Cdc20-associated APC/C complex was the principle driver of 
chromosome segregation in the metaphase-to-anaphase transition (Pines, 2011). 
 To avoid the catastrophic effects resulting from chromosome missegregation, 
APC/C-Cdc20 activity is tightly regulated. APC/C binds Cdc20 only in mitosis, once APC/C 
has been phosphorylated (Golan, Yudkovsky et al., 2002, Kraft, Herzog et al., 2003, 
Kramer, Scheuringer et al., 2000, Lahav-Baratz, Sudakin et al., 1995). Even then, as 
detailed above (see section 1.3.1.4), the SAC can inhibit APC/C-Cdc20 activity until all 
chromosomes are correctly bioriented (Musacchio, 2015). Following APC/C-Cdc20-
mediated ubiquitination of B-type cyclins, which inhibits the kinase activity of CDK1, and 
of securin, an inhibitor of the protease separase, the subsequent proteolysis of securin 
activates separase and triggers sister chromatid separation through cleavage of cohesin 
(Figure 1-10) (Primorac & Musacchio, 2013). Cohesin is a component of the protein 
complex that mediates sister chromatid cohesion, thus its proteolysis promotes rapid  
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Figure 1-10: Modes of regulation of the anaphase-promoting complex/cyclosome 
(APC/C): When a kinetochore is unattached to a chromosome, the spindle assembly 
checkpoint (SAC), consisting of the proteins Mad2, Mad3, BUB1, BUB3 and BUBR1, is 
activated and sequesters the APC/C coactivator Cdc20. In the absence of Cdc20 binding, 
the APC/C substrates securin and cyclin B are stabilised, leading to inhibition of 
separase, and maintenance of CDK1-cyclin B activity respectively. CDK1-cyclin B 
phosphorylates the APC/C coactivator Cdh1 to inhibit it during this time. Once all 
kinetochores are engaged with the chromosomes, the SAC is turned off, and Cdc20 
associates with APC/C leading to APC/C activation. APC/C-Cdc20 ubiquitinates securin 
and cyclin B, leading to cohesin cleavage by separase, and inhibition of CDK1/cyclin B 
activity respectively. Following mitotic exit, Cdh1 associates with APC/C, and APC/C-
Cdh1 ubiquitinates Cdc20 and other target proteins such as PLK1 and AURKA.  
 
 
chromosome segregation. In contrast, the APC/C-Cdh1 complex is active throughout G1 
and in post-mitotic cells (Peters, 1998). 
 The E3 ligase activity of the APC/C is tightly coordinated to ensure that specific 
APC/C substrates are only degraded at the appropriate times during the cell cycle. The 
formation of both APC/C-Cdc20 and APC/C-Cdh1 complexes are subject to regulation by 
mitotic kinases (Golan et al., 2002, Kraft et al., 2003, Kramer et al., 2000, Lahav-Baratz 
et al., 1995). Phosphorylation of APC/C by CDK1 and PLK1 is thought to increase Cdc20 
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binding, and subsequently promote more APC/C E3 ligase activity (Golan et al., 2002, 
Kraft et al., 2003, Kramer et al., 2000, Lahav-Baratz et al., 1995). In contrast, CDK1-
mediated phosphorylation of Cdh1 inhibits APC/C-Cdh1 binding, and thereby prevents 
Cdh1-induced activation of the APC/C in mitosis (Blanco, Sanchez-Diaz et al., 2000, 
Kramer et al., 2000, Zachariae, Schwab et al., 1998). Thus, during the metaphase-to-
anaphase transition, where APC/C-Cdc20 activity results in the degradation of cyclin B 
and a concurrent reduction in CDK1 activity, CDK1-mediated Cdh1 phosphorylation is 
also reduced, allowing APC/C-Cdh1 complex formation following mitotic exit. 
Furthermore, a key APC/C-Cdh1 substrate during G1 is Cdc20, and Cdc20 proteolysis 
allows efficient APC/C-Cdh1 assembly, and prevents premature progression through the 
cell cycle (Robbins & Cross, 2010). The binding of Cdc20 or Cdh1 to APC/C, in addition 
to promoting activation of APC/C, is also thought to control substrate recognition (Pines, 
2011). Once bound to APC/C, these coactivators act to recruit substrates through their 
WD40 propeller domains. The WD40 domains recognise degron sequences in target 
proteins, such as the destruction (D) and KEN boxes (Pines, 2011). Once recruited to the 
APC/C, the substrates are ubiquitinated, promoting their proteasomal degradation 
(Pines, 2011).  
 Thus, there is an important interplay between the processes of ubiquitination 
and phosphorylation in mitosis, and these processes are tightly controlled to ensure the 
error-free transition through the cell cycle.  
 
1.2.3: Mechanisms of spindle positioning: 
 During mitosis, all animal cells establish a microtubule-based, diamond-shaped 
structure, known as the mitotic spindle (Figure 1-11). The central organiser of the 
spindle is the centrosome, from which microtubules are nucleated. Microtubules  
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Figure 1-11: Schematic overview of the cell division machinery: Centrosomes are 
anchored to the cell cortex by astral microtubules (astral MTs), and to the chromosomes 
by kinetochore microtubules (K-fibers). Kinetochores are the chromosome-associated 
protein complex to which K-fibers bind. The cell adheres to the extracellular matrix 
through the action of retraction fibers.  
 
 
emanating from the centrosome towards the chromosomes are called kinetochore 
microtubules, as they bind the kinetochores of sister chromatids (Figure 1-11). 
Microtubules emanating from the centrosome towards the cell cortex, an actin-rich 
cytoskeleton beneath the plasma membrane, are known as astral microtubules (Figure 
1-11). Astral microtubules are important in propagating the force required to pull apart 
the sister chromatids during the metaphase-to-anaphase transition (Grill & Hyman, 
2005, Siller & Doe, 2009).  
 As correct and efficient positioning of the mitotic spindle determines the axis of 
cell division, and is critically important in both development and in the maintenance of 
healthy adult tissues (Bergstralh, Dawney et al., 2017, Gonczy, 2008, Kiyomitsu & 
Cheeseman, 2012, Lu & Johnston, 2013), mechanisms regulating spindle orientation 











established of these spindle positioning mechanisms will now be examined in the 
following sections. 
 
1.2.3.1: Cortical pulling: 
 One of the major pathways contributing to spindle positioning in metazoans 
depends on forces generated at the cell cortex acting on astral microtubules, and thus 
centrosomes, which literally pull the spindle at both ends to establish correct spatial 
positioning. At the molecular level, seminal work in Caenorhabditis elegans identified 
that these pulling forces are primarily generated by a conserved protein complex 
composed of a large coiled-coil protein called LIN5 (abnormal cell lineage 5), two near-
identical tetratricopeptide and GoLoCo domain-containing proteins (GPR1/2), and 
heterotrimeric G protein alpha subunits (Gα) (Gotta, Dong et al., 2003, Grill, Howard et 
al., 2003, Park & Rose, 2008). Gα is localised to the plasma membrane through the 
process of myristoylation, and as such, the whole LIN5-GPR1/2-Gα complex is recruited 
to the cell cortex beneath the plasma membrane (Park & Rose, 2008). In higher 
eukaryotes such as humans, LIN5 is known as nuclear mitotic apparatus (NuMa), and 
GPR1/2 is called LGN (thus named for its 10 Leu-Gly-Asn repeats). NuMa directly 
associates with the minus-end directed motor protein dynein to promote dynein 
recruitment to the cell cortex (Kotak, Busso et al., 2012, Nguyen-Ngoc, Afshar et al., 
2007, Okumura, Natsume et al., 2018). This cortically-anchored dynein is then thought 
to generate pulling forces on the astral microtubules, to promote spindle positioning 
(Figure 1-12). In mammals, NuMa/dynein levels are drastically enriched at the cell cortex 
as the cell progresses from metaphase into anaphase (Kiyomitsu & Cheeseman, 2013, 





















Figure 1-12: Mechanisms of spindle positioning in mammals: A: Spindle pole-localised 
PLK1 negatively regulates dynein/dynactin localisation at the cell cortex, downstream of 
dynein recruitment to the cortex by LGN/NuMa. Simultaneously, RAN-GTP gradient 
emanating from the chromatin negatively regulates NuMa/LGN localisation to 
midcortical regions, creating LGN/NuMa/Dynein asymmetry. Forces pulling on astral 
microtubules (MTs) generated by dynein motor complexes, and extrinsic forces from 
retraction fibers help position the mitotic spindle. B: If a spindle pole gets too close to 
the cortex on one side, PLK1 activity strips the dynein motor complexes from the 
adjacent cortex, resulting in greater net pulling forces on the opposite side of the cell, 
causing the spindle to be pulled close towards the opposite cortex. Following 


























This intrinsic mechanism of spindle positioning is also subject to post-
translational control. Of note and of relevance here, the spindle-pole localised kinase 
PLK1 has been strongly implicated in spindle orientation (Connell et al., 2017, Kiyomitsu 
& Cheeseman, 2012, Tame, Raaijmakers et al., 2016). The current model proposes that 
when the spindle pole gets too close to the cell cortex (too much pulling force in one 
direction), the spindle pole-localised PLK1 activity acts to strip cortical dynein, thereby 
reducing the pulling forces emanating from that near-cortex (Kiyomitsu & Cheeseman, 
2012) (Figure 1-12). Pulling forces on the opposite spindle pole are therefore now 
greater, and the spindle is pulled closer towards the centre, before the dynein 
complexes are re-localised to the recently-depleted cortex (Kiyomitsu & Cheeseman, 
2012) (Figure 1-12). This elegant mechanism thereby acts to keep the spindle in a 
constant dynamic equilibrium, and acts to ensure the axis of division is precisely defined. 
 
1.2.3.2: Extrinsic mechanical forces: 
 Even though mammalian cells appear rounded as they enter mitosis, they still 
remain attached to the underlying substrate through the action of so-called retraction 
fibers, defined as membranous outgrowths containing dense actin filaments (McNally, 
2013). Intriguingly, when HeLa cells were grown on different shapes of fibronectin-
based micropatterns, cells adapted to these shapes, yet still divided along the long axis 
as determined by the interphase geometry of the micropattern (Thery, Racine et al., 
2005). Thus, the external environment appears to critically influence the positioning of 
the mitotic spindle. 
 As there was a good correlation between the organisation of the retraction 
fibers, and the geometry of the micropattern, it was hypothesised that retraction fibers 
might be instrumental in this extrinsic control of spindle positioning (Thery, Jimenez-
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Dalmaroni et al., 2007, Thery et al., 2005). Indeed, laser-induced severing of retraction 
fibers abolished the cells ability to effectively orientate their spindles, in a manner 
dependent on astral microtubules (Fink, Carpi et al., 2011). Thus, external forces 
controlled through the action of retraction fibers appear to rely on internal astral 
microtubules to coordinate spindle positioning, suggesting that the external information 
is being relayed intracellularly. Subcortical actin clouds have been proposed to mediate 
this relay function, but this is still a topic of active research (Fink et al., 2011). 
 Importantly, the NuMa-LGN-Gα complex is also required for spindle positioning 
when cells are grown on fibronectin-coated micropatterns (Kiyomitsu & Cheeseman, 
2012, Kotak, Busso et al., 2014), and the localisation of the NuMa-LGN-Gα complex is 
linked to the organisation of retraction fibers during metaphase (Machicoane, de Frutos 
et al., 2014, Tame et al., 2016). Thus, mounting evidence suggests that the intrinsic 
cortical pulling machinery can also detect and integrate information from the extrinsic 
retraction fibre cues.  
 
1.2.3.3: Chromosomal Ran-GTP gradient: 
 For the intrinsic and extrinsic spindle positioning mechanisms described above 
to function, the NuMa-LGN-Gα complex cannot be localised to the entire cell cortex. 
Indeed, the NuMa-LGN-Gα complex has been found primarily on cortical regions near 
the spindle poles, and excluded from midcortical regions near the spindle midzone, 
which is in proximity to the chromosomes (Kiyomitsu & Cheeseman, 2012). Thus, it was 
reasoned that a midzone- or chromosome-derived signal was responsible for excluding 
the NuMa-LGN-Gα complex from these cortical regions (Kiyomitsu & Cheeseman, 2012). 
Through a series of elegant experiments involving the manipulation of chromosome 
position during mitosis, it was found that a chromosome-derived signal is responsible 
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for removing NuMa-LGN-Gα complexes from the midzone cell cortex (Kiyomitsu & 
Cheeseman, 2012). Subsequent investigation found that the chromosome signal 
responsible for this NuMa-LGN-Gα exclusion, was the Ras-related GTPase Ran 
(Kiyomitsu & Cheeseman, 2012) (Figure 1-12). 
 The cycling of Ran between its GTP- and GDP-bound forms is coordinated, like 
most GTPases, by a guanine nucleotide exchange factor (GEF), and a GTPase-activating 
protein (GAP) (Kalab & Heald, 2008). In the case of Ran, the RanGAP is cytoplasmic, and 
the RanGEF is nuclear and localises to chromatin. The RanGEF is called regulator of 
chromatin condensation 1 (RCC1), and RCC1 promotes the Ran-GTP conformation 
(Klebe, Prinz et al., 1995). As RCC1 is on chromatin, the ratio of RanGTP/RanGDP is much 
higher on chromatin than in the cytoplasm. As a consequence of this, the RanGTP 
gradient emanates from the chromosomes, and diminishes as the signal diffuses away 
from the chromatin (Klebe et al., 1995). This RanGTP gradient was found to be 
instrumental in restricting the localisation of the NuMa-LGN-Gα complex to the cell 
cortex, and thus is a key determinant of correct and efficient spindle positioning 
(Kiyomitsu & Cheeseman, 2012). However, the molecular details surrounding how 
RanGTP can accomplish this function remain to be defined. 
 Collectively, there appears to be multiple mechanisms coordinating spindle 
positioning in mammals (Figure 1-12), and they likely act cooperatively to ensure proper 
spindle orientation in response to mechanical, environmental and spatio-temporal 
signals. Whilst the general framework of spindle positioning has been well established, 
the molecular details remain to be fully elucidated, and there is scope for many new 
players to have a role in this vital physiological process. In line with this, in this thesis, I 
report the involvement of the kinase CK1α and an associated regulatory protein termed 
FAM83D, in spindle positioning. Whilst CK1 has been extensively studied (see chapter 
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1.2), FAM83D remains relatively uncharacterised. FAM83D belongs to the FAM83 family 
of proteins, which will be discussed further in the following section. 
 
1.3: FAM83 proteins: 
1.3.1: Overview of the FAM83 family of proteins: 
The FAMily of sequence similarity 83 (FAM83) group of proteins consists of eight 
members, designated FAM83A-H. Each FAM83 protein is encoded by a distinct gene 
and, interestingly, the genes encoding the FAM83 proteins are only found in vertebrates 
(Bartel, Parameswaran et al., 2016, Cipriano, Miskimen et al., 2014b). FAM83 proteins 
are classified based on the presence of a conserved, globular, domain of unknown 
function (termed DUF1669, aka Pfam PF07894) within their N-termini (Bozatzi & 
Sapkota, 2018, Cipriano et al., 2014b) (Figure 1-13). Outside of this domain, the C-
termini are not conserved between FAM83 members, and differ in both their length 
(Figure 1-13) and sequence composition (Bozatzi & Sapkota, 2018, Cipriano et al., 
2014b) (Figure 1-14). By definition, domains are functional and/or structural units of a 
protein (Ponting & Russell, 2002). Thus, grouping proteins together based on the 
presence of a conserved domain such as the DUF1669, can potentially provide clues into 
their functions and facilitate hypothesis-driven research into the role of those domain-
containing proteins. With this notion in mind, deciphering the biochemical role of the 
DUF1669 will be a prerequisite in determining the cellular functions of FAM83 members.  
Annotation databases such as UniProt suggest that, within the DUF1669, there 
is a single, short stretch of amino acids that resembles the catalytic motif of the 
phospholipase D (PLD) enzyme (Bartel et al., 2016, Bozatzi & Sapkota, 2018). The 





Figure 1-13: Schematic overview of the FAM83 family of proteins: The relative size and 
location of the conserved N-terminal domain of unknown function 1669 (DUF1669) for 
the human FAM83 proteins is highlighted in blue, and the non-conserved C-termini are 
in grey. The scale at the bottom refers to protein length in amino acids. The putative 
phospholipase D-like catalytic motif (PLDc) is highlighted in red. 
 
 
X-X-D/E (hereafter referred to as HKD motif), where x is any amino acid (Selvy, Lavieri et 
al., 2011, Sung, Roper et al., 1997). With the exception of PLD6 which has only one HKD 
motif, PLD1-5 present with two HKD motifs within a single polypeptide (Figure 1-15), 
and both are crucial for maximal catalytic activity (Choi, Huang et al., 2006, Selvy et al., 
2011). PLD6 is phylogenetically closer to the bacterial endonuclease Nuc, which 
interestingly also contains a single HKD motif (Choi et al., 2006) (Figure 1-15). The crystal 
structure of Nuc revealed that Nuc dimerises in order to form a functional complex 
(Stuckey & Dixon, 1999). Whilst dimerisation, either between the two HKD motifs of a 
single PLD enzyme or between HKD motifs of distinct PLD enzymes, has also been 
suggested to be a prerequisite for PLD activity (Kam & Exton, 2002), this has yet to be 
determined with structural studies.  
PLDs act to hydrolyse the most abundant membrane lipid phosphatidylcholine, 
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FAM83B    1 ---------METSSML-----SSLND---ECKSDNY-I--EPHYKEWYRVAIDILIEHGLEAYQEFLVQERVSDFLAEEEINYILKNVQK 
FAM83H    1 --------------MARRSQSSSQGD---NPLAPGY-L--PPHYKEYYRLAVDALAEGGSEAYSRFLATEGAPDFLCPEELEHVSRHLRP 
FAM83E    1 --------------MAA-SQLAALEGVDSGPRVPGASP--GFLYSEGQRLALEALLSKGAEAFQTCVQREELWPFLSADEVQGLAAAAED 
FAM83F    1 --------------MAE-SQLNCLDEAHVNEKVTEAQA--AFYYCERRRAALEALLGGGEQAYRERLKEEQLRDFLSSPERQALRAAWSP 
FAM83G    1 --------------MAF-SQVQCLDDNHVNWRSSESKP--EFFYSEEQRLALEALVARGRDAFYEVLKRENIRDFLSELELKRILETIEV 
FAM83D    1 ---------------MA-LLSEGLDEVPAACLSPCGPPNPTELFSESRRLALEELVAGGPEAFAAFLRRERLARFLNPDEVHAILRAAER 
FAM83A    1 ---------MSRSRHLG-KIRKRLEDVKSQWVRPAR-A--DFSDNESARLATDALLDGGSEAYWRVLSQEGEVDFLSSVEAQYIQAQARE 
FAM83C    1 MFGGPGPGVLGAQGMAG-PLRGRVEELKLPWWRESSPL--VLRHSEAARLAADALLERGEAAYLRVISEERELPFLSALDVDYMTSHVRG 
 
 
FAM83B   71 VAQSTA----------------------H--GTDDSCDDTLSSGTYWPVESDVEAPNLDLGWPYVMPGLLGGT-HIDLLFHPPRA---HL 
FAM83H   71 PQYVTREPPE---------------------GSLLDVDMDGSSGTYWPVNSDQAVPELDLGWPLTF--GFQGTEVTTLVQPPPPDS---- 
FAM83E   74 WTVAKQEPSGMA-------------------EGATTTDVDAGSLSYWPGQSEQPAPVLRLGWPVDS--AWKGITRAQLYTQPPGEG--Q- 
FAM83F   74 YEDAVPAANARGKS------------KAKAKAPAPAPAESGESLAYWPDRSDTEVPPLDLGWTDTG--FYRGVSRVTLFTHPPKDE--KA 
FAM83G   74 YDPGSEDPRGTGPSQGPEDNGVGDGEEASGADGVPIEAEPLPSLEYWPQKSDRSIPQLDLGWPDTI--AYRGVTRASVYMQPPIDG--Q- 
FAM83D   75 PGEEG---------AA---------AAAAA-EDSFGSSHDCSSGTYFPEQSDLEPPLLELGWPAFYQGAYRGATRVETHFQPRGAGEGGP 
FAM83A   78 PPCPP-------DTLG---------GAEAG-PKGLDS-SSLQSGTYFPVASEGSEPALLHSWASAEKPYLKEKSSATVYFQTVKH----- 
FAM83C   88 GPELS-------EAQG---------QEASG-PDRLSLLSEVTSGTYFPMASDIDPPDLDLGWPEVPQATGFSPTQAVVHFQRDKA----- 
 
 
FAM83B  133 LTIKETIRKMIKEARKVIALVMDIFTDVDIFKEIVEAST-RGVSVYILLDESNFNHFLNMTEKQGCSVQRLRNIRVRTVKGQDYLSKTGA 
FAM83H  134 PSIKDEARRMIRSAQQVVAVVMDMFTDVDLLSEVLEAAA-RRVPVYILLDEMNAQHFLDMADKCRVNLQHVDFLRVRTVAGPTYYCRTGK 
FAM83E  140 PPLKELVRLEIQAAHKLVAVVMDVFTDPDLLLDLVDAATRRWVPVYLLLDRQQLPAFLELAQQLGVNPWNTENVDVRVVRGCSFQSRWRR 
FAM83F  148 PHLKQVVRQMIQQAQKVIAVVMDLFTDGDIFQDIVDAACKRRVPVYIILDEAGVKYFLEMCQDLQLTDFRIRNIRVRSVTGVGFYMP-MG 
FAM83G  159 AHIKEVVRKMISQAQKVIAVVMDMFTDVDIFKDLLDAGFKRKVAVYIIVDESNVKYFLHMCERACMHLGHLKNLRVRSSGGTEFFTRSAT 
FAM83D  146 YGCKDALRQQLRSAREVIAVVMDVFTDIDIFRDLQEICRKQGVAVYILLDQALLSQFLDMCMDLKVHPEQEKLMTVRTITGNIYYARSGT 
FAM83A  145 NNIRDLVRRCITRTSQVLVILMDVFTDVEIFCDILEAANKRGVFVCVLLDQGGVKLFQEMCDKVQISDSHLKNISIRSVEGEIYCAKSGR 
FAM83C  156 KNIKDLLRFLFSQAHTVVAVVMDIFTDMELLCDLMEASSRRGVPVYLLLAQEHLRHFLEMCYKMDLNGEHLPNMRVRSTCGDTYCSKAGR 
 
 
FAM83B  222 KFHGKMEQKFLLVDCQKVMYGSYSYMWSFEKAHLSMVQIITGQLVESFDEEFRTLYARSCVPSSFAQEESARVKHGKALW-ENGTYQHSV 
FAM83H  223 SFKGHVKEKFLLVDCAVVMSGSYSFMWSFEKIHRSLAHVFQGELVSSFDEEFRILFAQSEPLVPSAAALARMDAYALAPYAGAGPLV-GV 
FAM83E  230 QVSGTVREKFVLLDGERVISGSYSFTWSDARLHRGLVTLLTGEIVDAFSLEFRTLYAASCPLPPA-------PPQKPSVI----GG---L 
FAM83F  237 RIKGTLSSRFLMVDGDKVATGSYRFTWSSSHVDRNLLLLLTGQNVEPFDTEFRELYAISEEVDLYR----------QLSLAGRVGL---H 
FAM83G  249 KFKGALAQKFMFVDGDRAVCGSYSFTWSAARTDRNVISVLSGQVVEMFDRQFQELYLMSHSVSLKGIPMEKEPEPEPIVLPSVVPL---V 
FAM83D  236 KIIGKVHEKFTLIDGIRVATGSYSFTWTDGKLNSSNLVILSGQVVEHFDLEFRILYAQSKPISPKLLS----------HFQSSNKFDH-- 
FAM83A  235 KFAGQIREKFIISDWRFVLSGSYSFTWLCGHVHRNILSKFTGQAVELFDEEFRHLYASSKPVMGLKSP------RLVAPVPPGAA----- 
FAM83C  246 RFTGQALEKFVLIDCEQVVAGSYSFTWLCSQAHTSMVLQLRGRIVEDFDREFRCLYAESQPVEGFCGGEDPLSPRALRPPPVALAFRPDV 
 
 
FAM83B  311 SSLASV--SSQRNLFGRQD--KIHKLDSSYFKNRGIYT----LNEHDKYNIRSHG----------------YKPHFVP------------ 
FAM83H  312 PGVGAPTPFSFPK--------RAHLLFPPPREEGLGFPSFLD----PDR----HFLSAFRREEPPRMPGGALEPHAGLRPLSRRLEAE-- 
FAM83E  306 QRGRSPHRVSRRR--------SVAPASPPPP-D--------G----PLA----HRLAACRVSPATPGP--------ALSDILRSVQRA-- 
FAM83F  314 YSSTVAR-----K--------LIN----------------------PKY----ALVSGCRHPPGEMMR--------WAARQQR--EAG-- 
FAM83G  336 PAGTVAK-----K--------LVN----------------------PKY----ALVKAKSVDEI--AK--------ISSEKQ----EA-- 
FAM83D  314 --LTNRKPQSKELTLGNLLRMRLARLSSTPRKADLD-PEMPAEGKAE------RKPHDCESS--TVSEEDYFSSHRDELQSRKAIDAATQ 
FAM83A  314 -PANGRLSSSSGSA--------SDRTSSNPFSGRSA-------GSHPGTRSVSASSGPCSPAAPHPPPPPRFQPHQGPWG-APSPQAHLS 
FAM83C  336 PSPTSSLPSSTS----------LSSIKQSPLMGRSSYLALPGGGDCSDTGVVSSSLGPARREA---------------SG-QPSLHRQLS 
 
 
FAM83B  365 --NFNGP-----NAIRQFQP---NQINENWKRHSYAGEQPETVPYLLLNRALNR----------TNNPPGNWKKPSD------------- 
FAM83H  384 ----AGPAGELAGARGFFQARHLE--MDAFKRHSFATEGAGAVENFAAARQV--SRQTFLSHGDDFRFQTSHFHRDQ----------LYQ 
FAM83E  361 ----RTPSG--PPARPSRSMWDL----SRLSQLS------GSSDG-------------------DNELKKSWGSKD-TPAKAL------- 
FAM83F  353 ----GNPEGQEEGASGGESAWRL----ESFLKDL------VTVEQVLPPVEPIPLGELSQKDGRMVSHMHRDLKPKSREAPS-------- 
FAM83G  371 ----KKPLGLKGPA---------------LAEHP------GELPELLPPIHPGL---LHLERANMFEYLPTWVEPDPEPGSDILGYINII 
FAM83D  393 TEPGEEMPGLSVSEVGTQTSITTAC----------AGTQTAVITRIAS------------------------------------------ 
FAM83A  387 PRPHDGPPAAVYSNLGAYRPTRLQ-----L-------EQLGLVPRLTPT----------------------------------------- 
FAM83C  400 DPNHGSPPGLYRANLGKLGAYPWSQSSPALNHNSTSPLTLAVGSPLLPR----------------------------------------- 
 
 
FAM83B  422 ----------S------LSVASSSREGYVSH-----------------------------------HNTPA---------------QSFA 
FAM83H  456 QQYQWDPQLTPARPQGLFEKLRGGRAGFADPDDFTLGAGPRFPELGPDGHQRLDYVPSSASREVRHGSDPAFAPGPRGLEPSGAPRPNLT 
FAM83E  408 ----------------MRQ------------------------------------------RGTG------------------------G 
FAM83F  421 --------RNG-----MGEAARG---------------------------------EAAPARRFS------------------------S 
FAM83G  433 DPNIWNPQPSQ-----MNRIKIR---------------------------------DTSQA-SAQ------------------------H 
FAM83D  431 ---------------------------------------------------------------------------------------SQT 
FAM83A  424 ----WRPFLQA---------S---------------PHF--------------------------------------------------- 
FAM83C  449 ----SRPLLQF---------HRGA------------PALSRFPENGLPGSQ---------------------------------EPSPLR 
 
 
FAM83B  446 NRLAQRKTTNLADR-NS--NVRRSFNGTDNHIRFLQ-QRMPTLEHTTKSFLRNWRIESYLNDH-SEATPD-------------------- 
FAM83H  546 QRFPCQAAARPGPDPAPEAEPE--------------RRGGPEG----RAGLRRWRLASYLSGCHGEDGGDDGLPAPMEAEAYEDDVLAPG 
FAM83E  416 GPWGEV------------------------------DSRPPWGGALPLPPAHRLRYLSPA-RR--RFGGDATFKL--------------- 
FAM83F  441 RLFSR-----RAKRPAAP-------------------NGM-------------------A-SSVSTETSEVEF----------------- 
FAM83G  460 QLWKQSQDSRPRPEPCPPPEPSAPQD----GVPA--ENGLPQGDPEPLPPVPKPRTVPVA-DVLARDSSDIGW----------------- 
FAM83D  434 TIWSRSTTTQ---------------TDMDENILFPRGTQSTEGSPVSK--MSVSRSSSLKSS---S-------------SVSSQGSVA-S 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C  481 GRWVPGTTLETVEEKEKKASPSQSRGQLDLLVPFPRARE--VGDPDSG--VTPN-SGPLRPG---E-------------QAPEDRRLSPS 
 
 
FAM83B  511 SN------------------------GSALG---DRFEGYDNPENLKAN--------ALYTHSRLRSSLVFKPTLPEQKEVNSCTTGSSN 
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Figure 1-14: Multiple sequence alignment of the human FAM83 proteins: The 
alignment was performed using Clustal Omega and visualised in boxshade. Shading 
indicates the % sequence similarity (black = identical, grey = similar; in more than 50% 
of sequences). The positions of the putative phospholipase D-like catalytic motifs 
(HXKXXXXD) are highlighted in purple. 
 
FAM83B  511 SN------------------------GSALG---DRFEGYDNPENLKAN--------ALYTHSRLRSSLVFKPTLPEQKEVNSCTTGSSN 
FAM83H  618 GRAPAGDLLPSAFRVPAAFPTKVPVPGPGSGGNGPEREGPEEPGLAKQDSFRSRLNPLVQRSSRLRSSLIFSTSQAEGAAGAA------- 
FAM83E  458 -------------QEPRGVRPSDWAPRAGLGGQP-------------------------------------------------------- 
FAM83F  470 ---------------LTGKRPNENSSADISGKTSPSSAKPSNCVIS-------------------------------------------- 
FAM83G  526 ---------------VLEL-PKEEAPQNGTDHRLPRMAGPGHAPLQRQLSVTQDD------PESL------GVGLPNGLDGVE------- 
FAM83D  490 STGSPASIRTTDF---------------HNP-GYPKYLGTPHLELYLSDSLRN------LNKERQ-----FHF---AGIRSRL------- 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C  550 QADSQLDLLSRAL---------------GTG-GAPELGSLRPGDRALEDRRLS------LNQSRGQSDLLMQYPKAQGSRVPLETNSSAR 
 
 
FAM83B  566 STIIGSQGSETPKEVPDTP-T-----NVQHLTD----------KPLPES------------------------IPKLPLQSEAPKMHTLQ 
FAM83H  701 -------------AATEK---------VQLLHKEQTVSE--TLGPGGE--AVRSAAS--------TKVAELLE----------------- 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G  581 -------------EEDDDD--------YVTLSDQDSHSGSSGRGPGPRRPSVASSVS--------EEYFEVREHS-VPLR----RRHSEQ 
FAM83D  543 -----------------------NH-MLAMLSRRTL---FTEN--------------HLGLHSGNFSRVNLLAVRDVALYPSYQ------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C  618 P----------ARRAPDERRQTLGHSQLDLITKFGP---FRGEGPGPNGLPISSPARTAGAGSGDEKRLTL-GHSKLDLITKYHQLHGAR 
 
FAM83B  616 VPENHSVALNQTTNGHTE-----SNNYIYKTLGVNKQTENL----------KNQQTENLLKRRSFPLFDNSKANLDPGNSKHYVYSTLTR 
FAM83H  740 KYKGPA----RDPGGGAG--AITVASHSK-AVVSQAWREEVAAPGAVGGERRSLESCLLDLRDSFAQQLHQEAERQPGAASLTAAQLLDT 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G  637 VANGPT----PPPRRQLSAPHITRGTFVG-PQGGSPWAQSRGREEADAL--KRMQAQRSTDKEAQGQQFHHHRV--PA------SGTRDK 
FAM83D      ------------------------------------------------------------------------------------------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C  694 QGTEPG----GPKGGHLN-----GGN-------SDLVRDE---------KRLTLGHSKLD--------------------------LITK 
 
 
FAM83B  691 N-----------------RVRQPEKPKEDLLKSSKSMHNVTHNLEEDEEEVTK---R--NSPSGTTTKSVSIAALLDVN----------- 
FAM83H  823 LGRSGSDRLPSRFLSAQSHSTSPQGLDSPLPLEGSGAHQVLHNESKGSPTSAYPERKGSPTPGFSTRRGSPTTGFIEQKGSPTSAYPERR 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G  712 DGFPGP----PRYRSAADSVQSS------TRNAGPAMAGPHHWQAKG-----------GQVPR-----------LLPDPGSP-------- 
FAM83D      ------------------------------------------------------------------------------------------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C  733 YNKSKFKQLRSRFES--------------------------------------------------------------------------- 
 
 
FAM83B  748 -----------------------------KEESNKELASKKEVKGSPSFLKKGSQKLRSLLSLTPDKKENLSKNKAPAFYRLCS-----S 
FAM83H  913 GSPVPPVPERRSSPVPPVPERRGSLTLTISGESPKAGPAEEGPSGPMEVLRKGSLRLRQLLSPKGERRME--D-E--GGFPVPQENGQPE 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G  762 -------------------------------------------------------RLAQNARPMTDGRAT--E-EHPSPFGIPYSKL--S 
FAM83D      ------------------------------------------------------------------------------------------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C      ------------------------------------------------------------------------------------------ 
 
 
FAM83B  804 SDTLVSEGEENQKPKKSDT-KVDSSPRRKHSSSSNSQGSIHKSKEDVTVSPSQEINAPPDENK--RTPSPGPVESKF-LERA--GDASAP 
FAM83H  998 SPRRLSLGQGDST----EAATEERGPRARLSSATAN-ALYSSNLRDDTKAILEQISAHGQKHRAVPAPSPGPTHNSPELGRPPAAGVLAP 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G  792 QSKHLKARTGGSQWASSDSKRRAQAPRDRKDP---------------------------------------------------------- 
FAM83D      ------------------------------------------------------------------------------------------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C      ------------------------------------------------------------------------------------------ 
 
 
FAM83B  888 RFNTE----QIQYRDSREINAVVTPERRPTSSPRPTSSELLRSHSTDRRVYSRFEPFCKIESSIQPTSNMPNTSINRPEIKSATMGNSYG 
FAM83H 1083 DMSDKDKCSAIFRSDSLGTQGRLSRTLPASAEERDRLLRRMESMRKEKRVYSRFEVFCKKEEASSPGAGEGPAEEGTR-------DSKVG 
FAM83E      ------------------------------------------------------------------------------------------ 
FAM83F      ------------------------------------------------------------------------------------------ 
FAM83G      ------------------------------------------------------------------------------------------ 
FAM83D      ------------------------------------------------------------------------------------------ 
FAM83A      ------------------------------------------------------------------------------------------ 
FAM83C      ------------------------------------------------------------------------------------------ 
 
 
FAM83B  974 RSSPLLNYNTGVYRSYQPNENKFRGFMQKFGNFIHKNK 
FAM83H 1166 K---FVPKILGTFKSKK--------------------- 
FAM83E      -------------------------------------- 
FAM83F      -------------------------------------- 
FAM83G      -------------------------------------- 
FAM83D      -------------------------------------- 
FAM83A      -------------------------------------- 
FAM83C      -------------------------------------- 
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converted to diacylglycerol through the action of phosphatidic phosphatase, and the 
resulting diacylglycerol serves to activate isoforms of the protein kinase C (PKC) family 
of kinases (Roffey, Rosse et al., 2009, Selvy et al., 2011). PLDs are thus involved in the 
regulation of phospholipid metabolism, and intracellular signal transduction (Jenkins & 
Frohman, 2005). In humans there are six PLD isoforms termed PLD1-6. PLD1 and 2 are 
ubiquitously expressed, whereas PLD3 and 4 are transmembrane proteins localised to 
the endoplasmic reticulum (Nelson & Frohman, 2015). PLD5 does not contain a HKD 
motif, and is thus thought to be catalytically-inactive (Nelson & Frohman, 2015). 
Intriguingly, PLD6, which harbours only a single HKD motif, localises to the mitochondrial 
network (Nelson & Frohman, 2015).  
The combination of biochemical and structural studies have led to a strong 
understanding of how PLD enzymes act to hydrolyse phosphatidylcholine (Selvy et al., 
2011). The histidine of the HKD motif mediates nucleophilic attack of the phosphate 
within phosphatidylcholine, yielding a covalent intermediate. The subsequent 
completion of the hydrolysis reaction is mediated by a water molecule (Selvy et al., 
2011). Alternatively, a primary alcohol can act on the covalent intermediate via a 
transphosphatidylation reaction (Selvy et al., 2011). Thus, due to this critical biochemical 
role, the histidine of the HKD motif is essential for enzymatic function, and is often 
mutated to an alanine in order to abolish PLD activity in functional studies of PLD 
enzymes.  
In the case of FAM83 proteins, which contain this PLD-like catalytic motif within 
their DUF1669, the histidine of the HKD motif is absent in all members apart from 
FAM83D, and the lysine of the HKD is substituted by an arginine in FAM83F (Figure 1-
12). Furthermore, there is only one HKD motif present in each FAM83 member, opposed 
to the two HKD motifs seen in most PLD isoforms, and outside this pseudo-PLD motif  
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Figure 1-15: Multiple sequence alignment of the human phospholipase D (PLD) 
proteins: The alignment was performed using Clustal Omega and visualised in boxshade. 
Shading indicates the % sequence similarity (black = identical, grey = similar; in more 
than 50% of sequences). The positions of the catalytic motifs (HXKXXXXD) are 
highlighted in red. 
PLD1    1 MSLKNEPRVNTSALQKIAADMSNIIENLDTRELHFEGEEVDYDVSPSDPKIQEVYIPFSAIYNTQGFKEPNIQTYLSGCPIKAQVLEVERFTSTTRVPSI 
PLD2    1 -------------MTATPESLFPTGDELDSSQLQMESDEVDTLKEGEDP--ADRMHPFLAIYELQSLKVHP-LVFAPGVPVTAQVVGTERYTSGSKVGTC 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5    1 ---------------------------------------------------------------------------------------------------- 
PLD3    1 ---------------------------------------------------------------------------------------------------- 
PLD4    1 ---------------------------------------------------------------------------------------------------- 
 
 
PLD1  101 NLYTIELTHGEFKWQVKRKFKHFQEFHRELLKYKAFIRIPIPTRRHTFRRQNVREEPREMPSLPRSSENMIREEQFLGRRKQLEDYLTKILKMPMYRNYH 
PLD2   85 TLYSVRLTHGDFSWTTKKKYRHFQELHRDLLRHKVLMSLLPLARFAVAYSPARDAGNREMPSLPRAGPEGST-RHAASKQKYLENYLNRLLTMSFYRNYH 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5    1 ---------------------------------------------------------------------------------------------------- 
PLD3    1 ---------------------------------------------------------------------------------------------------- 
PLD4    1 ---------------------------------------------------------------------------------------------------- 
 
 
PLD1  201 ATTEFLDISQLSFIHDLGPKGIEGMIMKRSGGHRIPGLNCCGQGRACYRWSKRWLIVKDSFLLYMKPDSGAIAFVLLVDKEFKIKVGKKETETKYGIRID 
PLD2  184 AMTEFLEVSQLSFIPDLGRKGLEGMIRKRSGGHRVPGLTCCGRDQVCYRWSKRWLVVKDSFLLYMCLETGAISFVQLFDPGFEVQVGKRSTEARHGVRID 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5    1 -----MEIRQHEWLSASPHEGFEQMRLKSRPKEPSP--SLT----------------------------------------------------------- 
PLD3    1 ---------------MKPKLMYQE--LKVPAEEPAN--ELP----------------------------------------------------------- 
PLD4    1 --------------------MLKP--LWKAAVAPTW--PCS----------------------------------------------------------- 
 
 
PLD1  301 NLSRTLILKCNSYRHARWWGGAIEEFIQKHGTNFLKDHRFGSYAAIQENALAKWYVNAKGYFEDVANAMEEANEEIFITDWWLSPEIFLKRPVVEGNRWR 
PLD2  284 TSHRSLILKCSSYRQARWWAQEITELAQGPGRDFLQLHRHDSYAPPRPGTLARWFVNGAGYFAAVADAILRAQEEIFITDWWLSPEVYLKRPAH-SDDWR 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5   35 ---------------------------------------------------------------------------------------------------- 
PLD3   23 ---------------------------------------------------------------------------------------------------- 
PLD4   18 ---------------------------------------------------------------------------------------------------- 
 
 
PLD1  401 LDCILKRKAQQGVRIFIMLYKEVELALGINSEYTKRTLMRLHPNIKVMRHPDHVSSTVYLWAHHEKLVIIDQSVAFVGGIDLAYGRWDDNEHRLTDVGSV 
PLD2  383 LDIMLKRKAEEGVRVSILLFKEVELALGINSGYSKRALMLLHPNIKVMRHPDQV----TLWAHHEKLLVVDQVVAFLGGLDLAYGRWDDLHYRLTDLGDS 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5   35 ---------------------------------------------------------------------------------------------------- 
PLD3   23 ---------------------------------------------------------------------------------------------------- 
PLD4   18 ---------------------------------------------------------------------------------------------------- 
 
 
PLD1  501 KRVTSGPSLGSLPPAAMESMESLRLKDKNEPVQNLPIQKSIDDVDSKLKGIGKPRKFSKFSLYKQLHRHHLHDADSISSIDSTSSYFNHYRSHHNLIHGL 
PLD2  479 SESAAS-----QPPTP------------------------------------------------------------------------------------ 
PLD6    1 ---------------------------------------------------------------------------------------------------- 
PLD5   35 ---------------------------------------------------------------------------------------------------- 
PLD3   23 ---------------------------------------------------------------------------------------------------- 
PLD4   18 ---------------------------------------------------------------------------------------------------- 
 
 
PLD1  601 KPHFKLFHPSSESEQGLTRPHADTGSIRSLQTGVGELHGETRFWHGKDYCNFVFKDWVQLDKPFADFIDRYSTPRMPWHDIASA-------------VHG 
PLD2  490 ------------------R---------PDSPATPDLSHNQFFWLGKDYSNLITKDWVQLDRPFEDFIDRETTPRMPWRDVGVV-------------VHG 
PLD6    1 ---------------------------------------------------------------------------------MGRLSWQVA----AAAAVG 
PLD5   35 ------------------R----------------------------------------VGANFYSSVKQQDYSASVWLRRKDKLEHSQQKCIVIFALVC 
PLD3   23 -----------------------------------------------------------------------MNEIEAWKAAEKKARWVL--LVLILAVVG 
PLD4   18 -----------------------------------------------------------------------MPPRRPWDREAGT---LQ--VLGALAVLW 
 
 
PLD1  688 KAARD-VARH----------------FIQRWNFTKIMKSKYRSLSYPFLLPK-SQTTAHELRYQVPGSVHANVQLLRSAADWSAGIKYHEESIHAAYVHV 
PLD2  550 LPARD-LARH----------------FIQRWNFTKTTKAKYKTPTYPYLLPK-STSTANQLPFTLPGGQCTTVQVLRSVDRWSAGTL--ENSILNAYLHT 
PLD6   16 L-ALTLEALPWV----LRWLRSRRRRPR------REALF------------FPSQVTCTEALLRAPGAELA---ELPEGCPC--GL-PHGESALSRLLRA 
PLD5   77 CFAIL-VALIFS--------------------AVDIMGEDEDG-----LSEKNCQNKCRIALV-------E---NIPEGLNYSENA-PFHLSLFQGWMNL 
PLD3   50 FGALMTQLFLWE--------------------YGDLHLFGPNQ------RPAPCYDPCEAVLV-------E---SIPEGLDFPNAS-TGNPSTSQAWLGL 
PLD4   42 LGSVALICLLWQVPRPPTWGQVQPKDVPRSWEHGSSPAWEPLE-----AEARQQRDSCQLVLV-------E---SIPQDLPSAAGS-PSAQPLGQAWLQL 
 
 
PLD1  770 IENSRHYIYIENQFFISCADDKV---VFNKIGDAIAQRILKAHRENQKYRVYVVIPLLPGFEGDISTGGGNALQAIMHFNYRTMCRGENSILGQLKAELG 
PLD2  630 IRESQHFLYIENQFFISCSDGRT---VLNKVGDEIVDRILKAHKQGWCYRVYVLLPLLPGFEGDISTGGGNSIQAILHFTYRTLCRGEYSILHRLKAAMG 
PLD6   87 LLAARASLDLCLFAFSS-----------PQLG----RAVQLLHQRGVRVRVVTDCDYMALNGSQIGL--------L-------------------RK-AG 
PLD5  140 LNMAKKSVDIVSSHWDLNH-----THPSACQGQRLFEKLLQLTSQNIEIKLVSDVT---ADSKVLEA--------L-------------------KL-KG 
PLD3  113 LAGAHSSLDIASFYWTLTNNDTHTQEPSAQQGEEVLRQLQTLAPKGVNVRIAVSKPSGPQPQADLQA--------L-------------------LQ-SG 
PLD4  126 LDTAQESVHVASYYWSLTGPDIGVNDSSSQLGEALLQKLQQLLGRNISLAVATSSPTLARTSTDLQV--------L-------------------AA-RG 
 
 
PLD1  867 NQWINYISFCGLRTHAELEGNLVTELIYVHSKLLIADDNTVIIGSANINDRSMLGKRDSEMAVIVQDTET-VPSVMDG-KEY-----------------Q 
PLD2  727 TAWRDYISICGLRTHGELGGHPVSELIYIHSKVLIADDRTVIIGSANINDRSLLGKRDSELAVLIEDTET-EPSLMNG-AEY-----------------Q 
PLD6  144 IQ-VRH----------------DQDPGYMHHKFAIVDKRVLITGSLNWTTQAIQNNREN--VLITE-DDEYVRLFLEE-------------FERIWEQFN 
PLD5  204 AE-VTYMNM------------TAYNKGRLQSSFWIVDKQHVYIGSAGLDWQSLGQMKEL--GVIFYNCSCLVLDLQRIFALYSSLKF-KSRVPQTWSKRL 
PLD3  185 AQ-VRMVDM------------QKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKEL--GVVMYNCSCLARDLTKIFEAYWFLGQAGSSIPSTWPRFY 
PLD4  198 AH-VRQVPM------------GRLTRGVLHSKFWVVDGRHIYMGSANMDWRSLTQVKEL--GAVIYNCSHLAQDLEKTFQTYWVLGVPKAVLPKTWPQNF 
 
 
PLD1  948 AGRFARGLRLQ-CFRVV----LGYLDDPSEDIQDPVSDKFFKEVWVSTAARNATIYDKVFRCLPNDEVHNLIQLRDFINKPVLAKEDPIRAEEELKKIRG 
PLD2  808 AGRFALSLRKH-CFGVI----LGANTRPDLDLRDPICDDFF-QLWQDMAESNANIYEQIFRCLPSNATRSLRTLREYVAVEPLATVSPPLARSELTQVQG 
PLD6  211 PTKYTFFPPKKS---------HGSCAPPVSRAGG--RLLSWHRTCGTSSESQT----------------------------------------------- 
PLD5  288 YGVYDNEKKLQLQLNETKSQAFVSNSPKLFCPKN--RSFDIDAIYSVIDDAKQYVYIAVMDYLPISSTSTKRTYWPDLD-------AKIREALVLRSVRV 
PLD3  270 DTRYNQETPMEICLNGTPALAYLASAPPPLCPSG--RTPDLKALLNVVDNARSFIYVAVMNYLPTLEFSHPHRFWPAID-------DGLRRATYERGVKV 
PLD4  283 SSHFNRFQPFHGLFDGVPTTAYFSASPPALCPQG--RTRDLEALLAVMGSAQEFIYASVMEYFPTTRFSHPPRYWPVLD-------NALRAAAFGKGVRV 
 
 
PLD1 1043 FLV--------QFPFYFL------SEESLLPSVGTKEAIVPMEV---------------------------------WT--------------------- 
PLD2  902 HLV--------HFPLKFL------EDESLLPPLGSKEGMIPLEV---------------------------------WT--------------------- 
PLD6      ---------------------------------------------------------------------------------------------------- 
PLD5  379 RLLLSFWKETDPLTFNFISSLKAICTEIANCSLKVKFFDLERENACATKEQKNHTFPRLNRNKYMVTDGAAYIGNFDWVGNDFTQNAGTGLVINQADVR- 
PLD3  361 RLLISCWGHSEPSMRAFLLSLAALRDNHTHSDIQVKLFVVPADE-----AQARIPYARVNHNKYMVTERATYIGTSNWSGNYFTETAGTSLLVTQNGR-- 
PLD4  374 RLLVGCGLNTDPTMFPYLRSLQALSNPAANVSVDVKVFIVPVGN------HSNIPFSRVNHSKFMVTEKAAYIGTSNWSEDYFSSTAGVGLVVTQSPGAQ 
 
 
PLD1      --------------------------------------------------------------- 
PLD2      --------------------------------------------------------------- 
PLD6      --------------------------------------------------------------- 
PLD5  478 -NNRSIIKQLKDVFERDWYSPYAKTLQPTKQ---PNCSSLFKLKPLSNKTATDDTGGKDPRNV 
PLD3  454 ---GGLRSQLEAIFLRDWDSPYSHDLDTSADSVGNACRLL----------------------- 







Figure 1-16: The FAM83 family of proteins do not appear to possess any PLD activity: 
A: Schematic representation of the assay used to measure phospholipase D (PLD) 
activity. PLD cleaves phosphatidylcholine into phosphatidic acid and choline. Choline is 
then turned into hydrogen peroxide (H2O2) and betaine through the action of choline 
oxidase. The Amplex red reagent, in combination with horseradish peroxidase (HRP) act 
on H2O2 to form a fluorescent species called resorufin. Resorufin fluorescence is 
subsequently measured as a read-out of PLD activity. B: Mean resorufin fluorescence 




there is very little homology between PLDs and the DUF1669. Collectively, these 
observations suggest that the PLD-like catalytic motif in the DUF1669 of FAM83 proteins 
is not active. Indeed, no PLD activity could be detected for any FAM83 member, 
including FAM83D which harbours an intact HKD motif, when evaluated for their ability 
to cleave phosphatidylcholine in vitro (Figure 1-16). However, preliminary structural 
studies on the DUF1669 of both FAM83A and B suggest that the features and positioning 
of the HKD motif closely mirrors that seen in PLD structures (Figure 1-17). Thus, taking 
all these data into account, FAM83 proteins are classified as pseudo-PLD enzymes. 
Pseudoenzymes, defined as sequence-predicted enzymes without any 
detectable enzymatic activity, are thought to have evolved from gene duplication events 
that remove the selective pressure on the catalytic activity of the additional copies 






































































Figure 1-17: Crystal structure of the FAM83A DUF1669: A: Structure of the FAM83A 
DUF1669 domain, resolved in collaboration with the Bullock laboratory (Structural 
Genomics Consortium, Oxford). The structure reveals a unique dimer with a 
phospholipase D (PLD)-like fold, that brings the putative PLD catalytic motif together at 
the catalytic cleft (shown in green). B: The structure of PLD1 from PDB entry 1F01. C: 
Ribbon diagram depicting the folding of the FAM83A DUF1669 into a dimer, with two 
alpha helices perpendicular to that of PLD. The putative PLD-like catalytic cleft is shown 
in green. Unique beta-hairpins, which are absent from PLD1, are circled in grey. D: 
Ribbon diagram depicting the folding of PLD1, with the analogous alpha helices to panel 
C. circled in red (adapted from Leiros et al, 2000). Figure taken from Polyxeni Bozatzi’s 
doctoral thesis, 2018, University of Dundee. 
 
 
redundant additional copies are then able to mutate and adopt new functions. The full 
extent of the role of pseudoenzymes in cells is only beginning to be unravelled, but 
mounting evidence suggests that pseudoenzymes can regulate signalling pathways 
through multiple, diverse avenues (Eyers & Murphy, 2013, Murphy et al., 2017a, 
Murphy, Mace et al., 2017b). For example, pseudoenzymes can act on their ancestral 
catalytic counterparts to allosterically activate them, modulate signalling outputs, or act 
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as signalosome assembly platforms (Eyers & Murphy, 2013, Murphy et al., 2017b). 
Currently, the knowledge on FAM83 protein biology is limited, and as such, whether 
FAM83 members can act on their putative PLD ancestors to modulate PLD function is 
not known. That said, FAM83B overexpression in HME1 mammary epithelial cells was 
shown to increase PLD1 activity, although this was attributed to an indirect effect 
resulting from activation of the epidermal growth factor receptor (EGFR) following 
FAM83B overexpression (Cipriano, Bryson et al., 2014a).  
Due to the amino acid compositions of FAM83 proteins not revealing any robust 
functional clues into FAM83 or DUF1669 function, research into the cellular roles of 
FAM83 proteins has often been serendipitous in nature. Often appearing in biochemical 
screens and interactome studies, the reported roles of FAM83 proteins highlight the 
diverse, often unrelated, pathways in which these FAM83 members appear to 
participate in. The findings of some of these studies will be summarised in the 
subsequent subsections. 
 
1.3.2: FAM83A and B in chemoresistance and oncogenesis: 
FAM83A was originally identified in a phenotypic screen searching for proteins 
that, when overexpressed, were capable of reversing the cytostatic effects of the EGFR 
inhibitor AG1478 in human breast cancer HMT3522 cells (Lee, Meier et al., 2012). 
FAM83A overexpression increased the proliferation and invasion rates of these cells, 
whilst its deletion rendered the cells sensitive to tyrosine kinase inhibitors (Lee et al., 
2012). At the molecular level, FAM83A was proposed to mediate this chemoresistant 
function through binding and promoting the phosphorylation of c-Raf and the p85 




Figure 1-18: The proposed model by which FAM83A and FAM83B act to modulate 
receptor tyrosine kinase signalling: Growth factors such as epidermal growth factor 
(EGF) bind to their cognate cell surface tyrosine kinase receptors (TKRs) to trigger 
receptor dimerisation, autophosphorylation, and activation. The signal is then 
transduced through the RAS/RAF/MEK/ERK and PI3K-AKT-mTORC1 signalling pathways, 
resulting in cell growth and proliferation. Lee et al, 2012 suggested that FAM83A binds 
to the p85 subunit of PI3K and to RAF, to sustain the activation of the pathway. 
Subsequently, Cipriano et al, 2013 suggested that FAM83B associates with RAS and RAF, 
with the latter interaction proposed to prevent association of RAF with inhibitory 14-3-
3 proteins. FAM83B was also shown to bind the p85 subunit of PI3K. As FAM83A and B 
act downstream of the receptors, they were proposed as candidates capable of 
bypassing inhibition of growth signalling caused by tyrosine kinase inhibitors (TKIs) in 
chemotherapy, thereby contributing to TKI resistance. 
 
 
mitogen-activated protein kinase (MAPK) pathway, downstream of EGFR stimulation 


























In a similar vein, FAM83B was discovered through its ability to promote 
oncogenic transformation in a screen searching for proteins whose overexpression 
could act as a substitute for Ras-induced transformation of immortalised human 
mammary epithelial cells (Cipriano, Graham et al., 2012). Like FAM83A, FAM83B was 
also proposed to bind c-Raf, and also Ras, to trigger activation of MAPK signalling 
cascade (Cipriano et al., 2012) (Figure 1-18). FAM83B was suggested to mediate this 
function through blocking the association of c-Raf with 14-3-3, thereby increasing c-Raf 
membrane localisation and downstream signalling (Cipriano, Miskimen et al., 2013). In 
the same study, FAM83B overexpression was shown to activate the PI3K-Protein kinase 
B (PKB) signalling pathway (Figure 1-18), and promote resistance to inhibitors of the 
PI3K, PKB and mammalian target of rapamycin (mTOR) kinases (Cipriano et al., 2013). 
As mentioned in section 1.1.1, FAM83B-driven hyperactivation of the EGFR-MAPK 
pathway was shown  
to activate PLD1, and this PLD1-activation effect was essential for transformation of 
these cells (Cipriano et al., 2014a).  
However, whilst these overexpression-based studies are informative, no 
information on the endogenous functions of FAM83A or B have yet been described, and 
as such, this has limited the understanding into the physiological roles of these FAM83 
members.  
 
1.3.3: FAM83D in mitosis and proliferation: 
FAM83D was uncovered in a proteomic screen of isolated human mitotic 
spindles from HeLa cells, designed to identify novel components of the spindle 
apparatus (Sauer, Korner et al., 2005). Subsequently, FAM83D (aka Chica) was shown to 
localise to the mitotic spindle, and knockdown of FAM83D by RNA interference 
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approaches was shown to trigger chromosome congression and alignment defects 
(Santamaria, Nagel et al., 2008). At the molecular level, FAM83D was shown to bind the 
microtubule-binding protein hyaluronan mediated motility receptor (HMMR, aka 
RHAMM, CD168), in order to localise to the spindle microtubules (Dunsch, Hammond et 
al., 2012). Other FAM83D-interacting proteins include the light chain of the motor 
protein dynein (DYNLL1) (Dunsch et al., 2012) and the chromokinesin Kid (Santamaria et 
al., 2008), and these interactions are reported to be important in regulating the function 
of FAM83D in coordinating chromosome alignment in mitosis.  
At the transcript level, FAM83D mRNA expression is elevated in many types of 
cancer, with increased FAM83D expression predicting reduced survival rates (Huang, Ma 
et al., 2017, Perez-Pena, Alcaraz-Sanabria et al., 2017, Shi, Sun et al., 2016). As such, 
FAM83D transcript levels have been suggested to offer some prognostic value (Walian, 
Hang et al., 2016). 
 
1.3.4: FAM83G in cell signalling and disease: 
A proteomic screen aimed at identifying novel interacting proteins of the human 
mothers against decapentaplegic homologue 1 (SMAD1) transcription factor, which is a 
mediator of the bone morphogenetic protein (BMP) signalling pathway, identified 
FAM83G [thereafter also referred to as protein associated with SMAD1 (PAWS1)] as a 
SMAD1-interacting partner (Vogt, Dingwell et al., 2014). FAM83G was shown to be a 
substrate of the type I BMP receptor kinases, and to modulate non-canonical BMP 
signalling (Vogt et al., 2014). Subsequently, FAM83G was shown to regulate actin 
cytoskeletal dynamics through association with a cytoskeleton-regulating protein 
termed cluster of differentiation 2 (CD2)-associated protein (CD2AP) (Cummins, Wu et 
al., 2018). More recently, FAM83G was shown to promote hyperactive wingless/int1 
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(Wnt) signalling and subsequent body axis duplication, when overexpressed in Xenopus 
embryos (Bozatzi, Dingwell et al., 2018). Wnt signalling was diminished when FAM83G 
was knocked out in U2OS osteosarcoma cells, implying an essential role for FAM83G in 
the regulation of the Wnt signalling pathway (Bozatzi et al., 2018). 
In terms of disease, a large proportion of knowledge into the role of FAM83G has 
arisen from non-human genetic studies. Mice presenting with a spontaneous woolly hair 
phenotype were determined to possess homozygous mutations in the FAM83G gene 
(Radden, Child et al., 2013), and an autosomal recessive FAM83G mutation in dogs 
(R52P) was shown to cause hereditary palmoplantar hyperkeratosis syndrome, a skin 
disorder characterised by thickening of the footpads, epidermal hyperplasia and hair 
morphology defects (Drogemuller, Jagannathan et al., 2014, Sayyab, Viluma et al., 
2016). Recently, a FAM83G  mutation (A34E) in humans was shown to cause analogous 
hyperkeratotic phenotypes to those reported to result from the R52P substitution in 
dogs (Maruthappu, McGinty et al., 2018). As Wnt signalling has been extensively linked 
to the development of skin and hair, these disease mutations may disrupt the Wnt-
dependent FAM83G functions. Indeed, this tantalising hypothesis was recently tested, 
and expression of FAM83G(A34E) or FAM83G(R52P) mutant proteins could not rescue 
Wnt signalling in FAM83G knockout cells (Wu, Jones et al., 2019). 
 
1.3.5: FAM83H in cytoskeletal regulation and disease: 
FAM83H is perhaps unique amongst the FAM83 proteins in that it has a very well 
documented disease phenotype following its mutation. Autosomal dominant mutations 
in FAM83H have been reported in patients presenting with hereditary hypocalcified 
Amelogenesis Imperfecta (AI), a rare dental disease characterised by soft, hypocalcified 
enamel (Kim, Lee et al., 2008, Lee, Lee et al., 2011, Pourhashemi, Ghandehari Motlagh 
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et al., 2014, Urzua, Martinez et al., 2015). Many of the FAM83H mutations found in AI 
are predicted to encode truncated FAM83H protein fragments, but the precise 
molecular mechanism(s) by which FAM83H promotes AI are yet to be defined. However, 
as FAM83H knockout mice appear to have normal, functional enamel, the most likely 
explanation is that FAM83H acquires a novel function(s) when it is truncated in the 
disease state (Kuga, Kume et al., 2013, Lee et al., 2011, Wang, Hu et al., 2016). 
FAM83H was found to regulate the keratin cytoskeleton through its ability to 
interact and co-localise with specific keratins and casein kinase 1 (CK1) isoforms (Kuga 
et al., 2013). Both the knockdown and overexpression of FAM83H resulted in disruption 
of the keratin cytoskeleton, and similar defects resulted from chemical inhibition of CK1 
(Kuga et al., 2013). In ameloblasts, the disease-relevant cells, FAM83H and CK1α were 
found on keratin filaments, and also on desmosomes, implying a potential role in cell 
junction regulation (Kuga, Sasaki et al., 2016b). In these cells, the truncated, disease-
associated forms of FAM83H triggered disruption of both desmosomes and the keratin 
cytoskeleton following their overexpression (Kuga et al., 2016b), in agreement with a 
possible newly-acquired role in the disease state. In colorectal cancer cells with a 
compromised keratin cytoskeleton, FAM83H and CK1 isoforms were found to bind and 
co-localise with the DNA binding protein SON in nuclear speckles, where they may act 
to regulate invasion of these cancer cells (Kuga, Kume et al., 2016a). 
Despite these advances, molecular knowledge on the physiological role of 
FAM83H is lacking, and as such, has limited the understanding into how FAM83H 





1.3.6: The cellular roles of FAM83C, E and F remain to be defined: 
Other than clinical studies suggesting a pro-oncogenic role for FAM83C and E in 
certain cancers, no studies have yet explored the physiological functions of these 
proteins. FAM83F, on the other hand, has been the subject of some recent reports, 
implying a role for FAM83F in the p53 tumour suppressor pathway (Salama, Benitez-
Riquelme et al., 2019). FAM83F was reported to bind p53 and promote p53 stabilisation, 
and knockdown of FAM83F was associated with a reduction in p53-dependent target 
gene transcription in response to DNA damage (Salama et al., 2019). FAM83F was also 
found to activate MAPK signalling in papillary thyroid cancer (Fuziwara, Saito et al., 
2019), and three micro-RNAs were found to suppress oesophageal squamous cell 
carcinoma and non-small-cell lung carcinoma by targeting FAM83F transcripts (Gu, Zhan 















2. Materials and Methods: 
2.1: Materials: 
 
2.1.1: Chemicals and other reagents: 
 
 The chemicals and reagents used in this thesis are listed in Table 2-1. 
 
Reagent Source Cat. Number 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) 
Sigma-Aldrich H3375 
Acetic Acid Sigma-Aldrich 71251 
Acetone Sigma-Aldrich 90872 
Acetonitrile (HPLC grade) Sigma-Aldrich 271004 
Acrylamide [bis-acrylamide 40% (w/v)] National Diagnostics EC-852 
Agarose  Thermo Fisher 
Scientific 
16500 
Agarose beads Cell Signalling 
Technology 
37478 
Amersham Hyperfilm ECL GE Healthcare GE28-9068-36 
Ammonium Bicarbonate Sigma-Aldrich 09830 
Ammonium Persulfate (APS) Sigma-Aldrich 09913 
Ampicillin Formedium AMP100 
Amplex Red Phospholipase D Assay Kit Thermo Fisher 
Scientific 
A12219 
β-mercaptoethanol (BME) Sigma-Aldrich M6250 
BCA assay kit Pierce 23225 
Blasticidin Thermo Fisher 
Scientific 
R210-01 
Bortezomib (proteasome inhibitor) LC Laboratories B-1408 
Bovine Serum Albumin (BSA) Sigma-Aldrich A7906 
Bromophenol Blue Sigma-Aldrich B0126 
CellLight Actin-RFP Thermo Fisher 
Scientific 
C10502 
CK1tide (optimised CK1 substrate 
peptide) 
DSTT EP5630 
cOmplete, MINI, EDTA-free, protease 
inhibitor cocktail tablets 
Roche 4693159001 





D4476 (CK1 inhibitor) Merck 218696 
Dimethyl pimelimidate dihydrochloride 
(DMP) 
Sigma-Aldrich D8388 
Dimethyl Sulphoxide (DMSO) Sigma-Aldrich D8418 
Dithiobis Succinimidyl Propionate (DSP) Thermo Fisher 
Scientific 
22585 
Dithiothreitol (DTT) Sigma-Aldrich D9779 
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DNA gel loading dye, purple (6x) NEB 7025 
DNeasy Blood and Tissue kit Qiagen 69506 
Doxycycline (hydrochloride) Sigma-Aldrich D3072 












GE Healthcare RPN2109 
Ethanol Fisher Chemical 10000652 
Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid (EGTA) 
Sigma-Aldrich E8145 
Ethylenediaminetetraacetic acid (EDTA) Formedium EDTA250 
Fibronectin Sigma-Aldrich F2006 
FLAG M2 affinity agarose Sigma-Aldrich A2220 
Foetal Bovine Serum (FBS) Sigma-Aldrich F7524 
Formic acid VWR 84865 
Gelatin (from porcine skin) Sigma-Aldrich G1890 
Geneticin (G418) Thermo Fisher 
Scientific 
10131027 
GFP-TRAP agarose beads ChromoTek GTA 
Glutathione Sigma-Aldrich G4251 
Glycerol VWR 24386 
Glycine VWR 10119 
HA-magnetic beads Pierce 88837 
Hexadimethrine bromide (polybrene) Sigma-Aldrich H9268 
Hoechst DNA stain Thermo Fisher 
Scientific 
H3569 
HPLC-grade water VWR 22934 
Hydrochloric Acid (HCl) Sigma-Aldrich 258148 
Hygromycin-B Thermo Fisher 
Scientific 
10687010 
Immobilon-P Polyvinylidene Fluoride 
(PVDF), 0.45 µM membrane 
Merck IPVH00010 
InstantBlue Coomassie protein stain Expedeon SKU: ISB1L 
Iodoacetamide Sigma-Aldrich I1149 
iScript cDNA synthesis kit Bio-Rad 1708891 
Isopropanol Sigma-Aldrich I9516 
Kanamycin Sigma-Aldrich 60615 
KOD hot start polymerase kit Toyobo 71086-3 
LDS sample buffer (4x) Thermo Fisher 
Scientific 
NP0007 
L-Glutamine Sigma-Aldrich 25030024 
Lipofectamine RNAiMAX Thermo Fisher 
Scientific 
11668030 
LoBind Eppendorf Tubes Sigma-Aldrich Z666505 
L-shaped micropatterns CYTOO 20-013-00 
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Luria Bertani broth (LB) and LB agar 
plates 
Central Technical 
Services, University of 
Dundee 
N/A 
Lys-C protease Alpha Laboratories 125-05061 
Magnesium Acetate Sigma-Aldrich M5661 
Manganese chloride Sigma-Aldrich 244589 
Methanol Fisher Chemical 11976961 
MG132 (proteasome inhibitor) Sigma-Aldrich C2211 
MLN4924 (NEDDylation inhibitor) Active Biochem A-1139 




Nonidet P-40 substitute (NP40) Sigma-Aldrich 74385 





Opti-MEM Thermo Fisher 
Scientific  
31985062 
Paraformaldehyde 16% (w/v) Thermo Fisher 
Scientific 
28908 
Penicillin/Streptomycin Thermo Fisher 
Scientific 
15140122 
Phosphatase assay buffer New England Biolabs P0753S 
Phospholipase D from Streptomyces 
chromofuscus 
Millipore 525200 
PhosSTOP phosphatase inhibitor tablets Roche 4906837001 
Plasmid Maxi, Midi and Mini kits Qiagen 27104 
Polyethylenimine (PEI) Polysciences 23966-1 
Ponceau S Sigma-Aldrich P7170 
Precision Plus Protein All Blue standards Bio-Rad 1610373 
Prolong Gold Antifade mounting 




Propidium Iodide solution Sigma-Aldrich P4864 
ProTAME (APC/C inhibitor) Boston Biochem 1-440 
Protein G sepharose GE Healthcare 17061801 
Puromycin Sigma-Aldrich P9620 
Quick-load 1 kb DNA ladder NEB N0552 
RFP-TRAP agarose beads ChromoTek RTA 
RNAse A Thermo Fisher 
Scientific 
EN0531 
RNeasy kit Qiagen 74104 
RO-3306 (CDK1 inhibitor) Sigma-Aldrich SML0569 
RPMI Medium Thermo Fisher 
Scientific 
31870 
Sequencing grade modified Trypsin Promega V511 
Skimmed milk powder Marvel N/A 
Sodium Azide Sigma-Aldrich S2002 
Sodium β-glycerophosphate Sigma-Aldrich G6501 
Sodium borate Sigma-Aldrich B3545 
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Sodium Chloride Sigma-Aldrich S7653 
Sodium Fluoride Sigma-Aldrich S7920 
Sodium Orthovanadate Sigma-Aldrich S6508 
Sodium Pyrophosphate Sigma-Aldrich 221368 
Spin-X Column Corning 8161 
SsoFast EvaGreen Supermix Bio-Rad 172-5200 
StrataClone Blunt PCR cloning kit Agilent 240207 
S-Trityl L-Cysteine (STLC) (Eg5 inhibitor)  Sigma-Aldrich 164739 
Sucrose  VWR A15583.36 





SYBR Safe DNA stain Thermo Fisher 
Scientific 
S33102 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich T9281 
Triethylammonium bicarbonate Sigma-Aldrich T7408 
Trifluoroacetic acid (TFA) Thermo Fisher 
Scientific 
T6508 
Tris (hydroxymethyl) aminomethane 
(Tris) 
VWR 103157P 
Triton X-100 Sigma-Aldrich T8787 
Trypsin protease Pierce 13454189 
Trypsin/EDTA Thermo Fisher 
Scientific 
59417C 
Tween 20 Sigma-Aldrich P1379 
Universal nuclease Pierce 88701 
Urea VWR 28876.367 
X-gal (for blue-white colony screening) Sigma-Aldrich BG-3-G 
X-ray films Konica Minolta A9KN 
Zeocin Thermo Fisher 
Scientific 
R25001 
γ32P-ATP PerkinElmer N/A 
Table 2-1: Chemicals and reagents used in this thesis. 
 
2.1.2: Buffers and solutions: 
  
 Compositions of buffer and solutions used in this thesis are listed in Table 2-2. 
 
Buffer/Solution Composition 
6-13% (w/v) acrylamide gels 375 mM Tris-HCl (pH 8.6), 0.1% (w/v) SDS, and 6-13% 
(w/v) acrylamide. 0.1% (w/v) APS and 0.1% (v/v) 
TEMED were used to polymerise the gels. 
Blocking solution 5% (w/v) milk powder in TBS-T (1x) 
BSA primary antibody 
solution 
5% (w/v) BSA in TBS-T (1x), 0.02% sodium azide 
Buffer A 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA 
Cell freezing medium 90% (v/v) FBS, 10% (v/v) DMSO 
DNA staining buffer 50 µg/ml propidium iodide, 50 µg/ml RNAse A, in PBS 




1% (w/v) BSA in PBS (1x) 
Immunofluorescence 
quenching buffer 
10 mM HEPES pH 7.4 in DMEM 
Immunofluorescence 
permeabilisation buffer  
0.2% (v/v) NP40 in PBS 
Kinase assay buffer 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM 
magnesium acetate, 2 mM DTT 
LB plates 1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 
86 mM NaCl, 2% (w/v) bactoagar, 100 µg/ml 
ampicillin or 25 µg/ml kanamycin after autoclaving 
for 20 min 
LB broth 1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 
86 mM NaCl, 100 µg/ml ampicillin or 25 µg/ml 
kanamycin after autoclaving for 20 min 
Lysis buffer with DSP 40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM EDTA pH 
8.0, 1 mM sodium 2-glycerophosphate, 50 mM 
sodium fluoride, 1 mM activated sodium 
orthovanadate, 10 mM sodium pyrophosphate, 1% 
(v/v) Triton X-100, 1 tablet of cOmplete protease 
inhibitors per 25 ml lysis buffer. 2.5 mg/ml DSP (in 
DMSO) was added fresh before use. 
Mammalian cell lysis buffer 50 mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM EGTA pH 
8.0, 1 mM EDTA pH 8.0, 1 mM activated sodium 
orthovanadate, 1 mM sodium 2-glycerophosphate, 
50 mM sodium fluoride, 10 mM sodium 
pyrophosphate, 270 mM sucrose, 0.5% (v/v) NP40, 1 
tablet of cOmplete protease inhibitors per 25 ml lysis 
buffer. 
Milk primary antibody 
solution 
5% (w/v) milk powder in TBS-T (1x) 
PEI 1 mg/ml PEI in 25 mM HEPES, pH 7.5 
Phosphatase assay wash 
buffer 
200 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% (v/v) Triton 
X-100 
Sample buffer (5x) 312.5 mM Tris-HCl pH 6.8, 50% (v/v) glycerol, 10% 
(w/v) SDS, 0.1% (w/v) bromophenol blue, 5% (v/v) 
BME.  
SDS-PAGE running buffer 
(1x) 
25 mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1% (w/v) 
SDS 
SDS lysis buffer 1% (w/v) SDS. 1 tablet of PhosSTOP and 1 tablet of 
cOmplete protease inhibitors were added fresh 
before use. 
Stacking gel 125 mM Tris-HCl pH 6.8, 0.1 % (w/v) SDS, 4% (w/v) 
acrylamide. 0.075% (w/v) APS and 0.1% (v/v) TEMED 
were used to polymerise the gels. 
TAE buffer (1x) 40 mM Tris-acetate pH 8.0, 1 mM EDTA 
Tris buffered saline (TBS) 
buffer (1x) 
50 mM Tris-HCl pH 7.5, 150 mM NaCl 
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TBS-T buffer (1x) 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% (v/v) 
Tween 20 
Transfer buffer (1x) 25 mM Tris-HCl pH 8.3, 192 mM glycine, 10% (v/v) 
methanol 





 The antibodies used in this thesis, in addition to their optimised incubation 
conditions, are listed in Table 2-3. All the non-commercially available antibodies were 
raised in sheep by the Division of Signal Transduction Therapy (DSTT), University of 
Dundee, and purified in-house on CH Sepharose that was covalently coupled to the 
antigen used to raise the antibody. Antibodies were eluted with 50 mM glycine pH 2.5, 
and then dialysed for 16 h in PBS at 4°C. Species-specific HRP-coupled secondary 
antibodies were obtained from either Thermo Fisher Scientific or Cell Signalling 
Technologies (CST).  
Antibody Company Cat. Number Ab dilution Ab conditions 
ASC Adipogen AL177 1:1000 5% BSA TBS-T 
α-Tubulin Thermo Fisher 
Scientific 
MA1-80189 1:5000 5% BSA TBS-T 
Aurora A CST 12100 1:1000 5% milk TBS-T 
CK1α Bethyl 
Laboratories 
A301-991A 1:1000 5% BSA TBS-T 
CK1α DSTT SA527, Bleed 3 1:1000 5% milk TBS-T 
CK1δ CST 12417 1:1000 5% BSA TBS-T 
CK1δ DSTT SA609, Bleed 3 1:1000 5% milk TBS-T 
CK1ε CST 12448 1:1000 5% BSA TBS-T 
CK1ε DSTT SA610, Bleed 2 1:1000 5% milk TBS-T 
Cullin2 Invitrogen 51-1800 1:1000 5% BSA TBS-T 
Cyclin A2 CST 4656 1:1000 5% BSA TBS-T 
Cyclin B1 CST 4138 1:1000 5% BSA TBS-T 
DYNLL1 Abcam EP1660Y 1:1000 5% BSA TBS-T 
ERK 1/2 CST 4695 1:1000 5% BSA TBS-T 
FAM83B Abcam 143829 1:1000 5% BSA TBS-T 
FAM83B DSTT SA270, Bleed 3 1:1000 5% milk TBS-T 
FAM83D (C-
term) 
DSTT SA102, Bleed 3 
(depleted 
against N-term) 




DSTT SA102, Bleed 3 1:1000  5% milk TBS-T 
FAM83G DSTT S876C, Bleed 3 1:1000 5% milk TBS-T 
FAM83H  DSTT SA273, Bleed 4 1:1000 5% milk TBS-T 
FLAG-HRP Sigma-Aldrich A8592 1:2000 5% milk TBS-T 
GAPDH CST 2118 1:5000 5% BSA TBS-T 
GFP ChromoTek 3H9 1:2000 5% BSA TBS-T 
GFP DSTT S268B, Bleed 2 1:2000 5% milk TBS-T 




610959 1:1000 5% BSA TBS-T 
HMMR (human) Millipore ABC323 1:1000 5% milk TBS-T 
HMMR (mouse) Abcam 124729 1:1000 5% milk TBS-T 
phosphoHistone 
H3 (S10) 
CST 9701 1:1000 5% BSA TBS-T 
SHP2 (C-term) CST 3397 1:1000 5% BSA TBS-T 
SHP2 (N-term) CST 3752 1:1000 5% BSA TBS-T 
SMAD1 DSTT S618C, Bleed 3 1:1000 5% milk TBS-T 
Ubiquitin Dako 106260 1:2000 5% milk TBS-T 
UVRAG MBL M160-3 1:1000 5% BSA TBS-T 
VHL CST 68547 1:1000 5% BSA TBS-T 
VPS34 DSTT S672B 1:1000 5% milk TBS-T 
Table 2-3: Antibodies used for immunoblotting in this thesis. 
 
The antibodies used for immunofluorescence are listed as a separate table in 
Table 2-4. Alexa Fluor 488 donkey anti-sheep IgG (A11015), Alexa Fluor 594 goat anti-
mouse IgG (A11005), Alexa Fluor 594 donkey anti goat IgG (A11058), and Alexa Fluor 
594 goat anti-rabbit IgG (A11012) were used at 1:500 dilution for immunofluorescence 
experiments, and were obtained from Thermo Fisher Scientific.  
 
Antibody Company Cat. Number Ab dilution 
CK1α Bethyl Laboratories A301-991A 1:500 
CK1α Santa Cruz Sc6477 1:100 
CK1α DSTT SA527, Bleed 3 1:500 
CK1ε Sigma Aldrich HPA026288 1:500 




HMMR (human) ABC323 1:1000 1:500 
HMMR (mouse) Abcam 124729 1:500 





 Human qPCR primers (Table 2-5) were either designed using the National Centre 
for Biotechnology Information (NCBI) Primer-BLAST online software tool (Ye, Coulouris 
et al., 2012), and generated by Invitrogen, or obtained from peer-reviewed published 
literature. For genomic DNA sequence amplification, primers (Table 2-6) were designed 
to have a melting temperature of 60°C using SnapGene. All primers were resuspended 
in nuclease-free water to a final concentration of 100 mM, and stored at -20°C. 
Target Sequence (5’-3’) 
CK1α F - AATGTTAAAGCAGAAAGCAGCAC  
R - TCCTCAATTCATGCTTAGAAACC 
Cyclin B1 F - GCAGTGC-GGGGTTTAAATCT  
R - GCCATGTTGATCTTCGCCTT  
FAM83D F - ACGTTGATTGATGGCATCCG  
R - CCTTGGACTGTGGTTTTCGG  
GAPDH F - TGCACCACCAACTGCTTAGC  
R - GGCATGGACTGTGGTCATGAG  
HMMR F - CAAAAGAGAAACAAAGATGAGGGG 
R - CCACTTGATCTGAAGCACAAC  
Table 2-5: qPCR primers used in this thesis. 
 
Target Application Sequence (5’-3’) 




F – AGTAACAGGTAACACCTGCTGAGC 
 







F – TGTGAGGTCTTGGTGTCATGACG 
 
R - CTCAGAAGTGGCACTGAAAGGC 
FAM83D Genomic DNA 
amplification to 
confirm knockout 
F - GTTGCCTATAAAGCGGGACTGC 
 
R – TACTCCCAGCAGGCCTCAATTTCC 
 
FAM83D Genomic DNA 
amplification to 
confirm C-term GFP 
knockin 
F – GGGAACACAAACCAGCATCACC 
 
R - AGGGGGGGAAAAAGTACAGAAGC 




F – CCCTCTGAGGCTGAGCATTTAGTG 
 
R - GTGGTGATGCTGGTTTGTGTTCC 









R - TCGGGGTTCAGGAAACGAGC 










GFP Genomic amplification 
of GFP knockin genes 
from within the GFP 
sequence 
F – GACCACTACCAGCAGAACACCC 
 
R - GCTGAACTTGTGGCCGTTTACG 
HMMR Genomic amplification 
to confirm knockout 
F – CTGCCGCTACCTTGAGGATCTC 
 
R – TGGTTACTGTGCTGTGCATTGC 
 
mCherry Genomic amplification 
of mCherry knockin 
genes from within the 
mCherry sequence 
F – GACTACACCATCGTGGAACAGTACG 
 
R - GTTGTGGGAGGTGATGTCCAAC 
Table 2-6: PCR primers used to amplify the genomic DNA from the CRISPR-modified 
cell lines generated in this thesis, for DNA sequencing. 
 
 
2.1.5: siRNA oligonucleotides: 
  
 All siRNA oligonucleotides used in this thesis were purchased from Dharmacon. 
The product references for siRNAs against human CK1α (CSNK1A1) are J-003957-13, J-
003957-14, J-003957-15, and J-003957-16, and against human SHP2 (PTPN11) are L-
003947-00-0005. The non-targeting control siRNA reference is D-001810-01-05. 
2.1.6: cDNA plasmids: 
  
 All the plasmids encoding the mammalian expression constructs used in this 
thesis were generated by the DSTT (University of Dundee) cloning team, and each given 
a unique identifier (DU) number. All DNA constructs were sequence verified by the DNA 
Sequencing and Services facility, University of Dundee, using Applied Biosystems Big-
Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. The details of all the plasmids used in this thesis are freely available to the 
research community worldwide, and can be found at 
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https://mrcppureagents.dundee.ac.uk. For the pRetroX Tet-On and pBABE retroviral 
systems, plasmids were commercially-sourced from Clontech. 
 cDNA constructs were cloned into pBABED-puro, pBABED-hygro, 
pcDNA5/FRT/TO, or pCMV5 vectors, with N- or C-terminal FLAG, HA, GFP or mCherry 
tags where indicated. pcDNA5-FRT-TO vectors were either transiently-expressed, or 
used to generate stable tetracycline-inducible Flp-In T-REx cell lines as per the 
manufacturers guidelines (Thermo Fisher Scientific). pBABED denotes a Dundee-
modified version of the pBABE vector. pBABED plasmids were either transiently-
expressed, or used to generate stable cell lines through retroviral infection.  
 All the plasmids used in this thesis are listed in Table 2-7. 
 
Expressed Vector DU number / source 
aGFP pBABED P 54218 
aGFP.16 pBABED P 54238 
aGFP.16-CK1α pBABED P 29403 
aGFP.16-CK1α (K46D) pBABED P 29555 
aGFP.16-CK1α (D136N) pBABED P 28707 
aGFP.16-CK1ε  pBABED P 29613 
aGFP.16-CK1ε (D128N) pBABED P 29629 
aGFP-VHL pBABED P 54023 
Empty vector pRetroX-Tight Clontech 
FAM83A-GFP pcDNA5 FRT/TO 42864 
FAM83B-GFP pcDNA5 FRT/TO 42833 
FAM83C-GFP pcDNA5 FRT/TO 42825 
FAM83D-GFP pcDNA5 FRT/TO 42835 
FAM83E-GFP pcDNA5 FRT/TO 42826 
FAM83F-GFP pcDNA5 FRT/TO 42832 
FAM83G-GFP pcDNA5 FRT/TO 42816 
FAM83H-GFP pcDNA5 FRT/TO 42865 
FLAG-aASC pBABED P 54821 
FLAG-aCS3 pBABED P 60195 
FLAG-aNSa1 pBABED P 54816 
FLAG-VHL-aASC pBABED P 54832 
FLAG-VHL-aCS3 pBABED P 54844 
FLAG-VHL-aCS3 pRetroX-Tight 57058 
FLAG-VHL-aNSa1 pBABED P 54843 
GAG/POL pCMV Clontech 
GFP only pcDNA5 FRT/TO 41455 
GFP-FAM83A pcDNA5 FRT/TO 44235 
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GFP-FAM83B pcDNA5 FRT/TO 44236 
GFP-FAM83C pcDNA5 FRT/TO 42473 
GFP-FAM83C (D259A) pcDNA5 FRT/TO 28479 
GFP-FAM83C (F293A) pcDNA5 FRT/TO 28480 
GFP-FAM83D pcDNA5 FRT/TO 29092 
GFP-FAM83D (D249A) pcDNA5 FRT/TO 29110 
GFP-FAM83D (F283A) pcDNA5 FRT/TO 29109 
GFP-FAM83E pcDNA5 FRT/TO 44237 
GFP-FAM83E (D243A) pcDNA5 FRT/TO 28481 
GFP-FAM83E (F277A) pcDNA5 FRT/TO 28482 
GFP-FAM83F pcDNA5 FRT/TO 44238 
GFP-FAM83F (D250A) pcDNA5 FRT/TO 28268 
GFP-FAM83F (F284A) pcDNA5 FRT/TO 28488 
GFP-FAM83G pcDNA5 FRT/TO 33272 
GFP-FAM83G (D262A) pcDNA5 FRT/TO 28476 
GFP-FAM83G (F296A) pcDNA5 FRT/TO 28477 
GFP-FAM83H pcDNA5 FRT/TO 44239 
GFP-FAM83H (D236A) pcDNA5 FRT/TO 28428 
GFP-FAM83H (F270A) pcDNA5 FRT/TO 28487 
GFP-FAM83H (M1-L284) – 
FAM83G (S311-P823) 
pcDNA5 FRT/TO 28683 
HA-CK1α pCS2 28216 
mCherry-CK1α pcDNA5 FRT/TO 28407 
mCherry-CK1α (N141A) pcDNA5 FRT/TO 28839 
mCherry-CK1ε pcDNA5 FRT/TO 28406 
Tet-On pRetroX-Tet-On Clontech 
VHL pBABED P 54217 
VHL-aGFP pBABED P 54024 
VHL-aGFP.16 pBABED P 54294 
VHL-aGFP.16 pRetroX-Tight 54388 
VSV-G pCMV Clontech 
Table 2-7: List of cDNA plasmids used in this thesis. 
 
 All plasmids relevant to CRISPR/Cas9 gene editing, including both the guide 
RNAs and donor constructs, are listed in Table 2-8. 
Target KO/KI? gRNA / Donor? DU number 
CSNK1A1 N-term mCherry 
KI 
Sense gRNA 57522 
Antisense gRNA 57527 
Donor 57578 
CSNK1E N-term mCherry 
KI 
Sense gRNA 54377 
Antisense gRNA 54383 
Donor 57623 
FAM83D KO Sense gRNA 52007 
Antisense gRNA 52023 
FAM83D C-term GFP KI Sense gRNA 54048 
Antisense gRNA 54054 
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Donor 54198 
FAM83D C-term GFP KI 
with F283A 
mutation 
Sense gRNA 57831 




Sense gRNA 60528 
Antisense gRNA 60530 
Donor 60707 
HMMR KO Sense gRNA 60921 
Antisense gRNA 60934 




 Proteins tagged with GST at the N-terminus were expressed and affinity 
purified by the protein production team within the DSTT, University of Dundee, with 
the exception of GST-FAM83G-6xHis, which was purified by Dr. Polyxeni Bozatzi, a 
previous lab member. A complete list of proteins used in this these is provided in Table 
2-9. 
Protein Tag DU or cat. number Source 
CK1α GST (N-term) 329  DSTT 
FAM83A GST (N-term) 24611 DSTT 
FAM83B MBP (N-term) 28495 DSTT 
FAM83C GST (N-term) 28269 DSTT 
FAM83D GST (N-term) 28270 DSTT 
FAM83E GST (N-term) 28271 DSTT 
FAM83F GST (N-term) 28272 DSTT 
FAM83G GST (N-term), 
6xHis (C-term) 
28293 Polyxeni Bozatzi 




GST (N-term) 28049 DSTT 
FAM83H GST (N-term) 28403 DSTT 
PLD N/A 525200 Millipore 











2.2.1: Mammalian cell culture: 
 
2.2.1.1: Cell culture: 
 
 U2OS osteosarcoma, HeLa, A549 adenocarcinoma, HaCaT human keratinocytes, 
human embryonic kidney HEK 293, retroviral production HEK 293 FT, J774 mouse 
monocyte and mouse embryonic fibroblasts (MEFs) were grown in DMEM 
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, and 100 U/ml pen/strep 
(hereafter referred to as full medium). Human MDA-MB-231 breast cancer, MDA-MB-
468 mammary gland adenocarcinoma and K-562 erythroleukemia cells were grown in 
RPMI medium supplemented with 10% (v/v) FBS, 2 mM L-glutamine, and 100 U/ml 
pen/strep. Cells were maintained at 37°C in a humidified incubator set to 5% CO2. All 
cell culture procedures were performed under aseptic conditions. 
 Cells were grown to 80-90% confluency in a 10 or 15 cm Nunclon-coated dish 
(Thermo Fisher Scientific). For passaging the cells, cell medium was aspirated from the 
dish, and the cells washed 1 x in PBS (or 2 x for HaCaTs). The PBS was then aspirated and 
washed cells were incubated with 1-2 ml trypsin/EDTA at 37°C until all cells were 
detached from the culture surface. Detached cells were resuspended in fresh full 
medium, and pipetted a few times to detach cell clumps. Cells were seeded into new 
culture plates at the desired dilutions/densities. For cell counting, a Countess automated 
cell counter (Thermo Fisher Scientific) was used. 
 The HMMR-/- knockout and wild-type MEFs from close littermates were a kind 





2.2.1.2: Freezing/thawing cells: 
 Confluent cells were trypsinised as described above, and resuspended in full 
medium. The cell suspension was briefly centrifuged (3 min, 500 xg) to pellet the cells. 
The medium was then aspirated and cells were resuspended in freezing medium (Table 
2-2). Equal volumes of the cells:freezing medium mix were aliquoted into 1 ml cryovials 
and stored in a cell-freezing chamber (Mr. Frosty, Thermo Fisher Scientific), for 24 h at -
80°C. For long-term storage, frozen cryovials were transferred to liquid nitrogen. 
 To thaw cells, frozen cryovials were placed in a 37°C water bath for 2 min. 
Thawed cells were resuspended in 5 ml of full medium, followed by a brief centrifugation 
(3 min, 500 xg) to pellet the cells. The freezing medium was aspirated, and cells were 
resuspended in fresh full medium before transferring to a new culture dish. 
 
2.2.1.3: Transient transfection of cells: 
 
 Transient transfections of cDNA plasmids were performed on sub-confluent (60-
70%) cells. For a 10 cm dish of cells, 2 µg cDNA, 20 µl PEI, and 1 ml Opti-MEM were 
vortexed for 20 s, incubated at room temperature for 20 min, and added dropwise to 
target cells. For an individual well of a 6-well dish, transfections were performed as for 
a 10 cm dish, except 500 ng cDNA, 4 µl PEI, and 250 ml Opti-MEM were used. Cells were 
incubated in the transfection mix for 24 h prior to lysis. 
 
2.2.1.4: RNA interference (RNAi): 
 
 Cells were seeded at 1 x 105 cells per well in a 6-well culture dish. The cells were 
transfected with 10 nM of the relevant small interfering RNA (siRNA) oligonucleotides, 
using 4 µl of Lipofectamine RNAiMAX per well in 250 µl Opti-MEM, as recommended by 
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the manufacturer. 16 h post-transfection, the transfection medium was aspirated, and 
replaced with fresh full medium. Cells were lysed and processed 48 h post-transfection. 
 
2.2.1.5: Retroviral infection: 
 
 Stable cell lines obtained through retroviral infections were generated in 
accordance with the relevant biological safety regulations. For generating the retroviral 
particles encoding the protein of interest (POI), 6 µg of the pBABED plasmid encoding 
the POI was incubated with 2.2 µg of vesicular stomatitis virus G (VSV-G) and 3.8 µg of 
GAG/POL expression plasmids, in 300 µl Opti-MEM in a 1.5 ml Eppendorf tube. In a 
separate tube, 24 µl of PEI was incubated with 300 µl Opti-MEM. Following 5 min, the 
two tubes were combined, and the resulting mix incubated at room temperature for 20 
min. Following incubation, the mix was added dropwise to a 10 cm dish of 70% confluent 
HEK 293 FT cells. 16 h post-transfection, the transfection mix was safely disposed of, and 
fresh medium was added to the HEK 293 cells. 24 h later, the retroviral medium was 
collected and syringe filtered through 0.45 µM sterile filters. On occasion, fresh medium 
was applied to the HEK 293 cells, and a second batch of retrovirus was collected 24 h 
later. Target cells (60-70% confluent) were infected with the optimised titre of the 
retroviral medium, which was diluted in fresh medium and supplemented with 8 µg/ml 
polybrene to aid infection (Hesse, Ebbesen et al., 1978). 24h-post infection, the 
retroviral medium was safely disposed of, and replaced with fresh full medium 
containing the appropriate antibiotic to select cells that had successfully integrated the 
retroviral construct (2 µg/ml for puromycin, 50 µg/ml for hygromycin). Selected cells 
were used for subsequent experiments, and the successful expression of the POI was 
confirmed by Western blotting. Uninfected cells were selected with the relevant 
antibiotic as a selection control.  
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 For the pRetroX-Tet-On retroviral system, stable cell lines were produced 
following the manufacturers’ protocol (Clontech). In brief, cells were first infected with 
retroviruses encoding the Tet-On plasmid, and selected in G418. Following selection, 
Tet-On-positive cells were then infected with the pRetroX-tight retrovirus encoding the 
gene of interest. Following successful selection with puromycin, Tet-inducible 
expression was tested through titration with different doxycycline concentrations (0.02-
2 µg/ml) and confirmed through Western blotting. 
 
2.2.1.6: Generation of tetracycline-inducible Flp-In T-REx cells: 
 
 Flp-In T-REx U2OS and HEK 293 cells were maintained in full medium 
supplemented with 15 µg/ml blasticidin and 100 µg/ml zeocin, in order to maintain 
expression of the Tet-repressor and integrity of the Flp-recombination site respectively. 
For a 10 cm dish, subconfluent (60-70%) cells were transfected with 1 µg of the pcDNA5-
FRT/TO vector encoding the POI, along with 9 µg of the pOG44 Flp recombinase plasmid. 
Plasmids were diluted in 1 ml Opti-MEM with 20 µl of 1 mg/ml PEI. The transfection mix 
was vortexed for 20 s, and left to incubate at room temperature for 20 min. Following 
incubation, the transfection mix was applied dropwise to cells. 24 h post-transfection, 
the medium was replaced with fresh full medium supplemented with 15 µg/ml 
blasticidin and 50 µg/ml hygromycin-B for 2-3 weeks. The selection medium was 
replenished every 2-3 days until positive clones were selected, verified and expanded. 
The addition of hygromycin B acts to ensure correct integration of the cDNA of interest. 
Tet-inducible protein expression was induced with 20 ng/ml doxycycline for 16 h prior 
to lysis, unless otherwise stated in the figure legends, and confirmed with 
immunoblotting and/or immunofluorescence. 
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2.2.1.7: Generation of fluorescent tag knockin cells using CRISPR/Cas9: 
 
 The CRISPR/Cas9 system (Cong, Ran et al., 2013) was employed to perform 
genome editing. The guide RNAs (gRNAs) and donor plasmids used in this thesis are 
listed in Table 2-8. Transfection of the CRISPR plasmids was performed on subconfluent 
(60-70%) cells. For a 10 cm culture dish, 1 ml Opti-MEM and 20 µl of PEI were combined 
with 1 µg each of the sense and antisense gRNA plasmids, along with 3 µg of the 
fluorescent tag donor plasmid flanked by 500 bp homology arms at the 5’ and 3’ ends. 
The antisense gRNA plasmid also carried the Cas9 D10A nickase sequence. Nickase 
cleaves one strand of the DNA that is complementary to the gRNA, therefore successful 
double strand breaks require target-specific nicks on both strands recognised by the 
sense and antisense gRNAs simultaneously. Thus, the potential off-target double strand 
breaks are vastly reduced compared to the wild-type Cas9 enzyme. The transfection mix 
was vortexed for 20 s, incubated at room temperature for 20 min, and added dropwise 
to cells. 24 h post-transfection, the transfection medium was replaced with fresh full 
medium supplemented with 2 µg/ml puromycin for selection of transfected cells. 24 h 
later, the puromycin-containing medium was replenished. 24 h later, the medium was 
replaced with normal full medium for a further 24 h, and the transfection process was 
repeated once more. GFP or mCherry positive cells were then sorted by fluorescence-
activated cell sorting (FACS), and individual GFP or mCherry positive cells were plated 
on individual wells of a 96-well plate, which had been pre-coated with 1% (w/v) gelatin, 
and filled with 200 µl of conditioned medium supplemented with 20% (v/v) FBS. For 
FACS, the transfected cells were trypsinised, resuspended in full medium and pelleted, 
before being resuspended in 3 ml DMEM containing 1% (v/v) FBS. To minimise the 
chance of cells getting trapped in the meniscus, the 96-well plate was briefly centrifuged 
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(30 s, 500 xg). Viable clones were expanded and positive cells were analysed by 
immunoblotting, genomic PCR and DNA sequencing. 
 
2.2.1.8: Generation of knockout cells using CRISPR/Cas9: 
 
 To generate knockout cells, cells were transfected and processed as for 
fluorescent tag knockin cells (section 2.2.1.7) except that no donor plasmid was used in 
combination with the gRNAs, and instead of FACS, single cell sorting was utilised to 
obtain single cell clones. The guide RNAs (gRNAs) and donor plasmids used in this thesis 
are listed in Table 2-8. Successful knockouts were confirmed by immunoblotting, 
genomic PCR and DNA sequencing. 
 
2.2.1.9: Stimulation of cells with small molecule inhibitors: 
 The small molecule inhibitors used in this thesis are listed in Table 2-1. If not 
purchased from a commercial source, inhibitors were provided as 10 mM stocks 
dissolved in DMSO by the DSTT (University of Dundee), and stored in aliquots at -20°C. 
The commercially-sourced small molecule inhibitors were also dissolved in DMSO and 
stored in aliquots at -20°C, unless otherwise stated. Cells were treated with the 
inhibitors by adding the inhibitor straight to the culture medium, and incubating for the 
desired length of time at 37°C, as indicated in the figure legends. An equivalent volume 
of DMSO was used as a vector control.  
 
2.2.1.10: Synchronisation of cells using small molecules: 
 
 For synchronisation, cells were arrested at prometaphase with nocodazole (100 
ng/ml) for 12 h, before floating mitotic cells were isolated by mitotic shake-off. The 
presence of floating cells, and hence confirmation that the nocodazole treatment had 
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been successful, was monitored by brightfield microscopy. Collected mitotic cells were 
washed 3 x in PBS before re-plating in fresh full medium for 45 min prior to lysis, to allow 
them to re-establish their spindles and progress into mitosis. Brightfield microscopy was 
used to confirm cells had re-established their mitotic spindles and aligned their 
chromosomes, typically 45 min after release from nocodazole-containing medium. 
Alternatively, cells were synchronised in mitosis with 5 µM of the Eg5 inhibitor S-Trityl 
L-Cysteine (STLC) (Skoufias, DeBonis et al., 2006) for 16 h. Following STLC incubation, 
brightfield microscopy was used to confirm the presence of mitotic cells, and hence 
successful Eg5 inhibition. Floating, mitotic cells were isolated by shake-off and either 
lysed immediately, or washed 3 x in PBS and re-plated in fresh full medium. Where 
indicated, MG132 and ProTAME were used at 20 µM. For either G2 arrest or forced 
mitotic exit, cells were treated with 10 µM of the CDK1 inhibitor RO-3306 (Vassilev, 
2006) for 24 h or 1 h respectively, prior to lysis. 
 
 
2.2.1.11: Preparation of cells for flow cytometry: 
 
 U2OS cells treated with or without synchronisation agents as described in 
section 2.2.1.10 were collected and washed 2 x in PBS containing 1% (v/v) FBS. Cells 
were fixed in 90% (v/v) ice-cold methanol for 16 h overnight at -20°C.  
 
2.2.1.12: Analysis of cell cycle stage by DNA distribution profiling: 
 
 Following methanol fixation, cells were adjusted to around 200,000 cells, 
washed 2 x in PBS containing 1% (v/v) FBS, and stained with 300 µl DNA staining buffer 
(Table 2-2). Following 20 min incubation at room temperature protected from 
light, samples were analysed and data acquired on a fluorescence-activated cell sorting 
(FACS) Canto [Becton Dickinson, (BD)] using BD FACSDIVA software. Data was visualised 
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using FlowJo software (Tree Star, BD). Pulse-width analysis was used to ensure 
the exclusion of doublets and clumps prior to evaluation of cell cycle distribution using 
the Watson-Pragmatic model. 
 
2.2.1.13: Cell lysis: 
 
 Unless otherwise stated, cells destined for lysis were washed twice in ice-cold 
PBS and scraped on ice in lysis buffer supplemented with protease inhibitors (Table 2-
2). Extracts were transferred to Eppendorf tubes and incubated on ice for 10 min, and 
then clarified at 13,000 xg for 20 min at 4°C. Samples were either processed immediately 
or snap-frozen in liquid nitrogen and stored at -80°C. 
 If chemical cross-linking with DSP was required, cells were lysed on ice in DSP 
lysis buffer containing fresh DSP (Table 2-2), after two washes in ice-cold PBS. Lysed 
extracts were incubated on ice for 30 min, before quenching the cross-linking reaction 
with 0.2 M Tris-HCl pH 7.5. During the quenching process, samples were incubated on 
ice for 30 min with regular vortexing performed every 5 min. Samples were then clarified 
at 13,000 xg for 20 min at 4°C, and either processed immediately, or snap-frozen in 
liquid nitrogen and stored at -80°C. 
 For DNA or mRNA isolation, cells were lysed and processed using a Qiagen 
DNeasy blood and tissue kit or RNeasy kit respectively, as per the manufacturer’s 
instructions. 
 
2.2.1.14 Quantification of spindle orientation: 
 
U2OS cells were seeded at 3,000 cells per well in 96-well plates with L-shaped 
micropatterns (CYTOO) at a density of 15,000 cells/ml. Prior to seeding, plates were 
coated with 20 μg/ml fibronectin (Sigma-Aldrich) for 2 h at room temperature. Following 
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seeding, cells were imaged every 5 or 10 min for up to 24 h at 37°C in a 5% CO2 
environmental chamber using an ImageXpress Micro High Content Screening System 
(Molecular Devices Inc.).  
To measure spindle orientation in subconfluent cultures, cells were seeded at 
50% confluency, grown overnight and imaged as described above. Spindle angles were 
measured using a vector drawn through the division axis at anaphase bisecting a vector 
drawn through the cell’s long axis determined prior to prophase.  
 
2.2.2: General molecular biology: 
 
 
2.2.2.1: Plasmid transformation, amplification and purification: 
 
 Competent E. coli DH5α cells were generated and maintained by the DSTT, 
University of Dundee, and stored at -80°C. For transformation of plasmids, one vial of 
DH5α cells were thawed on ice, and 1 µl of plasmid DNA (10-20 ng) was added. The 
cell:plasmid mix was incubated on ice for 20 min, and then heat-shocked at 42°C for 45 
s to facilitate DNA uptake. Cells were then returned to ice for 2 min. Following 
incubation, 500 µl of LB medium was added to the cells, and they were incubated at 
37°C with shaking for 30 min, to allow them to recover. Subsequently, 150 µl of the 
transformed cells in LB were transferred and spread onto a LB agar plate containing 100 
µg/ml ampicillin or 50 µg/ml kanamycin as appropriate. Plates were then placed inside 
a 37°C incubator and left for 16 h overnight. 
 To amplify the plasmids, a single transformed bacterial colony was used to 
inoculate 4 ml (miniprep) or 100 ml (midiprep) LB medium containing 100 µg/ml 
ampicillin or 50 µg/ml kanamycin as appropriate. The bacteria:LB mix was placed inside 
a shaking incubator set to 37°C for 16 h overnight. Following incubation, cells were 
 83 
pelleted by centrifugation (2000 xg, 10 min, 4°C), and the plasmid DNA was isolated and 
extracted following the manufacturer’s instructions. Qiagen DNA mini or midi kits were 
used for this purpose. 
 
2.2.2.2: Measurement of DNA and RNA concentration: 
 
 The concentration of extracted DNA and RNA in an aqueous solution (elution 
buffer) was measured on a NanoDrop spectrophotometer (Thermo Fisher Scientific) at 
a wavelength of 260 nm. The 260/280 and 260/230 ratios were calculated to assess the 
purity of the DNA. The NanoDrop was calibrated with the appropriate elution buffer 
prior to use. The elution buffers were provided in the Qiagen kits. 
 
2.2.2.3: Agarose gel electrophoresis: 
 
 In order to analyse the size and purity of DNA products, they were assessed by 
electrophoresis on 1% (w/v) agarose gels. To visualise the DNA, each gel was stained 
with SYBR safe DNA stain at 1:10,000 dilution. The DNA to analyse (0.5 µg) was mixed 
with 1x DNA loading dye and loaded into the gel. A 1 kbp DNA ladder (NEB) was used in 
parallel for size reference. Gels were electrophoresed in 1x TAE running buffer (Table 2-
2) at 100 V for 30 min. Stained DNA was visualised using a UV transilluminator. 
 
2.2.2.4: Quantitative reverse transcription PCR (qRT-PCR): 
 
 The Qiagen RNeasy kit was used to isolate RNA from cells. cDNA was produced 
using 1 µg of isolated RNA using the SuperScript cDNA kit (Bio-Rad) as per the 
manufacturer’s instructions. 
 qPCR reactions were performed in triplicate, in 10 µl final volumes for 384-well 
plates. Each reaction contained cDNA equivalent to 1 ng/µl RNA, 50% (v/v) SsoFast 
EvaGreen Supermix (Bio-Rad), and 0.5 µM each of appropriate forward and reverse 
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primers (Table 2-5). qPCR was performed within a CFX384 real-time qPCR machine (Bio-
Rad). Data was normalised to the mean of the housekeeping gene GAPDH, and analysed 
using the 2-∆∆Ct method for comparing relative gene expression (Livak & Schmittgen, 





 The Qiagen DNeasy blood and tissue kit was used to isolate DNA from cells 
following the manufacturer’s instructions. PCR was performed using the KOD hot start 
DNA polymerase kit (Toyobo) following the manufacturer’s protocol, within a PCR 
thermal cycler (PT-200, MJ research). PCR reactions were performed in 50 µl final 
volumes, and each reaction contained 25 mM MgSO4, dNTPs (2 mM each), 3 µl DMSO, 
1x KOD hot start DNA polymerase buffer, 10 µM each of appropriate forward and 
reverse primers (Table 2-6), 200 ng template DNA, and 1 U KOD hot start DNA 
polymerase. PCR products were analysed by agarose gel electrophoresis as described in 
section 2.2.2.3. 
 
2.2.2.6: Subcloning of PCR products: 
 
 PCR products were ligated into pSC-B vectors using the StrataClone Blunt PCR 
cloning kit (Agilent), in accordance with the manufacturer’s instructions. Each ligation 
reaction contained 3 µl StrataClone cloning buffer, 1 µl StrataClone vector mix, and 2 µl 
of the PCR product. Reactions were incubated at room temperature for 5 min, and 5 µl 
of the reaction was subsequently transformed into a thawed vial of StrataClone 
SoloPack competent cells as per the manufacturer’s instructions. Following 
transformation and recovery in LB medium, 50 µl of the cell:LB mix was plated onto LB 
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agar plates containing 2% (w/v) X-Gal in order to enable blue-white colony screening. 
Plates were inverted and incubated at 37°C for 16 h overnight. Following incubation, 
white colonies were chosen and used to inoculate 4 ml LB medium, which was 
subsequently grown for 16 h overnight at 37°C with shaking. Plasmid DNA was then 
isolated using the Qiagen miniprep kit as per the manufacturer’s instructions. 
 
2.2.2.7: DNA mutagenesis: 
 
 DNA mutagenesis for all plasmids (Table 2-7) was performed by the DSTT 
(University of Dundee) cloning team. The QuikChange site-directed mutagenesis 
approach (Stratagene) was used in combination with KOD polymerase (Novagen). All 
mutations were verified by DNA sequencing (see section 2.2.2.8). 
 
2.2.2.8: DNA sequencing: 
 
 Sequencing of all plasmid DNA was performed by the DNA sequencing service 
(University of Dundee) using Applied Biosystems Big-Dye v3.1 chemistry, on an Applied 
Biosystems model 3730 automated capillary DNA sequencer, using the appropriate 
sequencing primers. 
 
2.2.3: General biochemistry: 
 
2.2.3.1: Measurement of protein concentration: 
 
 The Bradford method (Bradford, 1976) was used in order to determine protein 
concentration. For calibration, a standard curve was generated through plotting 
absorbance against a serial dilution of BSA standards (0.125 - 2 mg/ml). Samples to be 
measured were first diluted in water by a factor of 10, and then 5 µl aliquots were 
dispensed in triplicates into a 96-well plate, along with the standard curve, which was 
also in triplicate. A blank sample (water) was included to measure the background 
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absorbance. Just prior to measuring, 200 µl of the Coomassie-based Bradford reagent 
was added to each sample, and following a 5 min incubation at room temperature, 
absorbances at 595 nm were measured using a VersaMax microplate reader and 
SoftMax Pro v4.8 software (Molecular Devices). The protein concentration of each 
sample was subsequently calculated from the mean absorbance per triplicate, with 
reference to the standard curve. 
 
2.2.3.2: Immunoprecipitation (IP): 
 
 Clarified cell extracts were first incubated with blank agarose or protein-G 
sepharose beads, in order to pre-clear extracts and remove non-specific bead-
interacting proteins. This was performed for 1 h at 4°C on a rotating wheel. The pre-
cleared extracts (0.3-1 mg/ml for Western blot applications, or 10 mg final protein 
concentration for proteomics) were subsequently incubated with the appropriate 
antibody-coupled beads for 4 h, or overnight, at 4°C on a rotating wheel. An Input 
aliquot was taken from the pre-cleared sample prior to adding the beads, in order to 
confirm the presence of the protein of interest in the whole cell lysate. Following 
incubation, beads were pelleted and the flow-through extract was retained to assess IP 
efficiency by immunoblotting. Beads were then washed once in lysis buffer 
supplemented with NaCl to a final concentration of 500 mM, and twice in normal lysis 
buffer (Table 2-2). Beads were then resuspended in 1x SDS sample buffer (typically 30 
µl). Input, IP and flow-through samples were incubated at 95°C for 5 min to denature 





2.2.3.3: Covalent-coupling of antibodies to protein G sepharose beads: 
 
 To covalently cross-link an antibody to protein G sepharose beads, 1 µl of the 
beads per µg of the antibody were first incubated for 1 h at 4°C on a rotating wheel. The 
antibody-bound beads were then washed 5 x with 10 volumes of 0.1 M sodium borate, 
pH 9.0. Washed beads were subsequently resuspended in 20 mM dimethyl pimelimidate 
dihydrochloride (DMP) in 0.1 M sodium borate, followed by gentle agitation for 30 min 
at room temperature. This incubation step was repeated once more with fresh DMP in 
sodium borate. Beads were then washed in 10 volumes of 50 mM glycine pH 2.5 in order 
to strip the beads of any antibodies that had not been covalently bound. Finally, beads 
were neutralised by washing 2 x in 0.2 M Tris-HCl pH 8.0, with the second wash taking 
place for 30 min at room temperature. For storage, beads were resuspended in PBS 
containing 0.01% (w/v) sodium azide and stored at 4°C.  
 For elution of proteins bound to covalently-coupled beads, no reducing agent 
was added to the SDS sample buffer, in order to keep the antibody bound to the beads. 
 
2.2.3.4: Separation of proteins by SDS-PAGE: 
 
SDS-PAGE was performed using either the commercially available NuPAGE bis-
tris electrophoresis system (Thermo Fisher Scientific), or the ATTO vertical 
polyacrylamide slab gel electrophoresis system (ATTO Corp.). Protein-based samples 
were prepared for SDS-PAGE by first heating in 1x SDS sample buffer at 95°C for 5 min. 
For precast NuPAGE novex gels, electrophoresis was carried out in an XCell SureLock 
Mini-Cell filled with 1x MOPS running buffer, and performed at a constant voltage of 
150 V for 80 min. 
For the ATTO system it was necessary to prepare the gels prior to 
electrophoresis. The Slab minigels (90 mm x 80 mm x 1 mm) were poured between glass 
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plates. The separating gel was typically prepared at final acrylamide concentrations of 
6-13% (w/v) (Table 2-9). Polymerisation was initiated by addition of 0.075% (w/v) APS 
and 0.1% (v/v) TEMED, and the gel mix was poured into the gel assembly unit. 100% 
(v/v) isopropanol was gently applied to the gel surface to remove any bubbles, and the 
separating gel was allowed to polymerise for 20 min at room temperature. Following 
polymerisation, the isopropanol was completely poured off and the stacking gel (Table 
2-9) was prepared and poured directly on top of the separating gel. A Teflon comb was 
immediately inserted into the stacking gel, and the gel was allowed to polymerise for 20 
min at room temperature. Gels were either used immediately, or stored at 4°C wrapped 
in a damp paper towel to prevent them from drying out. Gels were introduced into the 
ATTO electrophoresis chamber, and filled with 1x SDS-PAGE running buffer (Table 2-2). 
Electrophoresis was performed at a constant voltage of 150 V for around 80 min, until 
the dye front had reached the bottom of the gel. 
For both the NuPAGE and ATTO systems, samples (typically 10-20 µg protein) 
were loaded on to the gel using a Gilson pipette equipped with gel-loading tips, and pre-
stained protein standards were loaded in parallel for molecular weight reference.  
 
2.2.3.5: Staining proteins with InstantBlue: 
 
Following SDS-PAGE, gels were washed in deionised water and incubated in 20 
ml InstantBlue (Expedeon) on a rocking platform for 20-60 min. Following incubation, 






 Stacking Separating 
Percentage 
acrylamide 
4 6 8 10 12 13 
H2O (ml) 7.6 11.6 10.6 9.6 8.6 8.1 
1 M Tris-HCl 
pH 6.8 (ml) 
1.25 N/A N/A  N/A  N/A  N/A  
1.5 M Tris-HCl 
pH 8.8 (ml) 
N/A 5 5 5 5 5 
10% (w/v) SDS 
(µl) 
100 200 200 200 200 200 
40 % (w/v) 
polyacrylamide 
(ml) 
1 3 4 5 6 6.5 
10% (w/v) APS 
(µl) 
100 200 200 200 200 200 
TEMED (µl) 10 16 16 16 16 16 
Table 2-10: Recipes for stacking and separating gels used to make the Slab minigels 
used in combination with the ATTO electrophoresis system. 
 
 
2.2.3.6: Immunoblotting (Western blotting): 
 
Following the successful resolution of protein samples by SDS-PAGE, proteins 
were transferred onto PVDF membranes which had been pre-activated in 100% (v/v) 
methanol just prior to transfer assembly. Transfer was performed at 80 V for 80 min 
using the Bio-Rad transfer apparatus filled with transfer buffer (Table 2-2), and a cooling 
block to limit over-heating. When blotting for smaller molecular weight proteins, the 
length of transfer time was reduced to 50 min. 
In order to visualise transfer efficiency in a reversible manner, PVDF membranes 
were briefly immersed in Ponceau S staining buffer for 1-2 min, before rinsing in 100% 
(v/v) methanol to visualise the stained protein bands. Where appropriate, membranes 
were cut into smaller strips with a scalpel, to enable proteins of different molecular 
weights to be probed at the same time. Membranes were washed in blocking buffer 
(Table 2-2) for 5 min to remove the ponceau stain, before continuing the block in fresh 
blocking buffer for 30 min at room temperature on a rocking platform. Blots were briefly 
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washed in 1x TBS-T to remove the blocking buffer, and incubated with the primary 
antibody solution (Table 2-2) for either 1 h at room temperature, or 16 h at 4°C. 
Following incubation, membranes were washed 3 x for 10 min in 1x TBS-T, before 
incubating with the HRP-conjugated secondary antibodies (typically 0.2 µg/ml) in 
blocking solution (Table 2-2) for 1 h at room temperature. Membranes were again 
washed for 3 x 10 min in 1x TBS-T, and incubated with enhanced chemiluminescence 
(ECL) reagent for 1 min. The excess ECL was drained off the membrane, and membranes 
were either developed using an X-ray cassette with films (Konica Minolta) in the dark 
room, or on the ChemiDoc imaging system (Bio-Rad). X-rays were developed using a 
Konica automatic developer. 
 
2.2.3.7: Immunofluorescence microscopy: 
 
Cells were seeded onto 22 x 22 mm sterile coverslips in 6-well culture plates. 
Coverslips were sterilised in 100% (v/v) ethanol and allowed to dry prior to plating cells. 
For imaging of mitotic cells, sterilised coverslips were coated in poly-L-lysine solution 
prior to seeding cells. Cells were washed 2 x in PBS and fixed in 4% (w/v) 
paraformaldehyde for 20 min at room temperature. Paraformaldehyde was diluted in 
PBS from a 16% (w/v) stock solution. Following incubation, the paraformaldehyde was 
removed, and the cross-linking reaction was quenched by washing 2 x in quenching 
buffer (Table 2-2), before incubating in quenching buffer for 10 min at room 
temperature. Coverslips were subsequently washed in PBS and permeabilised with 0.2% 
(v/v) NP40 in PBS for 3 min. Coverslips were then washed 2 x in IF blocking buffer (Table 
2-2), followed by a 15 min incubation in blocking buffer to reduce non-specific epitope 
binding. Primary antibodies (Table 2-4) were prepared in blocking solution (Table 2-2) 
and added directly to the coverslip within a humidified chamber (typically 100 µl 
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antibody solution). Coverslips were incubated with the primary antibody for 1-1.5 h at 
37°C. Following the incubation period, the coverslips were returned to the 6-well dish 
and washed for 3 x 10 min in blocking solution, and then incubated with the Alexa Fluor-
conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at room 
temperature, protected from light. Next, coverslips were washed again for 3 x 10 min in 
blocking solution, and then processed for mounting. To mount, coverslips were briefly 
dipped into deionised water using tweezers, dried on a paper towel, and then mounted 
onto glass slides using ProLong Antifade reagent with DAPI. The mounted coverslips 
were left to dry overnight at room temperature, protected from light. Clear nail polish 
was used to seal the edges of the coverslip onto the glass slide once the mounting media 
had dried. For freeze-thaw permeabilisation with liquid nitrogen and PI3P staining, the 
Ganley method was used (Munson & Ganley, 2016). To image, cells were either 
visualised on a DeltaVision system (Applied Precision) with an immerse-oil 63X objective 
and processed with SoftWoRx (Applied Precision), or on a Zeiss LSM710 confocal 
microscope using a 63X Plan-Apochromat objective (NA 1.40). Alternatively, cells were 
imaged on a Nikon TiE inverted microscope (60x objective) and visualised with NIS 
Elements (Nikon). Where applicable for the DeltaVision system, Z-series were collected 
at 0.2 µM intervals, and deconvolved using SoftWoRx. Images were processed and 
figures assembled using Adobe Photoshop or OMERO software (Allan, Burel et al., 2012). 
 
2.2.3.8: Quantification of CK1α spindle localisation: 
For quantification of CK1α spindle localisation on STLC-induced monopolar 
spindles, the mean pixel intensities of CK1α staining on the spindle were calculated by 
measuring the mean pixel intensities of CK1α in the region of interest (roi) demarcated 
by the outer border of the DAPI ring (hereafter referred to as the spindle roi). 
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Subsequently, the ratio between the spindle roi and the background cytoplasmic CK1α 
staining was calculated, by measuring the mean cytoplasmic CK1α pixel intensities in the 
cytoplasmic roi, defined as the whole cell minus the spindle roi. The resulting ratios were 
plotted on a box plot with whiskers indicating the highest and lowest values. A ratio of 
>1 indicates CK1α is present on the spindle, and a ratio of ≤ 1 indicates CK1α is not 
present on the spindle. One might expect the theoretical ratio to be close to 1 in the 
FAM83D-/- cells. However, lower mean CK1α intensity in the DAPI-stained area relative 
to the cytoplasm implies exclusion of CK1α in DNA-rich regions. This results in a lower 
mean CK1α staining intensity in the overall spindle roi versus the cytoplasmic roi and 
therefore a ratio of less than 1. The ImageJ macro developed by Graeme Ball (Dundee 
Imaging Facility), used for this purpose is included in the appendix.  
2.2.3.9: Live cell imaging: 
 
For the mitotic assays, U2OS cells were grown in 96-well plates (Corning) and 
imaged for up to 24 h at 37°C in a 5% CO2 environmental chamber using a 40X 0.75 NA 
dry objective with the MetaXpress v 5.0.2.0 software (Molecular Devices Inc.) on the 
ImageXpress Micro XL epifluorescence microscope (Molecular Devices Inc.). For the 
analysis of cell division kinetics, cells were first stained with Hoechst (1 μg/ml) to label 
DNA, and images were taken every 5 min. Movies were made in the MetaXpress v 
5.0.2.0 software (Molecular Devices Inc.). For actin localisation experiments, U2OS cells 
were seeded at 20% confluency in 24-well plates, and 1 µl CellLight Actin-RFP (Thermo 
Fisher Scientific) was added per 5000 cells, and incubated at 37° C for 16 h. Following 
the incubation, U2OS cells were seeded on L-shaped micropatterns (CYTOO) at 30,000 
per ml. For the analysis of actin localisation, images were taken every 2 min, and movies 
were made using MetaXpress v 5.0.2.0 software (Molecular Devices Inc.). Images of 
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actin localisation were projected from prophase to metaphase (Image J, z-projection 
standard deviation) for analysis. For the analysis of cortical asymmetric membrane 
elongation, images were taken every 1 min, and movies were made in the MetaXpress 
v 5.0.2.0 software (Molecular Devices Inc.). 
 
2.2.4: In vitro assays: 
 
2.2.4.1: In vitro kinase assays: 
 
In order to assay kinase activity, 25 µl reactions were prepared encompassing 
200 ng of the kinase and 2 µg of the protein substrate, within kinase assay buffer (Table 
2-2) containing 0.1 mM γ32P-ATP (~500 cpm/pmol). Reactions were incubated at 30°C 
for 30 min with shaking, and terminated through addition of 9 µl 1x SDS sample buffer 
containing 5% (v/v) β-mercaptoethanol, and subsequent heating at 95°C for 5 min. 
Samples were then resolved by SDS-PAGE, and gels stained with InstantBlue in order to 
visualise the protein bands. Gels were then de-stained as described in section 2.2.3.5, 
and dried. Radioactivity within the gel was analysed by autoradiography by exposing the 
dried gel on Hyperfilm for different exposure times within a cassette. For long 
exposures, the cassette containing the Hyperfilm (typically 3 films on top of each other) 
was placed at -80°C to enhance the autoradiographic signal. Films were then developed 
using a Konica automatic developer. 
Alternatively, for kinase assays against a substrate peptide instead of a protein 
substrate, reactions were set up as per the method described by Hastie et al (Hastie, 
McLauchlan et al., 2006). In short, 50 µl reactions were prepared containing the 
substrate peptide. An optimised CK1 substrate peptide (CK1tide, DSTT, EP5630) was 
used to assay CK1 kinase activity. Following incubation at 30°C for 30 min with shaking, 
40 µl of the reaction was spotted onto p81 phosphocellulose (2 x 2 cm, Whatman) and 
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immediately immersed in 75 mM phosphoric acid, stirring continuously with a magnetic 
stirrer. The p81 papers were washed for 3 x 5 min with fresh 75 mM phosphoric acid 
each wash, until the γ32P-ATP that that not been incorporated into the peptide was 
washed off. Following the final wash, the p81 papers were briefly immersed in 100% 
(v/v) acetone and dried with a hair dryer within a fume hood. Dried p81 papers were 
transferred into 1.5 ml Eppendorf tubes, and radioactivity was measured using a 
scintillation counter (PerkinElmer). To measure the specific radioactivity (cpm/pmol) of 
the γ32P-ATP, 1 µl of the stock γ32P-ATP was diluted 1:100 and measured in parallel. This 
was performed in order to determine the stoichiometry of the reaction. 
 
2.2.4.2: In vitro phosphatase assays: 
In order to assay phosphatase activity, lysed extracts from asynchronous and 
mitotic FAM83DGFP/GFP knockin U2OS cells were subjected to immunoprecipitation with 
GFP TRAP beads (ChromoTek), and washed 3 x in wash buffer (Table 2-2). Beads were 
resuspended in 20 μl phosphatase-assay buffer (New England Biolabs) containing 1 mM 
MnCl2, with or without λ-phosphatase (1 U, DSTT) for 30 min at 30°C with shaking. 
Following incubation, beads were washed 3 x in wash buffer and eluted at 95°C for 5 
min in 1x SDS sample buffer. Input and immunoprecipitation samples were subjected to 
Western blotting as described in section 2.2.3.6.  
2.2.4.3: In vitro phospholipase D assays: 
 
In order to assay phospholipase D (PLD) activity, purified FAM83 proteins were 
subjected to the Amplex Red Phospholipase D assay kit (Thermo Fisher Scientific) as per 
the manufacturers’ instructions. As a positive control, 1 U phospholipase D from 
Streptomyces chromofuscus was analysed in parallel. As FAM83 proteins are thought to 
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not possess any PLD-like activity, protein mass, rather than units of activity, was used to 
assay any putative PLD activity in vitro. 
 
2.2.5: Mass spectrometry: 
 
2.2.5.1: Preparation of samples for mass spectrometry: 
 
 For mass spectrometric analysis, cells were first lysed in lysis buffer (Table 2-2) 
as described in section 2.2.1.13. Next, clarified lysates were incubated with Protein A 
agarose beads for 1 h on a rotating wheel at 4°C, in order to pre-clear non-specific 
binding proteins. Pre-cleared extracts were then filtered through Spin-X columns 
(Corning) by centrifugation for 5 min at 13,000 xg, and filtered extracts (5 – 10 mg 
protein) were incubated with 10-20 µl packed beads for 16 h at 4°C on a rotating wheel. 
Following incubation, beads were washed once in lysis buffer supplemented to a final 
concentration of 500 mM NaCl, and twice with normal lysis buffer. Bead-bound proteins 
were denatured and eluted in 1x SDS sample buffer supplemented with 2% (v/v) β-
mercaptoethanol for 5 min at 95°C. Samples were then filtered through Spin-X columns 
to remove the beads from the eluate. The filtered eluate was loaded onto a 4-12% bis-
tris gradient gel, and proteins were separated by SDS-PAGE as described in section 
2.2.3.4. Gels were stained with InstantBlue for 20 min, and de-stained in deionised water 
as described in section 2.2.3.5. A small portion of the eluate was retained for analysis by 
Western blotting. 
 
2.2.5.2: In-gel digestion of proteins for mass spectrometry: 
 
 In an attempt to minimise potential protein contaminants, all steps from this 
point were performed under a laminar flow hood (model A3VB, Bassaire Ltd.). 
Disposable scalpels were used to cut protein bands of interest from the InstantBlue 
stained gels into 1-2 cm cubes, which were subsequently transferred into LoBind 1.5 ml 
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Eppendorf tubes. Gel pieces were washed once in HPLC grade water, and then shrank in 
100% (v/v) acetonitrile for 5 min with gentle shaking. The acetonitrile was aspirated, and 
gel pieces were re-swollen with 50 mM Tris-HCl pH 8.0 for 5 min with shaking. The 
shrinking-swelling process was repeated once more, and the proteins within the gel 
pieces were reduced with 5 mM DTT in 50 mM Tris-HCl pH 8.0 for 20 min at 65°C. Next, 
the proteins within the gel pieces were alkylated with 20 mM iodoacetamide in 50 mM 
Tris-HCl for 20 min at room temperature. Gel pieces were subsequently shrank again in 
acetonitrile for 5 min, and re-swollen in 50 mM triethylammonium bicarbonate pH 8.0 
containing 5 µg/ml trypsin for 16 h overnight at 37°C for digestion. The next day, an 
equivalent volume of acetonitrile was added to the digest for 15 min with shaking, and 
the supernatant was collected into a new LoBind 1.5 ml Eppendorf tube. Gel pieces were 
then re-swollen with 0.1% (v/v) TFA for 5 min with shaking, and peptides were extracted 
twice with acetonitrile for 5 min each with shaking. After each extraction, the 
supernatant was removed and combined with the previous supernatant. The 
supernatants were then dried using a SpeedVac, and dried peptides were submitted for 
analysis by the mass spectrometry team (MRC PPU, University of Dundee). 
 
2.2.5.3: Peptide analysis by liquid chromatography-tandem mass spectrometry (LC-
MS/MS): 
 Digested peptides were reconstituted in HPLC-grade 5% (v/v) acetonitrile 
containing 0.1% (v/v) formic acid, and injected into a U3000 RSLC HPLC chromatography 
system (Thermo Fisher Scientific) coupled to a linear ion trap-orbitrap hybrid mass 
spectrometer (Orbitrap-VelosPro, Thermo Fisher Scientific). Peptides were trapped on 
a nanoViper Trap column (2 cm x 100 µM, C18 5 µM, 100 Å, Thermo Fisher Scientific), 
and subsequently separated on a 15 cm EasySpray column (Thermo Fisher Scientific), 
equilibrated with a flow rate of 300 nl/min. Data was acquired in the data-dependent 
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mode, automatically switching between MS and MS-MS acquisition. Full scan spectra 
(m/z 400-1,600) were acquired in the orbitrap with resolution set to 60,000 at m/z 400. 
The 20 most intense ions, above a specified minimum signal threshold of 2,000, were 
fragmented by collision induced dissociation and recorded in the linear ion trap (full AGC 
target; 30,000. Msn AGC target; 5,000). Raw files were subsequently converted into a 
list of identified peptides, along with the precursor intensity of  the identified peptides, 
and submitted to the in-house Mascot server (MRC PPU, University of Dundee). Data 
was searched against the SwissProt human database with variable modifications 
allowing for oxidation of Met, phosphorylation of Ser/Thr or Tyr residues, along with 
oxidation or dioxidation modifications. Carbamidomethylation of Cys was set as a fixed 
modification. Error tolerances were set to 10 ppm for MS1 and 0.6 Da for MS2. LC-MS-
MS analysis was performed by Dr. David Campbell, Robert Gourlay and Joby Varghese 
(MRC PPU, University of Dundee). Data analysis was performed using Scaffold v 4.4.6 
(Proteome Software).  
 
2.2.6: Statistical analysis: 
 
 All experiments, with the exemption of protein interactome mass spectrometry-
based experiments that were performed in a qualitative manner and subsequently 
verified by additional approaches, are representative of at least 3 biological replicates. 
qRT-PCR and in vitro assay experiments comprised 3-4 technical replicates per biological 
replicate, unless otherwise stated. Data are presented as the mean with error bars 
indicating the standard error of the mean. For box plots, the whiskers denote the 
minimum and maximum measured values. The middle line represents the median, and 
the box ranges depict the 25th/75th percentiles. 
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 Statistical significance of any differences between experimental groups was 
assessed with either a student’s t-test (two tailed, homoscedastic), or one-way ANOVA 
with post-hoc Tukey’s test, using GraphPad Prism software with standard settings. 
Differences in means were considered significant if P < 0.05. 
 All immunoblots and immunofluorescence images are displayed as 























Following the discovery that FAM83G interacted with the transcription factor 
SMAD1 (Vogt et al., 2014), and the demonstration that this interaction promoted the 
transcription of non-canonical bone morphogenetic protein (BMP) target genes (Vogt et 
al., 2014), it was hypothesised that the other FAM83 proteins may act in a similar way. 
To test this in a non-biased manner, transgenic human embryonic kidney HEK 293 cell 
lines, each stably expressing a single copy of a FAM83 gene under the control of the 
tetracycline (Tet)-inducible promoter, were generated. Each FAM83 protein was tagged 
with a green fluorescent protein (GFP) at the N-terminus. In these cell lines, expression 
of each GFP-FAM83 protein was induced in response to doxycycline in a time-dependent 
manner, with detectable amounts evident 30 min after doxycycline treatment (Figure 3-
1A). In a similar vein, U2OS osteosarcoma cell lines, stably integrated with a single copy 
of each FAM83 gene tagged at the C-terminus with GFP, also under the control of the 
Tet-inducible promoter, were generated. This time, all FAM83-GFP proteins displayed 
robust expression following 24 h treatment with doxycycline, except FAM83B, which did 
not express (Figure 3-1B). As a control, HEK 293 and U2OS cells expressing free GFP 
under the Tet-inducible promoter were also generated (Figure 3-1A&B). 
Following successful induction with doxycycline, extracts from these HEK 293 
and U2OS cell lines were subjected to anti-GFP immunoprecipitation, and the eluates 
were separated by SDS-PAGE. The gel sections corresponding to the entire lane for each 
sample were excised and digested with the protease trypsin. The resulting tryptic 
peptides were analysed by mass spectrometry, and assigned to human proteins within  
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Figure 3-1: Generation of HEK 293 and U2OS cells for tetracycline-inducible expression 
of FAM83 proteins: A: A single copy of each FAM83A-H gene was tagged with GFP at 
the N-terminus, and stably inserted downstream of a tetracycline-inducible promoter in 
Flp-In T-REx HEK 293 cells. GFP-FAM83 expression was induced by treating cells with 20 
ng/ml doxycycline, and cells were lysed at the indicated times after treatment. Extracts 
(10  µg protein) were resolved by SDS-PAGE and separated proteins were subjected to 
immunoblotting (IB) with the indicated antibodies (credit: Sabin Shrestha, n=2). B: As in 
A, except that Flp-In T-REx U2OS cells were used and the GFP tag was inserted at the C-
terminus of the FAM83 genes. FAM83B-GFP expression  could not be detected in U2OS 
cells. Unconjugated GFP was used as a control (credit: Tim Cummins, n=2).  
 
 
the UniProt database. Each FAM83 protein was correctly identified within each sample, 
and some known interactors were also found. These included SMAD isoforms in 
FAM83G immunoprecipitates (Vogt et al., 2014), and HMMR and DYNLL1 in FAM83D 
immunoprecipitates (Dunsch et al., 2012). Under these conditions, common FAM83 
interacting proteins that did not depend on the cell line used or position of the GFP tag 
were screened. This approach resulted in the surprising identification of isoforms of the 











Table 3-1: Mass fingerprinting identifies CK1 isoforms as putative FAM83-interacting 
proteins: Mass fingerprinting of protein interactors of N-terminal (HEK 293 cells) or C-
terminal (U2OS cells) GFP-tagged FAM83A-H proteins identified one or more CK1a, a-
like, d and e isoforms. Included in the tables are values of the top 3 precursor ion 
intensities for the indicated CK1 isoforms identified in each GFP-FAM83A-H (HEK 293) 
and FAM83A-H-GFP (U2OS), and control GFP pull-down obtained using Scaffold Q/Q+S 
V4.4.6 (HEK 293 cells) and V4.3 (U2OS cells) analysis of the LC-MS-MS data. Note: 




partners. Analysis of the top three precursor ion intensities of the individual identified 
CK1 isoforms found within the HEK 293 samples revealed that, whilst all GFP-FAM83 
proteins interacted with CK1α and α-like isoforms, GFP-FAM83A, B, E, and H also 
interacted with CK1δ and ε (Table 3-1). Similar patterns in spectral intensities were 
observed for CK1α, δ and ε isoforms, bound to FAM83-GFP proteins within the U2OS 
cell extracts, however CK1α-like was not detected in FAM83C, D or H 
immunoprecipitations (Table 3-1). Thus, these data suggested that FAM83 proteins may 
interact with CK1 isoforms in cells, and that there may be some selectivity with regard 
to which CK1 isoforms can bind each FAM83 member. 
CK1 isoforms identified by mass-spectrometry in FAM83 IPs
GFP-FAM83 A B C D E F G H GFP
CK1⍺ 185 828 211 99 662 283 1380 144 10
CK1⍺-like 143 787 176 76 501 232 1060 118 8
CK1δ 127 412 46 7 381 5 16 117 8
CK1ε 127 412 46 8 389 5 19 118 9
HEK 293 Top 3 precursor ion intensities (x 107)
FAM83-GFP A B C D E F G H GFP
CK1⍺ 101 N/A 36 84 709 902 905 234 1
CK1⍺-like 100 N/A 0 0 668 833 817 0 0
CK1δ 78 N/A 18 13 468 4 9 198 1
CK1ε 99 N/A 28 19 599 5 11 198 2
U2OS Top 3 precursor ion intensities (x 107)
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Regarded as promiscuous, constitutively-active protein kinases (Knippschild et 
al., 2005a, Schittek & Sinnberg, 2014, Venerando et al., 2014), the regulation of CK1 
isoforms in cells is critically important, yet poorly understood. Interacting proteins that 
are capable of regulating CK1 isoforms, in terms of modulating their localisation within 
the cell, their access to substrates, their stability and/or catalytic activity, remain elusive. 
That said, two scaffold proteins, the centrosomal and Golgi N-kinase anchoring protein 
(CG-NAP) (Sillibourne et al., 2002), and the DEAD-box RNA helicase DDX3 (Cruciat et al., 
2013), have been reported to regulate the centrosomal localisation of CK1δ, and the 
phosphorylation of Dvl by CK1ε, respectively. The potential existence of regulatory CK1-
interacting proteins is supported by the analogous role of the A-kinase anchoring 
proteins (AKAPs). AKAPs are well-established protein scaffolds that act to control the 
activity, localisation, and substrate specificity of protein kinase A (PKA), through direct 
association (Hoshi, Langeberg et al., 2005). Thus, I postulated that FAM83 proteins, if 
they do indeed interact with CK1 isoforms in cells, may act to regulate the constitutively-




3.2.1: FAM83 members interact with CK1 isoforms: 
To verify the putative interactions between FAM83 proteins and CK1 isoforms, 
GFP-FAM83A-H and control free GFP immunoprecipitates from HEK 293 extracts were 
probed for co-immunoprecipitation of endogenous CK1α, δ and ε isoforms. In 
agreement with the proteomic data described above (Table 3-1), CK1α was found in the 










Figure 3-2: FAM83 proteins interact with CK1 isoforms: A: Anti-GFP 
immunoprecipitations (IP) of GFP control or GFP-FAM83A-H proteins expressed in Flp-
In T-REx HEK 293 cells, resolved by SDS-PAGE, were subjected to immunoblotting (IB) 
with antibodies against the indicated CK1 isoforms and other interacting proteins (n=3). 
B: Top panel: Wild-type (WT) HaCaT or GFP-FAM83B knockin (GFP/GFPFAM83B) HaCaT 
cells were lysed and extracts (5 mg protein) were subjected to IP with anti-GFP beads. 
IPs, Input extracts (20 µg), and post-IP flow through (FT) extracts (20 µg), were resolved 
by SDS-PAGE, before being subjected to IB with the indicated antibodies (n=3). Lower 
panel: As in Top panel, except that wild type (WT) U2OS and FAM83G-GFP 
knockin (FAM83GGFP/GFP) U2OS cells were employed (n=3). C: WT U2OS extracts 
(1 mg protein) were subjected to IPs using either pre-immune IgG or an anti-CK1a 
antibody coupled to Protein-G sepharose beads. Input extracts (20 µg) and IPs were 




GFP control (Figure 3-2A). The interaction of GFP-FAM83B, E, G and H with CK1α 
appeared stronger than that of GFP-FAM83A, C, D and F (Figure 3-2A). CK1δ and ε were 
more selective in their choice of GFP-FAM83 binding partner, with endogenous CK1δ 
and ε found only in GFP-FAM83A, B, E and H immunoprecipitates (Figure 3-2A), 
consistent with the proteomic data (Table 3-1). Concomitantly, endogenous SMAD1 was 
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only found in GFP-FAM83G eluates, whereas HMMR and DYNLL1 co-precipitated 
exclusively with GFP-FAM83D (Figure 3-2A).  
Next, I sought to verify the FAM83-CK1 interactions at more endogenous levels. 
In the absence of robust immunoprecipitating antibodies recognising FAM83 proteins, I 
turned to CRISPR/Cas9-engineered cell lines, previously generated within the lab. These 
were human HaCaT keratinocytes in which a GFP knockin tag was introduced at the N-
terminus of FAM83B (generated by Gopal Sapkota), and U2OS cells in which the GFP 
was knocked into the C-terminus of FAM83G (generated by Polyxeni Bozatzi). Lysates 
from these cells were subjected to anti-GFP immunoprecipitations. Whereas 
endogenous CK1α was found in the eluates of both GFP-FAM83B and FAM83G-GFP, 
CK1ε was only evident in the precipitates of GFP-FAM83B (Figure 3-2B), consistent with 
the over-expression data (Figure 3-2A). In agreement, in the reciprocal experiment in 
which endogenous CK1α was immunoprecipitated from U2OS cell extracts, FAM83G and 
H could be detected in the eluate (Figure 3-2C). Importantly, no FAM83G or H were 
found in the pre-immune IgG control precipitate (Figure 3-2C).  
Given that all eight FAM83 members contain the DUF1669 domain within their 
N-termini, and that the C-termini are not conserved between FAM83 proteins (Figure 1-
12), it seemed reasonable that the apparently common interaction between FAM83 
proteins and CK1 isoforms might take place via the conserved DUF1669 region of FAM83 
proteins. In order to map the minimal domain within FAM83 proteins that can bind CK1 
isoforms, Myc-tagged FAM83G fragments were co-expressed with hemagglutinin (HA)-
tagged CK1α in FAM83G knockout U2OS cells, and coimmunoprecipitation experiments 
were performed (Figure 3-3A). HA-CK1α immunoprecipitates harboured only those 
Myc-FAM83G fragments that contained residues 165-307 within the DUF1669 domain 
(Figure 3-3A). Next, to test if the DUF1669-CK1 interaction was direct, an in vitro binding  
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Figure 3-3: The DUF1669 of FAM83 members is sufficient in mediating the interaction 
with CK1 isoforms: A: The indicated fragments of Myc-tagged Xenopus FAM83G 
(xFAM83G) were co-expressed with HA-CK1a in FAM83G knockout U2OS cells for 48 h. 
Anti-HA immunoprecipitates (IP) or whole-cell extracts (Input) were subjected to 
immunoblotting (IB) with anti-myc and anti-HA antibodies as indicated (credit: Polyxeni 
Bozatzi, n=3). B: Ni-sepharose agarose resin was loaded with 6xHis-FAM83A(122-304) 
fragments and used to pull down the CK1ε kinase domain (a.a. 1-294). Resin was washed 
twice with buffer containing 5 mM imidazole before elution with 250 mM imidazole. The 
Input, flow through (FT), washes (W1 and W2) and eluate (E) were analysed by SDS-
PAGE, and staining the gel with Coomassie blue (credit: Daniel Pinkas, Joshua Bufton, 
and Alex Bullock, n=3). C: The GFP-FAM83G DUF1669 domain, which interacts with CK1a 
only, was switched with the DUF1669 domain of GFP-FAM83H, which interacts with 
both CK1a and CK1e. U2OS cells were transfected with this chimera (GFP-DUFH-
FAM83G) or wild type GFP-tagged FAM83 constructs. Input extracts and GFP-IPs were 
resolved by SDS-PAGE, and subjected to IB with the indicated antibodies (n=3). 
 
 
assay between the kinase domain of CK1ε and a purified recombinant His-tagged 
FAM83A fragment incorporating residues 124-304 was performed. Following nickel-
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purification of His-FAM83A(124-304) and its subsequent elution with imidazole, both 
the FAM83A fragment and the CK1ε kinase domain were evident in the eluate, 
suggesting a direct association (Figure 3-3B).  
To probe the isoform-specific nature of the FAM83-CK1 interaction, the 
DUF1669 domain of FAM83G, a CK1α-specific interactor, was switched with the 
DUF1669 domain of FAM83H, which interacts with both CK1α and ε. This chimeric 
protein (GFP-DUF1669FAM83H-FAM83G) was expressed in HEK 293 cells, and subjected to 
anti-GFP immunoprecipitation. Strikingly, the GFP-DUF1669FAM83H-FAM83G chimera 
interacted with both CK1α and ε, much like the wild-type GFP-FAM83H protein (Figure 
3-3C). Collectively, these results suggest that the DUF1669 domain of FAM83 proteins is 
sufficient to confer selectivity towards specific CK1 isoforms.  
A CK1 docking motif, comprised of the amino acid sequence F-X-X-X-F, was 
identified in some CK1 interacting proteins, namely nuclear factor of activated T cells 1 
(NFAT1), Period 1 (PER1) and PER2 (Okamura et al., 2004). Mutation of either 
phenylalanine residue within the F-X-X-X-F motif abolished the interaction between CK1 
and these proteins (Okamura et al., 2004). One such F-X-X-X-F motif is also present 
within the DUF1669 domain of every FAM83 protein, and is evolutionarily conserved. 
Interestingly, whereas FAM83A-G have just one F-X-X-X-F motif, FAM83H harbours four 
such motifs. Thus, whether mutations within the F-X-X-X-F motif of FAM83 proteins 
would be sufficient to disrupt their interaction with CK1 isoforms was tested. FLAG-
tagged wild-type and various mutant forms of FAM83G [FAM83G(F296A), 
FAM83G(F300A), FAM83G(F296A, F300A)] were co-expressed with HA-CK1α, and 
screened for their ability to bind immunoprecipitated HA-CK1α. Whereas wild-type 






Figure 3-4: Two conserved residues within the DUF1669 mediates CK1 binding: A: 
Control Flag empty vector or the indicated FLAG-tagged FAM83G mutants were 
overexpressed in FAM83G-/- U2OS cells. Anti-FLAG immunoprecipitates (IP) or whole-
cell extracts (Input) were subjected to immunoblotting (IB) with anti-FLAG and anti-
CK1a antibodies as indicated (credit: Polyxeni Bozatzi, n=3). B. Wild-type (WT),  FA and 
DA mutants of GFP-FAM83E-H were transiently expressed in U2OS cells. Input extracts 




FAM83G(F296A,F300A) mutants did not (Figure 3-4A). Somewhat surprisingly, the FLAG-
FAM83G(F300A) mutant still interacted robustly with HA-CK1α  (Figure 3-4A), 
suggesting that the mode in which FAM83 members interact with CK1 isoforms might 
be different to that of the NFAT1, PER1 and PER2, which required both phenylalanine 
residues to be intact. Consistent with this idea, mutational scanning of conserved 
residues within the 165-307 amino acid region of FAM83G uncovered another mutation, 
D262A, that also disrupted the interaction between FAM83G and CK1α (Figure 3-4A). 
Armed with the knowledge that the FAM83G D262A and F296A mutations both 
abolish the FAM83G-CK1α interaction, it was speculated that mutation of the equivalent 
residues within other FAM83 members might also disrupt their association with CK1α. 
The analogous residues to FAM83G D262 and F296 were mutated in FAM83E (D243 and 
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constructs were expressed in U2OS cells with an N-terminal GFP tag,  in parallel with the 
respective wild-type GFP-FAM83 member as a control. Hereafter, these aspartate and 
phenylalanine mutants are referred to as DA and FA respectively. Extracts from wild-
type, DA and FA GFP-FAM83E-H were subjected to anti-GFP immunoprecipitations, and 
probed for their ability to bind endogenous CK1α or ε isoforms. In comparison to wild-
type GFP-FAM83E-H, both the DA and FA mutations attenuated the interactions 
between FAM83E-H and CK1α and ε (Figure 3-4B). Consistent with previous 
observations, although GFP-FAM83E and H bound to both CK1α and ε, GFP-FAM83F and 
G only bound to CK1α (Figure 3-4B).  
Collectively, these observations suggest that the interaction between CK1 
isoforms and the DUF1669 domain of FAM83 proteins may be mediated through a 
conserved structural motif surrounding the residues equivalent to D262 and F296 in 
FAM83G.  
 
3.2.2: FAM83 proteins co-localise with CK1α in cells: 
Given the observed interactions between all of the FAM83 members and CK1α 
in cell extracts, I sought to explore whether FAM83 proteins also interact with CK1α in 
cells. For this purpose, mCherry-CK1α was co-expressed with each GFP-FAM83 member 
in U2OS cells, with the expression of GFP-FAM83A-H under the control of the Tet-
inducible promoter. Upon induction of GFP-FAM83 expression, overlapping co-
localisation between every GFP-FAM83 member and mCherry-CK1α was observed 
(Figure 3-5A). Interestingly, each GFP-FAM83 protein exhibited a distinct, largely unique, 
pattern of subcellular localisation. Both GFP-FAM83A and B exhibited pan-cellular 
staining, with additional perinuclear staining evident for GFP-FAM83A, and plasma  
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Figure 3-5: FAM83 proteins and mCherry-CK1a co-localise in cells. A: U2OS cells stably 
integrated with Tet-inducible expression of GFP-FAM83A-H were transfected with 
mCherry-CK1a. GFP-FAM83A-H expression was induced with doxycycline for 24 h, prior 
to fixing cells for fluorescence microscopy. Images were taken using a Nikon TiS inverted 
microscope. Images were processed using NIS Elements (Nikon) and Adobe Photoshop 
using identical parameters across all the images. The number of cells across 3 
independent experiments which displayed identical staining patterns as the 
representative image were documented for each experiment: GFP-FAM83A (n=50); 
GFP-FAM83B (n=31); GFP-FAM83C (n=37); GFP-FAM83D (n=32); GFP-FAM83E (n=55); 
GFP-FAM83F (n=44); GFP-FAM83G (n=43); GFP-FAM83H (n=32).Scale bars; 20 µM. B:  
As in A. except that U2OS cells stably integrated with Tet-inducible expression of 
unconjugated GFP, or wild-type U2OS cells, both transfected with mCherry-CK1a, were 




membrane staining for GFP-FAM83B (Figure 3-5A). GFP-FAM83C displayed distinct 
fibrous patterns of fluorescence, reminiscent of actin cytoskeletal staining (Figure 3-5A).  
GFP-FAM83D displayed some cytoplasmic staining, with some punctate staining in the 
nucleus (Figure 3-5A). FAM83D has previously been reported to localise to the spindle 
apparatus during mitosis (Dunsch et al., 2012, Santamaria et al., 2008) and a detailed 
investigation into FAM83D is presented later (see chapter 4). GFP-FAM83E was found in 
the cytoplasm and in the perinuclear region, whereas GFP-FAM83F was most 
prominently located on the plasma membrane, with some additional staining evident in 
the cytoplasm and nucleus (Figure 3-5A). In line with previous reports, GFP-FAM83G was 
diffusely localised within the cytoplasm and nucleus (Figure 3-5A) (Bozatzi et al., 2018, 
Cummins et al., 2018, Vogt et al., 2014). GFP-FAM83H was found primarily in 
cytoplasmic punctate structures, although analogous structures were also observed in 
the nucleus (Figure 3-5A). This GFP-FAM83H localisation pattern is consistent with that 
reported for FLAG-FAM83H overexpressed in HCT116 cells (Kuga et al., 2016a, Kuga et 
al., 2013). As a control, free, unfused GFP was co-expressed with mCherry-CK1α in U2OS 
cells. Under these conditions, the GFP signal was predominantly nuclear, and did not 
overlap with the mCherry-CK1 α signal, which was present throughout the cell (Figure 
3-5B). When expressed on its own, mCherry-CK1α was also found throughout the cells 
(Figure 3-5B). 
Given the potential caveats of exploring co-localisation between two over-
expressed proteins, I next sought to confirm whether endogenous CK1α also displayed 
similar overlapping subcellular distributions with certain GFP-FAM83 members. For this 
purpose, I chose GFP-FAM83B, F and H, due to their distinct and pronounced localisation 
patterns (Figure 3-5A). Overlapping plasma membrane and perinuclear staining was 
















Figure 3-6: FAM83 proteins and endogenous CK1a co-localise in cells: U2OS cells stably 
integrated with Tet-inducible expression of unconjugated GFP (negative control) or GFP-
FAM83B, F or H were treated with doxycycline for 16 h, prior to fixing cells for 
fluorescence microscopy. Following fixation, cells were stained with an anti-CK1a 
antibody to enable visualisation of endogenous CK1a. Images were taken using a 
DeltaVision widefield fluorescence microscope and deconvolved using SoftWoRx. The 
number of cells across 3 independent experiments which displayed identical staining 
patterns as the representative image were documented for each experiment: GFP-
FAM83B (n=56); GFP-FAM83F (n=60); GFP-FAM83H (n=48); GFP only (n=38); CK1a only 
(n=82). Scale bars; 20 µm (credit: Kevin Wu). 
 
 
exhibited overlapping fluorescence at the plasma membrane, and GFP-FAM83H co-
localised with CK1α on the cytoplasmic and nuclear puncta (Figure 3-6). No overlapping 
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fluorescence was detected between endogenous CK1α and free GFP, which was 
employed as a negative control (Figure 3-6).  
As a whole, these observations suggest that upon overexpression, each FAM83 
protein is capable of promoting a change in the localisation of endogenous CK1α, so that 
CK1α is relocated to the distinct subcellular compartments in which the FAM83 member 
in question resides.  
 
3.2.3: The association between FAM83 proteins and specific CK1 isoforms is selective 
in cells: 
The above data demonstrates co-localisation between GFP-FAM83 proteins and 
CK1α. However, FAM83A, B, E and H also interact with CK1δ and ε isoforms in cell 
extracts (Figure 3-2A). Thus, I sought to test whether this selectivity in the interactions 
between certain FAM83 members and CK1 isoforms persists in cells. I compared the 
subcellular distributions of mCherry-CK1α and mCherry-CK1ε with GFP-FAM83F, a 
selective CK1α-interacting protein, and GFP-FAM83H, which interacts with both CK1α 
and ε, in U2OS cells. As observed earlier, overlapping fluorescence was detected 
between both GFP-FAM83F and H, and mCherry-CK1α, at the plasma membrane and 
cytoplasmic puncta, respectively (Figure 3-7A). In contrast, GFP-FAM83H, but not GFP-
FAM83F, appeared to co-localise with mCherry-CK1ε, at these cellular sites (Figure 3-
7A). 
To verify if this binding specificity of GFP-FAM83F and H extended to endogenous 
CK1α and ε, the experiment was repeated with endogenous CK1α and ε staining. In wild-
type U2OS cells, endogenous CK1α and ε both exhibited pan-cellular staining (Figure 3-
7B). Consistent with the mCherry-CK1α and ε overexpression data above (Figure 3-7A), 
endogenous CK1α co-localised with GFP-FAM83F on the plasma membrane, whereas  
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Figure 3-7: The association between FAM83 proteins and specific CK1 isoforms is selective in 
cells: A: U2OS cells stably integrated with Tet-inducible expression of GFP-FAM83F or GFP-
FAM83H were transfected with either mCherry-CK1a or mCherry-CK1e. GFP-FAM83F and GFP-
FAM83H expression was induced with doxycycline for 24 h, prior to fixing cells for fluorescence 
microscopy. Images were taken using a DeltaVision widefield fluorescence microscope and 
deconvolved using SoftWoRx. The number of cells across 3 independent experiments which 
displayed identical staining patterns to the representative image were documented for each 
experiment: GFP-FAM83F + mCherry-CK1a (n=44); GFP-FAM83F + mCherry-CK1e (n=40); GFP-
FAM83H + mcherry-CK1a (n=32); GFP-FAM83H + mCherry-CK1e (n=40). Scale bars; 20 µm 
(credit: Kevin Wu). B. U2OS cells stably integrated with Tet-inducible expression of GFP-FAM83F 
or H were induced with doxycycline for 16 h, prior to fixing cells for fluorescence microscopy. 
Cells were stained with anti-CK1a or CK1e to visualise endogenous CK1a and CK1e respectively. 
Untransfected cells stained with anti-CK1a or CK1e were used as negative controls. Images were 
taken using a DeltaVision widefield fluorescence microscope and deconvolved using SoftWoRx. 
The number of cells across 3 independent experiments that displayed identical staining patterns 
to the representative image were documented for each experiment: GFP-FAM83F+CK1a (n=60); 
GFP-FAM83F+CK1e (n=43); GFP-FAM83H+CK1a (n=48); GFP-FAM83H+CK1e (n=35); CK1a only 
(n=82); CK1e only (n=27).  Scale bars; 20 µm (credit: Kevin Wu). 
 
endogenous CK1ε did not (Figure 3-7B). In contrast, both endogenous CK1α and ε co-
localised with GFP-FAM83H on the cytoplasmic punctate structures (Figure 3-7B). 
 114 
Collectively, these data recapitulate the distinct sets of interactions between FAM83 
members and CK1 isoforms detected in extracts, within the cellular environment. 
 
3.2.4: Association with CK1 determines the subcellular localisation of FAM83 proteins: 
Next, I asked whether the interaction between CK1 and FAM83 proteins was 
important for their subcellular localisations. To this end, I chose GFP-FAM83C because 
of its distinct localisation on the actin-like fibers (Figure 3-5A). Having confirmed that 
only wild-type GFP-FAM83C coimmunoprecipitated HA-CK1α, and that GFP-
FAM83C(D259A), GFP-FAM83C(F293A), and free GFP did not (Figure 3-8A), U2OS cells 
expressing these FAM83C constructs were subjected to fluorescence microscopy, with 
co-expressed mCherry-CK1α. Whereas GFP-FAM83C and mCherry-CK1α co-localised 
along the actin-like filaments, both GFP-FAM83C(D259A) and GFP-FAM83C(F293A)were 
predominantly found within the cytoplasm, in slightly distorted fibrous patterns, that 
did not overlap with mCherry-CK1α fluorescence (Figure 3-8B). These observations 
suggest that the interaction between FAM83C and CK1α is important in determining the 
subcellular localisation of both proteins. However, these experiments suffer from the 
possibility that the endogenous FAM83C protein, which is still present in the cells, may 
be influencing the association between the overexpressed GFP-FAM83C proteins and 
CK1α. Thus, I sought to examine the role of FAM83-CK1 interactions in determining 
subcellular localisation of each protein, in a more refined model. 
Having shown that FAM83H localises to distinct cytoplasmic punctate structures 
when over-expressed in U2OS cells (Figure 3-5A), FAM83H knockout U2OS cells were 
generated by Tim Cummins using CRISPR/Cas9, and either wild-type, FA or DA GFP-  
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Figure 3-8: The subcellular localisation of FAM83C is determined by its association with 
CK1α: A: U2OS cells were co-transfected with plasmids encoding either unconjugated 
GFP, wild-type GFP-FAM83C (WT), GFP-FAM83C-F293A (FA) or GFP-FAM83C-D259A 
(DA), and HA-CK1a as indicated. Untransfected and HA-CK1a only transfected cells were 
included as controls. Input extracts and anti-GFP immunoprecipitates (IP) were resolved 
by SDS-PAGE, and subjected to immunoblotting (IB) with the indicated antibodies (n=3). 
B: U2OS cells were transfected with plasmids encoding either wild-type GFP-FAM83C, 
GFP-FAM83C-F293A or GFP-FAM83C-D259A together with mCherry-CK1a as indicated. 
Representative images from cells expressing GFP-FAM83C or mCherry-CK1a alone are 
also included. 24 h-post transfection, cells were fixed and processed for fluorescence 
microscopy. Images were taken using a DeltaVision widefield fluorescence microscope 
and deconvolved using SoftWoRx. The number of cells across 3 independent 
experiments that displayed identical staining patterns to the representative image were 
documented for each experiment: GFP-FAM83C only (n=46); GFP-FAM83C + mCherry-
CK1a (n=44); GFP-FAM83C(F293A) + mCherry-CK1a (n=41); GFP-FAM83C(D259A) + 





Figure 3-9: FAM83H co-localises with, and in part determines the subcellular 
localisation of, endogenous CK1a: A: FAM83H-/- U2OS cells were transfected with 
rescue vectors encoding GFP-FAM83H, GFP-FAM83H(D236A), GFP-FAM83H(F270A) or 
left Untransfected. Cells were fixed in methanol and stained with anti-CK1α. DNA was 
stained with DAPI. Representative images from one field of view, representative of 3 
independent experiments are included. Scale bars; 10 µm. (credit: Theresa Tachie-
Menson and Graeme Ball). B: The boxplot shows the range, mean, lower and upper 
quartile of the Pearson’s correlation coefficients of GFP-FAM83H and endogenous CK1α 
within above-background pixels in the cytoplasm. n=3. (credit: Theresa Tachie-Menson 
and Graeme Ball). C: Analysis of protein expression of rescue constructs transfected in 
FAM83H-/- U2OS cells, in comparison to wild-type (WT) cells, as indicated by 
immunoblotting (IB) (credit: Theresa Tachie-Menson, n=3). 
 
 
FAM83H mutants were restored through transient transfections. In FAM83H knockout 
cells, CK1α was primarily cytoplasmic with few perinuclear puncta (Figure 3-9A). When 
GFP-FAM83H was expressed in the FAM83H knockout background, both GFP-FAM83H 
and endogenous CK1α adopted a pan-cellular punctate pattern with the majority of GFP-
FAM83H puncta overlapping with endogenous CK1α staining, suggesting robust co-
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localisation (Figure 3-9A). When the CK1-interaction deficient GFP-FAM83H DA and FA 
mutants were expressed in FAM83H knockout cells, they displayed cytoplasmic, non-
punctate fluorescence that did not overlap with endogenous CK1α (Figure 3-9A). The 
intensity of CK1α punctate staining both in FAM83H knockout cells, and in FAM83H 
knockout cells expressing the CK1-binding–deficient mutant forms of FAM83H, was 
lower compared to that seen in cells expressing wild-type GFP-FAM83H (Figure 3-9A), 
suggesting that the interaction with FAM83H determines the localisation of CK1α to the 
punctate structures.  
Next, the co-localisation correlation between CK1α and wild-type GFP-FAM83H, 
or the DA and FA GFP-FAM83H mutants was quantified. The localisation of CK1α 
positively correlated with that of wild-type GFP-FAM83H (Pearson correlation 
coefficient 0.7523), whereas it did not correlate with the GFP-FAM83H DA (0.001504) 
or GFP-FAM83H FA (0.001504) mutants (Figure 3-9B). Rescue of FAM83H knockout 
U2OS cells with wild-type or mutant GFP-FAM83H constructs was confirmed by 
immunoblotting, which suggested that the abundance of FAM83H in these cells was 
substantially higher than the amount of endogenous FAM83H in wild-type U2OS cells 
(Figure 3-9C). Consistently, in the FAM83H knockout U2OS cells, endogenous CK1ε 
displayed similar immunostaining patterns to CK1α and exhibited significant co-
localisation correlation with wild-type GFP-FAM83H, but not with the CK1-binding 






Figure 3-10: FAM83H co-localises with, and in part determines the subcellular 
localisation of, endogenous CK1e: A: FAM83H-/- U2OS cells were transfected with 
rescue vectors encoding GFP-FAM83H, GFP-FAM83H-D236A, GFP-FAM83H-F270A, or 
left Untransfected. Cells were fixed in methanol and stained with anti-CK1ε. DNA was 
stained with DAPI. Representative images from one field of view, representative of 3 
independent experiments are included. Scale bars; 10 µm (credit: Theresa Tachie-
Menson and Graeme Ball). B: The boxplot shows the range, mean, lower and upper 
quartile of the Pearson’s correlation coefficients of GFP-FAM83H and endogenous CK1ε. 
The boxplot shows the range, mean, lower and upper quartile of the Pearson’s 
correlation coefficients. Data were obtained from three independent experiments 
(credit: Theresa Tachie-Menson and Graeme Ball). 
 
 
3.2.5: The intrinsic catalytic activity of CK1 is not required for the association of CK1 
with FAM83 proteins: 
In their capacity as CK1-interacting proteins, it is possible that FAM83 members 





these CK1 kinases. Next, whether CK1α could phosphorylate FAM83 proteins in vitro 
was tested, using purified recombinant FAM83 proteins. Whereas FAM83B, C and G 
appeared to be robustly phosphorylated by CK1α, the other FAM83 members exhibited 
poorer phosphorylation (Figure 3-11A). The precise CK1α-dependent phosphorylation 
sites on most FAM83 proteins have not been mapped, and whether these 
phosphorylation events occur in cells, and the functional consequences of these 
phosphorylation events, if any, remain to be investigated. The low activity of CK1α 
towards some of the FAM83 substrates in this in vitro assay may be due to the poor 
purity of some of these recombinant proteins (Figure 3-11A). Alternatively, lack of 
detectable phosphorylation might simply reflect lack of a priming phosphorylation 
event, as the priming kinase is not present in the assay conditions. The optimal CK1 
consensus phosphorylation motif is pS/T-X-X-S/T (Knippschild et al., 2005a, Schittek & 
Sinnberg, 2014), thus lack of this priming phospho-Ser/Thr may render some of the 
FAM83 members unphosphorylatable by CK1. Previous work in the lab mapped the 
CK1α-dependent phosphorylation site on FAM83G to be S614 in vitro, but this 
phosphorylation event did not impact FAM83G function in Wnt signalling, which 
requires its association with CK1α (Bozatzi et al., 2018). Thus, the exact role and 
relevance of CK1-dependent FAM83 phosphorylation remains to be further defined. 
Next, in order to examine whether the intrinsic catalytic activity of CK1α was 
affected by its association with FAM83 proteins, an in vitro CK1α kinase assay with 
increasing concentrations of an optimised CK1 peptide substrate (CK1tide) was 
performed, and whether addition of equimolar amounts of either wild-type FAM83G, or  
 120 
 
Figure 3-11: Dissecting the links between intrinsic CK1 catalytic activity and the 
FAM83-CK1 interaction: A: An in vitro kinase assay was set up using 200 ng of GST-CK1α, 
2 µg of substrate (GST-FAM83A, C, D, E, F, or H, MBP-FAM83B, or GST-FAM83G-6XHis) 
and [γ32P]-ATP (~500 cpm/pmol). After reactions were stopped, samples were resolved 
by SDS-PAGE and the gel was stained with InstantBlue, dried and subjected to 32P 
autoradiography for the indicated times (credit: Polyxeni Bozatzi and Karen Dunbar, 
n=3). B: An in vitro kinase assay was set up with 50 ng of GST-CK1α and increasing 
amounts of CK1tide as indicated. The effects adding of equimolar amounts of wild-type 
(WT) GST-FAM83G-6xHis or the CK1 interaction-deficient GST-FAM83G(F296A,F300A) 
mutant on intrinsic CK1α activity were evaluated. Data points represent the average 
from 3 independent experiments, each containing 3 technical replicates. Error bars 
represent SEM. C: U2OS cells were transiently co-transfected with GFP-FAM83E-H and 
either mCherry-tagged WT CK1a or a catalytically inactive [kinase dead (KD)] mutant 
[CK1α(N141A)]. Following transfection, cells were lysed and extracts subjected to anti-
GFP immunoprecipitation (IP). Input and IP samples were resolved by SDS-PAGE, and 
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CK1-interaction-deficient FAM83G(F296A, F300A), altered the rate of CK1α catalysis or 
its Michaelis constant (Km) towards the CK1tide substrate was tested. Under these  
conditions, the addition of either wild-type FAM83G or mutant FAM83G(F296A, F300A) 
did not appear to significantly affect the intrinsic kinase kinetics of CK1α, at all CK1tide 
concentrations tested (Figure 3-11B).  
Finally, I assessed whether the kinase activity of CK1α was required for its 
interaction with FAM83 proteins. For this purpose, GFP-FAM83E, F, G or H were 
transiently co-expressed with either mCherry-tagged wild-type CK1α, or an mCherry-
tagged CK1α catalytic inactive mutant CK1α(N141A) in U2OS cells, and 
coimmunoprecipitation experiments were performed. Equal amounts of both the wild-
type and kinase-dead CK1α mutant were detected in the immunoprecipitates of GFP-
FAM83E-H, suggesting that CK1α kinase activity is dispensable for the interaction with 




CK1 isoforms are known to regulate a myriad of cellular processes (Del Valle-
Perez et al., 2011, Knippschild et al., 2005a, Venerando et al., 2014), yet how they are 
capable of achieving such a feat remains poorly defined. The identification of FAM83 
proteins as CK1-anchoring proteins may present one avenue of regulating the 
constitutively-active CK1 kinases in mammalian cells. These findings suggest that the 
DUF1669 of FAM83 proteins anchor CK1α, δ and ε isoforms to distinct cellular 
compartments, and in doing so, FAM83 members place themselves in an ideal position 
to regulate CK1 isoforms by a number of potential routes. One possibility is that, through 
sheer control of CK1 localisation, CK1 is physically unable to phosphorylate certain 
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substrates as they are not available within that cellular compartment. Alternatively, 
other proteins bound to FAM83 members might be optimally presented to CK1 as 
substrates, and in that capacity FAM83 proteins can act as signalosome assembly 
platforms. At least for FAM83G, it seems unlikely that direct binding of FAM83G to CK1α 
acts to allosterically activate or inhibit the intrinsic CK1α catalytic activity, although this 
will have to be assessed on a case-by-case basis for each FAM83 member. 
The way in which FAM83 proteins can bind and direct CK1 isoforms to specific 
cellular sites is reminiscent of the AKAPs that serve to regulate PKA (Hoshi et al., 2005). 
Unlike AKAPs, which bind to the regulatory domain of PKA, the DUF1669 of FAM83 
proteins appears to interact directly with the kinase domain of CK1 isoforms. There are 
many other examples of the crucial roles that scaffolding and anchoring proteins play in 
organising and streamlining signal transduction in cells. Of note, targeting protein for 
Xklp2 (TPX2) is a scaffold protein that recruits Aurora kinase A to the mitotic spindle, 
and also serves as an allosteric activator of the kinase (Bayliss et al., 2003, Chen et al., 
2014).  
Precisely how FAM83 members affect the diverse functions of CK1 isoforms in 
cells is largely unclear. However, some of the influences FAM83 members have on 
regulating CK1 functions are beginning to be uncovered. Previous work in the lab has 
established that FAM83G is a critical regulator of Wnt signalling in both human cells and 
Xenopus embryos, and its over-expression in Xenopus embryos leads to hyperactivation 
of Wnt signalling, and the subsequent formation of a secondary body axis (Bozatzi et al., 
2018). Whereas wild-type FAM83G over-expression drives Wnt signalling, two FAM83G 
mutants incapable of binding CK1α are unable to activate Wnt signalling, or induce axis 
duplication in Xenopus embryos, thus highlighting the key role the FAM83G-CK1α plays 
in correct development (Bozatzi et al., 2018). Future efforts aimed at establishing the 
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roles that other FAM83-CK1 interactions have in biology, both at the process and 
molecular levels, will shed light on how and where these FAM83-CK1 complexes act.  
Given the involvement of CK1 isoforms in such a wide range of cellular processes, 
it is perhaps unsurprising that the mis-regulation of CK1 kinases have been linked to 
diseases such as cancer and neurodegeneration (Knippschild et al., 2005a, Schittek & 
Sinnberg, 2014). The pleiotropic nature of CK1 within various signalling pathways, 
combined with poor understanding on how these kinases are regulated, have limited 
the exploration of CK1 isoforms as potential therapeutic targets. That said, several 
inhibitors of CK1 have been developed, including CKI-7, IC261, D4476, PF-670462, and 
PF-4800567 (Table 1-1). However, these compounds lack selectivity towards specific, 
individual CK1 isoforms, and as such, their use has often prevented the unequivocal 
identification of individual CK1 isoform-substrate relationships (Badura, Swanson et al., 
2007, Behrend et al., 2000, Chijiwa, Hagiwara et al., 1989, Rena, Bain et al., 2004, 
Walton, Fisher et al., 2009). Even if it were possible to target individual CK1 isoforms, 
given their involvement in many physiological processes, coupled with their conflicting 
roles within the same signalling pathways at different stages of signal amplification (Del 
Valle-Perez et al., 2011, Knippschild et al., 2005a, Schittek & Sinnberg, 2014), pan-
cellular inhibition of a CK1 isoform will likely not be beneficial. Thus, targeting distinct 
CK1-containing complexes, such as those of FAM83 proteins, may present an 
alternative, more specific means of shutting down selective CK1-dependent processes, 










Having identified FAM83 proteins as putative CK1-anchoring proteins in cells, I 
next sought to test this hypothesis in a focussed way, by exploring the roles of individual 
FAM83-CK1 interactions in more physiological settings. Whilst the function of the 
FAM83G-CK1α complex was characterised in Wnt signalling in parallel (Bozatzi et al., 
2018), and some evidence points to FAM83H-CK1 complexes having a role in 
cytoskeletal dynamics (Kuga et al., 2016a, Kuga et al., 2013), the biology of the other 
FAM83-CK1 interactions have not been investigated. With this in mind, I set off to 
characterise the function of FAM83D, and explore the role of its interaction with CK1. 
FAM83D (also known as c20orf129 and Chica) was originally identified in a 
proteomic screen of isolated human mitotic spindles (Sauer et al., 2005). Subsequently, 
FAM83D was shown to localise to the mitotic spindle apparatus, and knocking down 
FAM83D with RNA interference approaches was shown to result in both chromosomal 
alignment and congression defects, with a concurrent delay in the length of mitosis 
(Dunsch et al., 2012, Santamaria et al., 2008). Collectively, these observations pointed 
to a role for FAM83D in the cell division cycle. The current model proposes that FAM83D 
is recruited to the spindle through binding the microtubule-associated protein 
hyaluronan mediated motility receptor (HMMR, also known as RHAMM or CD168) at its 
C-terminus (Dunsch et al., 2012). In support of this model, FAM83D fragments lacking 
the C-terminal 394-615 amino acids fail to bind HMMR, and do not localise to the spindle 
apparatus in mitosis (Dunsch et al., 2012). Thus, it seems likely that FAM83D and HMMR 
exist in a stable complex. Recent reports have highlighted the critical role HMMR plays 
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in cell division, as mice or cells lacking HMMR take longer to progress through mitosis, 
and fail to resolve spindle positioning defects due to defective clearance of cortical 
dynein force-generating complexes (Chen, Connell et al., 2018, Connell et al., 2017). Few 
other FAM83D interacting proteins have been reported, however the interaction 
between FAM83D and dynein light chain 1 (DYNLL1) has been linked to correct and 
efficient spindle orientation dynamics (Dunsch et al., 2012), and FAM83D was reported 
to be required for the recruitment of the chromokinesin Kid to the spindle in HeLa cells 
(Santamaria et al., 2008). 
Previously, I identified FAM83D as a CK1α-specific interactor, although the 
relative amounts of CK1α co-precipitating with FAM83D, even at the over-expression 
level, were always much lower compared to the amounts of CK1α in the 
immunoprecipitates of the other FAM83 members (Fulcher, Bozatzi et al., 2018). Armed 
with the knowledge that FAM83D is a spindle-localised protein, I hypothesised that the 
FAM83D-CK1α interaction might take place in a cell cycle-dependent manner, thereby 
explaining the low amounts of CK1α in FAM83D immunoprecipitates from asynchronous 
cell extracts.  
In this chapter, I set out to explore the possibility that FAM83D interacts with 
CK1α in mitosis, and examine whether this interaction is indeed important for correct 




4.2.1: FAM83D interacts with CK1α only in mitosis: 
In order to explore the cellular roles of FAM83D at the endogenous level, I 
generated FAM83D knockout and FAM83DGFP/GFP knockin human osteosarcoma U2OS  
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Figure 4-1: Generation of FAM83D knockout and FAM83DGFP/GFP knockin U2OS cells: A: 
Immunoblot (IB) confirmation of wild-type (WT), FAM83D knockout (KO), and 
FAM83DGFP/GFP knockin (KI) U2OS cell lines. Extracts were probed with antibodies raised 
against the N- or C-terminus of FAM83D (n=3). B: Genomic DNA sequencing analysis of 
the FAM83D KO cell line (clone 9). Pink dashes show the deleted bases, relative to the 
WT sequence. C: The guide RNAs (gRNA), along with their DU numbers (Table 2-8) used 
to target FAM83D are shown in orange. A 22 bp deletion on one allele, and a 14 bp 
deletion on the other allele was found. as, antisense gRNA; s, sense gRNA. D: 
Amplification of genomic DNA from WT and KI clone 4 cells with PCR, using primers 
outside the 5’ and 3’ homology arms (HA), confirmed integration of green fluorescent 
protein (GFP) within the FAM83D locus. F, forward primer; R, reverse primer (n=1). E: 
Amplification of genomic DNA from WT and KI clone 4 cells with PCR, using primers 
within GFP and outside the HA, at both the 5’ and 3’ junctions of the donor cassette, 
confirmed successful integration of GFP into the C-terminus of FAM83D. 5’ F, 5’ Forward 
primer; 5’ R, 5’ Reverse primer; 3’ F, 3’ Forward primer; 3’ R, 3’ Reverse primer (n=1). 
 
 
cell lines using CRISPR/Cas9 gene editing technology (Figure 4-1A). Successful knockout 
of FAM83D was confirmed by immunoblotting (Figure 4-1A) and DNA sequencing (Figure 
4-1B). As the CRISPR guide RNAs were designed to target exon 2 of FAM83D, and 
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targeting this region could potentially result in expression of truncated FAM83D N-
terminal protein fragments, I checked a full range of molecular weights, and could not 
detect any N-terminal FAM83D truncated fragments (Figure 4-1A). DNA sequencing 
revealed a 14 bp deletion on one FAM83D allele, and a 22 bp deletion on another allele 
(Figure 4-1C). Both allelic deletions are predicted to create an out-of-frame shift, 
resulting in a premature stop codon. Successful knockin of the GFP tag onto the C-
terminus of FAM83D was confirmed by immunoblotting (Figure 4-1A), and genomic PCR 
(Figure 4-1D). Amplification of the 5’ and 3’ junctions between GFP and the surrounding 
FAM83D sequences confirmed that the GFP-tag had integrated at the correct position 
within the FAM83D locus (Figure 4-1E). 
Having verified the endogenous FAM83DGFP/GFP knockin U2OS cell line, whether 
FAM83D could interact with CK1α in mitosis in these cells was explored. To obtain 
mitotic cells, cells were treated with nocodazole to arrest them in prometaphase, 
followed by a brief release into fresh medium to allow them to progress into mitosis. 
Following treatment, mitotic cells were collected by shake-off. Asynchronous cells were 
employed as a control. Cells were lysed and subjected to anti-GFP immunoprecipitation, 
and subsequent immunoblotting. Interestingly, FAM83D exhibited a striking change in 
electrophoretic mobility in mitotic extracts, compared to asynchronous extracts, 
indicative of a potential post-translational modification (Figure 4-2A). This is consistent 
with a previous report suggesting that FAM83D is phosphorylated in mitosis (Santamaria 
et al., 2008). Probing the eluates with antibodies against CK1a, d and e, revealed that 
the only FAM83-relevent CK1 isoform to co-precipitate with FAM83D was CK1a, and this 
interaction only took place in mitotic, but not asynchronous, extracts (Figure 4-2A). The 
known interactions between FAM83D and HMMR or DYNLL1 were not significantly  
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Figure 4-2: FAM83D only interacts with CK1α in mitotic extracts: A: FAM83DGFP/GFP 
knockin U2OS cells were synchronised in mitosis (M) with nocodazole. Untreated, 
asynchronous (AS) cells were used as a control. Lysed extracts were subjected to anti-
GFP immunoprecipitations (IP), and whole cell lysate (Input) and IP samples were 
analysed by immunoblotting (IB) with the indicated antibodies (n=3). B: FAM83DGFP/GFP 
knockin U2OS cells were synchronised in mitosis (M) with either nocodazole (M Noc.) or 
STLC (M STLC) and collected by shake off. Cells treated were nocodazole or STLC that 
remained adherent after shake-off (AS Noc.; AS STLC) were used as drug-treated, non-
mitotic controls. Asynchronous (AS) cells were used as a control. For a GFP only control, 
2G-PAI1 U2OS cells which express low levels of GFP were used. Lysed extracts were 
subjected to anti-GFP IPs, and Input and IP samples were analysed by IB with the 
indicated antibodies (n=3). C: Propidium iodide staining analyses revealing cell cycle 
distribution profiles for the samples described in B.   
 
 
altered between asynchronous and mitotic samples, suggesting that their mode of 
interaction is more constitutive (Figure 4-2A).  
Next, I sought to eliminate the possibility that the FAM83D-CK1a interaction was 
occurring as an off-target effect of nocodazole treatment. FAM83DGFP/GFP cells were  
treated with either nocodazole, or the Eg5 inhibitor S-Trityl L-Cysteine (STLC) (Skoufias 
et al., 2006), which also arrests cells in mitosis, but, unlike nocodazole, results in 
monopolar spindle formation. Nocodazole-treated cells were washed in PBS and re-
plated in fresh full media to allow them to progress into mitosis prior to lysis. Mitotic 
nocodazole- and STLC- treated cells were collected by shake-off. The cells that remained 
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adherent after shake-off were collected for use as drug-treated, non-mitotic controls. 
Untreated, asynchronous FAM83DGFP/GFP cells were used as a negative control. To make 
sure that CK1a did not co-precipitate with the GFP tag of FAM83D-GFP, I made use of a 
PAI1 transcriptional reporter U2OS cell line (2G PAI1), in which low levels of GFP are 
expressed under basal conditions (Rojas-Fernandez, Herhaus et al., 2015). Following 
lysis, samples were subjected to immunoprecipitation with anti-GFP coupled beads. 
Consistent with previous observations (Figure 4-2A), FAM83D exhibited a change in 
electrophoretic mobility and CK1a only co-precipitated with FAM83D in the nocodazole-
treated mitotic lysates (Figure 4-2B). Critically, I observed the same result in STLC-
treated mitotic extracts, further demonstrating the mitotic nature of the FAM83D-CK1a 
interaction (Figure 4-2B). Importantly, I observed neither a FAM83D mobility shift, nor 
any CK1a in FAM83D immunoprecipitates, from non-mitotic nocodazole or STLC-
treated extracts, thereby suggesting that the FAM83D-CK1a interaction and FAM83D 
mitotic mobility shift are not off-target effects resulting from the drug treatments 
(Figure 4-2B). No CK1a co-precipitated with the free GFP protein in the 2G PAI1 control 
extracts (Figure 4-2B), demonstrating that CK1a does not interact with the isolated GFP 
protein. Staining cells from each of these treatments with propidium iodide, and 
subjecting them to flow cytometric-based DNA-profiling, confirmed the enriched G2/M 
cell populations in nocodazole- and STLC-treated mitotic cells (Figure 4-2C), whereas the 
DNA profiles were spread over G1, S and G2/M phases with the other treatments (Figure 
4-2C). 
Next, to address whether the GFP-tag knocked in to the FAM83D gene was 
artificially inducing the FAM83D mobility shift or interaction with CK1a in mitotic cells, 
I performed endogenous FAM83D immunoprecipitations using polyclonal antibodies 
raised against the C-terminus of FAM83D, in both mitotic and asynchronous extracts.  
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Figure 4-3: Confirming the mitotic FAM83D-CK1α interaction at the endogenous level: 
A: Wild-type U2OS cells were synchronised in mitosis with nocodazole (M). 
Asynchronous (AS) cells were used as a control. Lysed extracts were subjected to 
immunoprecipitation (IP) with either control IgG or anti-FAM83D antibody coupled to 
sepharose beads. Input and IP samples were analysed by immunoblotting (IB) with the 
indicated antibodies (n=3). B: As in A. except that anti-CK1α antibody coupled to 
sepharose beads were used for the IP (n=3). 
 
 
Sheep pre-immune IgG immunoprecipitations were performed in parallel as a control. 
Probing these samples confirmed that the FAM83D-CK1a interaction takes place only in 
mitotic extracts, and showed that the mitotic mobility shift of FAM83D occurs 
independently of the GFP fusion tag (Figure 4-3A). No FAM83D or CK1a was observed 
in the IgG control immunoprecipitates (Figure 4-3A). Analogous results were obtained 
when endogenous CK1α was immunoprecipitated under the same conditions (Figure 4-
3B). 
Finally, to decipher exactly when FAM83D associates with CK1a in the cell 
division cycle, I arrested FAM83DGFP/GFP U2OS cells in G2 using the CDK1 inhibitor RO-
3306, or in mitosis using STLC. STLC-treated mitotic cells were isolated by shake-off, 
washed and re-plated into fresh medium, and lysed every 2 h from 0 – 6 h, by which 
time the cells had entered G1. Asynchronous cells were included as a control. Lysates 
from these cells were subjected to anti-GFP immunoprecipitations, and evaluated for 
co-precipitation of CK1a by immunoblotting. FAM83D-GFP displayed a robust mobility  
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Figure 4-4: The mitotic FAM83D-CK1α interaction is not unique to U2OS cells: A: 
FAM83DGFP/GFP knockin cells were synchronised in G2 with RO-3306 for 20 h, or arrested 
in mitosis (M) using STLC for 16 h. STLC-treated mitotic cells were isolated by shake-off, 
washed and re-plated into fresh medium. Cells were lysed at the indicated time points 
after STLC wash-out, allowing them to pass through mitosis and enter G1. Asynchronous 
(AS) cells were used as a control. Cell lysates were subjected to anti-GFP 
immunoprecipitation (IP) and Input and IP extracts were subjected to SDS-PAGE and 
immunoblotting (IB) with the indicated antibodies (n=3). B: Propidium iodide-stained 
DNA distribution profiles for the samples described in A. C: AS or STLC-synchronised (M) 
wild-type HeLa, A549, or HaCaT cells were subjected to IP with either IgG- or anti-
FAM83D-coupled sepharose beads. Input and IP samples were analysed by IB with the 
indicated antibodies (n=3). 
 
 
shift only in the mitotic samples (Figure 4-4A). Consistently, CK1a only co-precipitated 
with FAM83D in mitotic, but not G2-arrested or G1 samples (Figure 4-4A). Successful 
treatments were confirmed through immunoblotting with antibodies against G2 and M  
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Figure 4-5: The C-terminus of FAM83D is inhibitory towards CK1α binding: A: FAM83D 
knockout U2OS cells were transiently transfected with plasmids encoding GFP-tagged 
FAM83D N-terminus incorporating the DUF1669 (N), FLAG-tagged FAM83D C-terminus 
(C) domain lacking the DUF1669, or with both N and C fragments together. Cells were 
lysed and extracts subjected to anti-FLAG immunoprecipitations (IP). Whole cell extracts 
(Input) and IP samples were separated by SDS-PAGE, before immunoblotting (IB) with 
the indicated antibodies (n=2). B: As in A. except that a GFP-tagged full-length (FL) 
plasmid was also included, and GFP IPs were performed instead of FLAG IPs (n=2). 
 
 
phase specific cyclins (Cyclin A and B respectively) (Figure 4-4A), and with DNA 
distribution profiling (Figure 4-4B). 
To test whether the mitotic FAM83D-CK1a interaction occurs in other 
mammalian cells, I expanded the interaction analysis to include three additional human 
cell lines, namely cervical cancer HeLa, lung adenocarcinoma A549, and human 
keratinocyte HaCaT cell lines. Endogenous FAM83D immunoprecipitated from these  
cells in STLC-synchronised mitotic extracts, but not from asynchronous extracts, co-
precipitated CK1a (Figure 4-4C). As in U2OS cells, FAM83D also displayed a pronounced 
electrophoretic mobility shift in mitotic extracts from these cell lines (Figure 4-4C).  
I next sought to probe the mitosis-dependent nature of the FAM83D-CK1a 
interaction. Given that the N-terminal DUF1669 of FAM83 proteins mediates CK1 
binding (Fulcher et al., 2018), I reasoned that the C-terminus of FAM83D may be acting 
in an autoinhibitory manner, to prevent CK1a binding until mitosis. In line with this 
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hypothesis, isolated FAM83D C-terminal fragments lacking the DUF1669 co-precipitated 
N-terminal FAM83D fragments, yet did not co-precipitate CK1a (Figure 4-5A). In 
contrast, the N-terminal DUF1669-containing fragment of FAM83D co-precipitated 
CK1a even under asynchronous conditions (Figure 4-5B). This suggests that the 
DUF1669 of FAM83D is both necessary and sufficient to interact with CK1a, and that the 
C-terminus of FAM83D may be having an autoinhibitory effect, to prevent the FAM83D-
CK1a interaction until mitosis.  
Collectively, these data suggest that FAM83D and CK1a associate robustly only 
in mitosis, at the endogenous level. This is the first FAM83-CK1 interaction identified 
which requires a stimulus, and that is dependent on cell cycle stage. 
 
4.2.2: FAM83D recruits CK1a to the spindle apparatus in mitosis: 
In the previous chapter, I proposed that FAM83 proteins act as cellular anchoring 
proteins for CK1 isoforms in cells and, in doing so, recruit CK1 isoforms to distinct cellular 
compartments to potentially regulate their substrate accessibility and/or availability 
(Fulcher et al., 2018). If this were the case, one might expect FAM83D to recruit CK1a 
to the spindle apparatus in mitosis. To address this, I subjected the FAM83DGFP/GFP 
knockin, FAM83D knockout, and wild-type U2OS cells to immunofluorescence 
microscopy, after they were synchronised in mitosis with STLC. In FAM83DGFP/GFP cells, I 
observed robust co-localisation between endogenous FAM83D-GFP fluorescence and 
endogenous CK1a signals on the STLC-induced monopolar spindles (Figure 4-6A). In 
wild-type cells, which express FAM83D without the GFP-tag fusion, I observed CK1a 
localisation on the mitotic spindle, and did not detect any contaminating fluorescence 
from the GFP channel (Figure 4-6A). Strikingly, in FAM83D knockout cells, I could not 
detect any CK1a on the spindle apparatus, suggesting that CK1a cannot localise to the  
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Figure 4-6: FAM83D directs CK1α, but not CK1ε or HMMR, to the mitotic spindle: A: 
STLC-synchronised mitotic (M) wild-type (WT), FAM83D knockout (KO), and 
FAM83DGFP/GFP knockin U2OS cells were subjected to anti-CK1a immunofluorescence 
and GFP fluorescence microscopy. DNA is stained with DAPI. Representative images 
representative of 3 independent experiments are included. B: As in A. except that cells 
were subjected to anti-CK1e immunofluorescence (n=2). C: As in A. except that cells 
were subjected to anti-HMMR immunofluorescence (n=2). Scale bars; 20 µM. 
 
spindle in the absence of FAM83D (Figure 4-6A). To validate the specificity of this assay, 
I repeated this experiment and instead stained for the CK1e isoform. In this context, no 
CK1e staining was detected at the spindle apparatus in either the wild-type, FAM83D 
knockout or FAM83DGFP/GFP cells (Figure 4-6B). Furthermore, the localisation of HMMR 
to the spindle  
was independent of whether FAM83D was present in the cell or not, in line with previous 
reports suggesting HMMR recruits FAM83D to the spindle in mitosis (Dunsch et al., 
2012) (Figure 4-6C). 
I previously identified two conserved residues (equivalent to D249 and F283 of 
FAM83D) that were critical for the FAM83-CK1 interaction (Fulcher et al., 2018) (see 
section 3.2.1). These phenylalanine and aspartate residues, which reside within the CK1-
binding DUF1669 of FAM83 members, abolished the FAM83-CK1 interaction when 
mutated to alanine in FAM83E-H (Fulcher et al., 2018). Armed with this insight, I first  
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Figure 4-7: Generation of FAM83DGFP/GFP (F283A) knockin U2OS cells: A: FAM83D-/- 
knockout (KO) U2OS cells were transiently transfected with vectors encoding GFP-
FAM83D (WT), GFP-FAM83D(F283A) (FA), or GFP-FAM83D(D249A) (DA). Untransfected 
cells were included as a control (-). Following transfection, cells were synchronised in 
mitosis with STLC. Mitotic cells were collected, lysed and subjected to anti-GFP 
immunoprecipitation (IP) with GFP TRAP beads. Whole cell extracts (Input) and IP 
samples were immunoblotted (IB) with the indicated antibodies (n=3). B: Genomic DNA 
sequencing analysis confirmed the F283A mutation in the FAM83DGFP/GFP (F283A) knockin 
cells (clone 15), relative to the WT sequence. C: FAM83D-/- KO, FAM83DGFP/GFP knockin 
(KI), and FAM83DGFP/GFP (F283A) knockin (FA) U2OS cells were STLC-synchronised and 
mitotic cells (M) isolated by shake off. Asynchronous (AS) cells were included as a 
control. Cells were lysed and subjected to GFP TRAP IP and subsequent IB with the 
indicated antibodies (n=3). 
 
 
confirmed that mutation of these Phe and Asp residues impact the FAM83D-CK1a 
interaction in mitotic cells, by transiently introducing GFP-tagged wild-type FAM83D, or 
the GFP-tagged F283A and D249A FAM83D mutants, into FAM83D knockout U2OS cells, 
and synchronising them with STLC. Subjecting lysates from these cells to anti-GFP 
immunoprecipitation revealed that, whilst wild-type GFP-FAM83D was able to co-
precipitate CK1a, both the D249A and F283A GFP-FAM83D mutants could not (Figure 4-
7A). Interestingly, the FAM83D mitotic mobility shift was visible for the wild- type GFP- 
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FAM83D protein, but not for the F283A and D249A GFP-FAM83D mutants (Figure 4-7A), 
suggesting that this FAM83D mitotic modification might be dependent on CK1a binding. 
In an attempt to bypass any potential limitations of over-expression systems, I 
decided to make a FAM83DGFP/GFP (F283A) cell line using CRISPR/Cas9, to allow us to 
evaluate this FAM83D CK1a-binding-deficient mutant at the endogenous level. After 
confirming successful homozygous knockin of the GFP tag and F283A mutation by DNA 
sequencing (Figure 4-7B), I synchronised these cells in mitosis using STLC, and subjected 
extracts from these cells to anti-GFP immunoprecipitations, to test the ability of 
FAM83D(F283A)-GFP to co-precipitate CK1a. This was performed in parallel with 
extracts from FAM83DGFP/GFP and FAM83D knockout cells. Asynchronous cells were used 
as controls for all the cell lines used. Whilst FAM83D-GFP could robustly co-precipitate 
endogenous CK1a in mitotic, but not asynchronous extracts, no CK1a was detected in 
the immunoprecipitates of the FAM83D(F283A)-GFP mutant (Figure 4-7C). Consistent 
with the over-expression data (Figure 4-7A), no mitotic mobility shift of the 
FAM83D(F283A)-GFP  knockin protein was observed (Figure 4-7C). 
To test if the FAM83D(F283A)-GFP mutant still localised to the spindle apparatus, 
I synchronised FAM83D knockout, FAM83DGFP/GFP, and FAM83DGFP/GFP (F283A) cells in 
mitosis using STLC, and subjected these cells to fluorescence microscopy, after co-
staining for endogenous CK1a. In FAM83DGFP/GFP cells, I observed robust GFP 
fluorescence from the mitotic spindle, which co-localised with endogenous CK1a (Figure 
4-8A). No CK1a was detected on the spindle in FAM83D knockout cells (Figure 4-8A), 
consistent with previous observations (Figure 4-6A). As predicted, I detected no CK1a 
on the spindle in FAM83DGFP/GFP (F283A) cells (Figure 4-8A), however, the relative GFP 
fluorescence on the spindle apparatus was lower in this cell line (Figure 4-8A). 
Quantification of the CK1a signal on mitotic spindles across these cell lines corroborated  
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Figure 4-8: FAM83DGFP/GFP (F283A) cells fail to recruit CK1α to mitotic spindles: A: FAM83D 
knockout (KO), FAM83DGFP/GFP knockin (KI), and FAM83DGFP/GFP (F283A) knockin (F283A) 
U2OS cells were subjected to anti-CK1a immunofluorescence and GFP fluorescence 
microscopy. DNA is stained with DAPI. Representative images representative of 2 
independent experiments are included. Scale bars; 20 µM. B: Quantification of CK1a 
spindle localisation for the cells described in panel A. and Figure 4-6A. Cell images 
denote the measured regions used to calculate the ratios on the box plot (1 = spindle 
roi, 2 = cytoplasm roi). Box plot whiskers denote the minimum and maximum measured 
values. ***, P<0.0001; ANOVA. Analysis was performed on the indicated number of 
cells, n=2. C: FAM83DGFP/GFP (F283A) knockin U2OS cells (clone 19) were synchronised in 
mitosis with STLC (M). Asynchronous (AS) cells were included as a control. Cells were 
lysed and subjected to anti-GFP immunoprecipitation (IP), and whole cell extracts 
(Input) and IP samples were immunoblotted (IB) with the indicated antibodies (n=2). D: 
The cell line described in C. was subjected to anti-CK1a immunofluorescence and GFP 
fluorescence microscopy. DNA is stained with DAPI. Representative images 
representative of 2 independent experiments are included. Scale bars; 20 µM. 
 
these observations (Figure 4-8B).Identical results for both the immunoprecipitation and 
immunofluorescence data were obtained with an independent CRISPR clone, confirming 
these results (Figure 4-8C&D).  
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Figure 4-9: Restoring FAM83D at the native locus in FAM83D knockout U2OS cells: A: 
STLC-synchronised mitotic wild-type U2OS cells were subjected to qRT-PCR analysis 
using primers for FAM83D, HMMR, CSNK1A1, and CCNB1. AS cells were used as a 
control. Error bars, SEM; *, P<0.01; Student’s T-test (n=3). B: Schematic illustrating the 
CRISPR-based strategy used to reintroduce FAM83D into the FAM83D-/- knockout 
background. KO InDels, insertion/deletion responsible for the FAM83D knockout; IRES, 
internal ribosome entry site; Pol-A, polyadenosine tail. C: Representative strategy for 
verifying correct integration of the cDNA rescue cassette. Amplification of genomic DNA 
from wild-type (WT) cells and the indicated putative knockin clones with PCR, using a 
primer pair recognising sequences within GFP and outside the pol-A tail (3’ Junction 
PCR), or a primer pair recognising sequences within the 5’ UTR and exon 1 (Exon 1 PCR), 
showed correct integration of the polycistronic cassette within the FAM83D locus. D: 
FAM83D-/- (KO), WT, and two independent clones from the CRISPR/Cas9-mediated 
knockin rescue of FAM83D cDNA into FAM83D-/- cells (c. 6 and c. 11), were synchronised 
in mitosis (M) with STLC. Asynchronous (AS) cells were included as a control. Cells were 
lysed and subjected to immunoblotting (IB) with the indicated antibodies (n=3). 
 
 
Having observed such a drastic ablation of spindle-localised CK1a in FAM83D 
knockout cells, I next sought to test whether reintroducing FAM83D into the knockout 
background could rescue this defect. However, transcriptional analysis of FAM83D 
transcripts by qRT-PCR showed a significant two-fold increase in transcript levels in  
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Figure 4-10: Restoring FAM83D at the native locus rescues CK1α spindle localisation: 
A-B: FAM83D-/- (KO), wild-type (WT), and two independent clones of a CRISPR/Cas9-
mediated knockin rescue of FAM83D cDNA into FAM83D-/- cells (c. 6 and c. 11), were 
STLC-synchronised in mitosis, fixed, and stained with antibodies recognizing FAM83D (A) 
or CK1⍺ (B). Representative images from 1 independent experiments are included. Scale 
bars; 20 µM. C: Quantification of CK1⍺ spindle localisation for the experiment described 
in B. using the same strategy employed in Figure 4-8B. ***, P<0.0001; ANOVA. Analysis 
was performed on the indicated number of cells, n=1. D: The cell lines described in A. 
were STLC-synchronised in mitosis (M) or left asynchronous (AS), lysed and subjected to 
immunoprecipitation (IP) with anti-FAM83D-coupled sepharose beads, before 
immunoblotting (IB) with the indicated antibodies (n=3). 
 
 
mitotic, over asynchronous cells (Figure 4-9A), suggesting FAM83D is a cell cycle-
regulated gene, similar to HMMR and CCNB1 (Figure 4-9A). In contrast, I did not detect 
any difference in CK1a transcript levels between asynchronous and mitotic cells (Figure 
4-9A).  Thus, given the inherent cell cycle-regulated nature of the FAM83D promoter, I  
worried that constitutive over-expression-based rescue experiments may disrupt this 
endogenous regulation. Therefore, I sought to develop a more elegant rescue method. 
To this end, a polycistronic cassette consisting of the wild-type FAM83D cDNA, 
an IRES element, a GFP reporter, followed by a polyadenosine tail, was knocked in 
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directly downstream of the endogenous FAM83D promoter (Figure 4-9B). Two 
homozygous rescue clones, clone 6 and 11, were obtained and verified by PCR (Figure 
4-9C) and DNA sequencing. In both clones, the expression of the FAM83D protein, along 
with its mitotic mobility shift, closely mirrored that seen in wild-type cells, however the 
expression of FAM83D in clone 11 was slightly lower than that observed in clone 6 
(Figure 4-9D). In both clones, both FAM83D and CK1a localised to the mitotic spindle 
(Figure 4-10A-C), and the reinstated FAM83D co-precipitated CK1a only in mitosis 
(Figure 4-10D). 
Collectively, these data suggest that FAM83D recruits CK1a to the spindle 
apparatus in mitosis, and in the absence of FAM83D, CK1a can no longer be directed to 
mitotic spindles.  
4.2.3: Exploring FAM83D and CK1a localisation in unperturbed cells: 
As most of the imaging so far had been performed on STLC-arrested mitotic cells, 
which present with non-physiological monopolar spindles, I next sought to examine the 
dynamics of the FAM83D-CK1a interaction in unperturbed cells, in the absence of any 
drug-induced cell synchronisation. To this end, and to enable imaging of live cells, a 
mCherry tag was knocked into the N-terminus of the CK1a-encoding CSNK1A1 gene, in 
FAM83DGFP/GFP U2OS cells. As a control, an mCherry tag was knocked into the N-terminus 
of CSNK1E, the gene encoding CK1ε. First, these cell lines were verified with 
immunoblotting (Figure 4-11A), and PCR (Figure 4-11B), and successful in-frame 
homozygous knockin of the mCherry tag confirmed with DNA sequencing. Subjecting 
STLC-arrested mitotic, or asynchronous, extracts from these cell lines to anti-mCherry 
immunoprecipitations, confirmed that the FAM83D-GFP knockin protein could still 
interact with mCherry-CK1a in mitosis (Figure 4-11C). Consistent with previous 
observations, no FAM83D-GFP was detected in mCherry-CK1ε immunoprecipitates  
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Figure 4-11: Generation of mCherry/mCherryCSNK1 knockin U2OS cell lines: A: Wild-type 
(WT), FAM83DGFP/GFP knockin (D-KI), FAM83DGFP/GFP knockin with mCherry/mCherryCSNK1A1 
(D-KI, a-KI), and FAM83DGFP/GFP knockin with mCherry/mCherryCSNK1E (D-KI, e-KI) U2OS cells 
were lysed, and subjected to immunoblotting (IB) with the indicated antibodies (n=2). 
B: Genomic DNA amplification with PCR using DNA isolated from WT and FAM83DGFP/GFP 
knockin with mCherry/mCherryCSNK1A1 clone 4 U2OS cells (upper panel), or from WT and 
FAM83DGFP/GFP knockin with mCherry/mCherryCSNK1E clone 5 U2OS cells (lower panel), using 
primers recognising sequences between mCherry and the 5’ UTR (5’ Junction), or 
between mCherry and exon 1 (3’ Junction), confirmed correct integration of mCherry 
within the CSNK1A1 and CSNK1E loci respectively (n=1). C: The cell lines described in A. 
were synchronised in mitosis with STLC (M) or left asynchronous (AS). Cells were lysed 
and subjected to immunoprecipitation (IP) with anti-mCherry beads, before IB with the 
indicated antibodies (n=2). D: The cell lines described in A. were lysed and subjected to 
IP with anti-mCherry beads, and IPs were subjected to an in vitro kinase assay using an 




(Figure 4-11C). Finally, I confirmed that the addition of an mCherry tag onto either CK1a 
or ε did not render these kinases inactive, by performing in vitro kinase assays against 





Figure 4-12: Exploring FAM83D-CK1α localisation in unperturbed cells: A: 
Asynchronous (AS) FAM83DGFP/GFP/ mCherry/mCherryCSNK1A1 knockin U2OS cells were fixed 
and imaged. Representative images from the indicated cell cycle stages are included 
(n=3). Scale bars; 10 µM. B: As in A. except that asynchronous FAM83DGFP/GFP / 
mCherry/mCherryCSNK1E knockin U2OS cells were used.  
 
 
Having been satisfied that these cell lines did not present with any concerning 
defects with regard to the FAM83D-CK1a interaction, I subjected these cells to 
fluorescence microscopy. I observed overlapping centrosomal and spindle fluorescence 
between FAM83D-GFP and mCherry-CK1a from prometaphase through to anaphase, 
with less intense co-fluorescence evident in the latter stages of mitosis (Figure 4-12A).  
In contrast, I did not observe spindle localisation of mCherry-CK1ε, nor co-localisation 


























Collectively, these data demonstrate that the FAM83D-mediated recruitment of 
CK1a to the mitotic spindle occurs in unperturbed cells, and is not an indirect effect of 
either drug-induced synchronisation, or fixation artefacts.  
 
4.2.4: Exploring the regulation of FAM83D during the cell cycle: 
Given the prominent mobility shift of the FAM83D protein in mitosis, I decided 
to investigate this intriguing FAM83D modification further. The mitotic electrophoretic 
mobility shift collapsed substantially when FAM83D-GFP knockin immunoprecipitates 
were subjected to λ-phosphatase treatment, suggesting that this mobility shift was due 
to phosphorylation (Figure 4-13A). Using the mobility shift as a read-out, I examined 
FAM83D phosphorylation over the course of a cell division through immunoblotting, 
following release from STLC arrest after synchronisation. The levels of cyclin B1 and 
phospho-Histone H3 were vastly reduced as cells exited mitosis and entered G1, as 
expected (Figure 4-13B). Interestingly, under these conditions, I observed concurrent 
reduction in the levels of both HMMR and phospho-FAM83D as cells exited mitosis, 
suggesting that the FAM83D-HMMR complex is also regulated in a cell cycle-dependent 
manner (Figure 4-13B).  
Such patterns in the levels of cell cycle-regulated proteins are often associated 
with their proteolytic degradation following mitotic exit, or during the metaphase-to-
anaphase transition (Chang et al., 2003, Koepp, 2014). In contrast, the protein levels of 
CK1α did not change after the STLC washout (Figure 4-13B). Considering that both 
FAM83D and CK1α appear to dissociate from mitotic spindles following the metaphase-
to-anaphase transition (Figure 4-12A), it seems likely that, following FAM83D  
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Figure 4-13: FAM83D is phosphorylated in mitosis and is degraded following mitotic 
exit: A: Nocodazole-synchronised mitotic FAM83DGFP/GFP knockin U2OS cells were lysed 
and subjected to GFP TRAP immunoprecipitation (IP), followed by incubation ± l-
phosphatase. Asynchronous (AS) cells were used as a control. Whole cell extracts (Input) 
and IP samples were subjected to SDS-PAGE and subsequent immunoblotting (IB) with 
the indicated antibodies (n=3). B: STLC-synchronised mitotic wild-type U2OS cells were 
lysed at the indicated time points following STLC washout. AS cells were used as a 
control. Lysed extracts were subjected to IB with the indicated antibodies (n=3). C: As in 
B. except that cells were released into medium ± MG132 (n=3). D: As in C. except that 
ProTAME was used instead of MG132 (n=3). E: Wild-type U2OS cells were either left 
asynchronous (AS), or arrested in mitosis with STLC and collected by shake-off (M). AS 
and M STLC-arrested cells were incubated in media containing combinations of RO-3306 
and MG132 as indicated, prior to lysis. MG132 was applied for 1.5 h, whereas RO-3306 
was applied for the last 1 h of incubation prior to lysis. Samples were lysed and extracts 
were subjected to SDS-PAGE, before IB with the indicated antibodies (n=3). 
 
 
degradation, CK1α can no longer localise to the spindle and subsequently dissociates 
into the cytoplasm.  
In line with this proteolytic degradation hypothesis, the reduction in FAM83D 
and HMMR protein levels following STLC washout could be blocked with MG132 (Figure 
4-13C), suggesting that both FAM83D and HMMR may indeed undergo proteasomal 
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degradation following mitotic exit. As expected, Cyclin B1 levels were also rescued by 
MG132 treatment (Figure 4-13C). As MG132 is also known to inhibit the metaphase-to- 
anaphase transition through the stabilisation of the anaphase-promoting 
complex/cyclosome (APC/C) E3 ligase substrate securin (Chang et al., 2003), this 
transitional delay could also potentially explain the lack of phospho-FAM83D and HMMR 
degradation in the presence of MG132. Indeed, analogous results on phospho-FAM83D 
and HMMR stabilisation were observed when STLC-arrested cells were released into 
medium containing the APC/C inhibitor ProTAME (Zeng, Sigoillot et al., 2010) (Figure 4-
13D). The protein levels of CK1α were unaffected by either MG132 or ProTAME 
treatments (Figure 4-13C&D). In an attempt to confirm that the mitotic post-
translational machinery triggers FAM83D and HMMR degradation in cells, I first arrested 
wild-type U2OS cells in mitosis with STLC, and isolated them by mitotic shake-off. Mitotic 
cells were released into medium containing either the CDK1 inhibitor RO-3306, or 
DMSO, in the presence or absence of MG132. CDK1 inhibition during mitosis triggers 
rapid mitotic exit (Vassilev, 2006, Vassilev, Tovar et al., 2006). Forced mitotic exit under 
these conditions resulted in robust FAM83D, HMMR and Cyclin B1 degradation, whereas 
the addition of MG132 blocked their proteolysis (Figure 4-13E). Thus, these data suggest 
that it is the mitotic post-translational machinery that regulates FAM83D and HMMR 
stability as cells progress through mitosis.  
The constitutive interaction between FAM83D and HMMR, along with their 
apparent synergistic regulation (Figure 4-13), prompted me to investigate a possible role 
for HMMR in the regulation of the FAM83D-CK1α complex in mitosis (Figure 4-14A). 
Indeed, as observed in U2OS cells, a robust FAM83D mitotic phospho-mobility shift was 
evident in wild-type mouse embryonic fibroblasts (MEFs), but this shift was completely 




Figure 4-14: The FAM83D-CK1α complex does not localise to the spindle in HMMR 
knockout MEFs: A: Schematic representing the predicted effects of HMMR knockout on 
FAM83D-CK1a delivery to the mitotic spindle. In the absence of HMMR, no FAM83D, 
and by extension no CK1a, can localise to the spindle. B: STLC-synchronised mitotic (M) 
wild-type (WT) and HMMR knockout (KO) mouse embryonic fibroblasts (MEFs) were 
lysed and subjected to immunoblotting (IB) with the indicated antibodies. Asynchronous 
(AS) cells were included as a control (n=3). C-D: The cells described in B. were STLC-
synchronised in mitosis and subjected to immunofluorescence microscopy with an anti-
HMMR antibody (C) or an anti-CK1a antibody (D). DNA is stained with DAPI. Scale bars; 
20 µM (n=2). 
 
 
notion that HMMR directs FAM83D to the mitotic spindle, and hence, in the absence of 
HMMR, FAM83D can no longer localise to the spindle, and is thus not phosphorylated. 
If this were the case, one would expect that CK1α should not be recruited to mitotic 
spindles in the absence of HMMR. After first confirming that HMMR localises to the 
spindle in wild-type, but not HMMR knockout MEFs (Figure 4-14C), I examined CK1α 




Figure 4-15: Confirming murine observations in HMMR knockout U2OS cells: A: 
Amplification of the region spanning the 5’UTR and the intronic region between exons 
1 and 2, revealed a deletion in the HMMR gene in HMMR knockout (KO) cells compared 
to wild-type (WT) cells, confirmed to be a 342 bp deletion by DNA sequencing. B: WT 
and KO cells were arrested in mitosis (M) with STLC and isolated by shake-off. 
Asynchronous cells (AS) were included as a control. Samples were lysed and subjected 
to immunoblotting (IB) with the indicated antibodies (n=3). C-E: WT and KO cells were 
synchronised in mitosis with STLC and stained with antibodies recognising HMMR (C), 
CK1α (D) and FAM83D (E). DNA is stained with DAPI. Scale bars; 20 µM (n=1). 
 
 
CK1α staining on mitotic spindles in wild-type MEFs, but not in HMMR knockout MEFs 
(Figure 4-14D). 
To confirm that these observations following genetic ablation of HMMR  were 
not unique to the mouse, I generated human HMMR knockout U2OS cells and confirmed 
successful knockout of HMMR with PCR using genomic DNA as a template (Figure 4-
15A), and immunoblotting (Figure 4-15B). DNA sequencing revealed a 342 bp deletion 
originating within exon 1 of the HMMR locus. Consistent with the observations in MEFs,  
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FAM83D did not undergo mitotic phosphorylation in the absence of HMMR (Figure 4-
15B), and both HMMR and CK1α were absent from mitotic spindles (Figure 4-15C-D). 
While HMMR still localises to the spindle in the absence of FAM83D (Figure 4-6C), no 
FAM83D was detected on spindles in HMMR knockout cells (Figure 4-15E). 
Collectively, these data add support to the model where HMMR directs FAM83D 
to the mitotic spindle, and present CK1α as a member of this protein complex. 
Furthermore, these findings suggest that the mitotic phospho-mobility shift of FAM83D 
relies on the recruitment of both FAM83D and CK1α to the spindle. 
 
4.2.5: Examining the role of CK1α in FAM83D phosphorylation: 
Given the absence of FAM83D(F283A)-GFP mitotic phosphorylation (Figure 4-7C) 
despite its spindle localisation (Figure 4-8A), I began to wonder whether CK1α may be 
directly or indirectly involved in FAM83D phosphorylation in mitosis. To test this, I 
designed an artificial recruitment strategy where CK1α was conjugated to an anti-GFP 
nanobody (aGFP.16), and examined whether this polypeptide (aGFP.16-CK1α) was 
capable of recruiting nanobody-bound CK1α to FAM83D(F283A)-GFP in FAM83DGFP/GFP 
(F283A) cells, and thereby artificially reconstitute the FAM83D-CK1α complex (Figure 4-
16A). Excitingly, expression of aGFP.16-CK1α rescued the phospho-mobility shift of 
FAM83D(F283A)-GFP, regardless of whether cells were in mitosis or not (Figure 4-16B). 
I also observed co-precipitation of aGFP.16-CK1α in FAM83D(F283A)-GFP 
immunoprecipitates (Figure 4-16B). During the course of these experiments, I noticed 
that this rescued FAM83D(F283A)-GFP mobility shift was slightly smaller than the 
mitotic mobility shift of FAM83D-GFP (Figure 4.16B). Thus, to confirm that aGFP.16-
CK1α was not phosphorylating random residues on FAM83D, I repeated this experiment 
in wild-type FAM83DGFP/GFP U2OS cells. As seen with FAM83D(F283A)-GFP, FAM83D-GFP  
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Figure 4-16: Artificial reconstruction of the FAM83D-CK1α interaction in 
FAM83DGFP/GFP (F283A) cells restores FAM83D phosphorylation. A: Schematic 
representation of the anti-GFP nanobody (aGFP.16)-based targeting strategy used to 
deliver CK1a to the CK1-binding-deficient FAM83D(F283A)-GFP mutant. B: STLC-
synchronised mitotic FAM83DGFP/GFP knockin (KI), FAM83DGFP/GFP (F283A) (FA), and 
FAM83DGFP/GFP (F283A) stably expressing aGFP.16-CK1a (FA + aGFP.16-CK1a) U2OS cells 
were subjected to anti-GFP immunoprecipitation (IP), followed by immunoblotting (IB) 
with the indicated antibodies. Asynchronous (AS) cells were used as controls (n=3). C: 
As in B, except that the aGFP.16-CK1a was targeted to wild-type FAM83D-GFP in 
FAM83DGFP/GFP knockin U2OS cells (n=3). 
 
 
also exhibited a constitutive phospho-mobility shift, regardless of cell cycle stage (Figure 
4-16C). Crucially, the aGFP.16-CK1α-induced phospho-shift migrated to the same level 
as the mitotic FAM83D-GFP in control cells (Figure 4-16C). Thus, as there is no apparent 
larger mitotic mobility shifts when wild-type FAM83D-GFP is bound to aGFP.16-CK1α, I 
attribute the slight reduction in mobility seen with the aGFP.16-CK1α-bound 
FAM83D(F283A)-GFP mutant to potential conformational defects resulting from the 
F283A mutation, potentially occluding one or more of the phospho-acceptor residues 




Figure 4-17: CK1 catalytic activity appears to be critical for mitotic FAM83D 
phosphorylation: A: FAM83DGFP/GFP (F283A) U2OS cells were infected with retroviruses 
encoding wild-type aGFP.16-CK1a (WT), or aGFP.16-CK1a with one of two distinct CK1a 
kinase-inactive mutants (D136N or K46D). Uninfected cells (-) were included as a control. 
Cells were lysed, subjected to anti-GFP IP and IB with the indicated antibodies (n=3). B: 
An in vitro kinase assay was set up using recombinant GST-FAM83D, and GST-CK1a. GST-
FAM83D without CK1a is a negative control. Recombinant GST-FAM83G-6xHis serves as 
a positive control for CK1a activity. Following incubation with [γ32P]-ATP, reactions were 
stopped and subjected to SDS-PAGE. The gel was stained with InstantBlue and imaged, 
before being subjected to autoradiography (autorad) (n=3). C: FAM83DGFP/GFP (F283A) cells 
were infected with retroviruses encoding wild-type aGFP.16-CK1e (WT), or a kinase-
dead aGFP.16-CK1e (D128N) mutant (KD). Uninfected cells (-) were included as a control. 
Cells were lysed, subjected to anti-GFP IP and IB with the indicated antibodies (n=3). D: 
STLC-synchronised mitotic FAM83DGFP/GFP knockin, FAM83DGFP/GFP (F283A), and 
FAM83DGFP/GFP (F283A) stably expressing aGFP.16-CK1a U2OS cells were fixed and stained 
using anti-CK1a antibody. DNA is stained with DAPI. Scale bar; 20 µM (n=2). 
 
 
The phosho-mobility shift of FAM83D(F283A)-GFP restored through the targeted 
delivery of aGFP.16-CK1α relied on CK1α catalytic activity, as two catalytically inactive 
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mutants of CK1α (K46D and D136N) failed to fully restore the phospho-mobility shift 
(Figure 4-17A). Indeed, a smaller, less intense phospho-mobility shift was observed 
when these aGFP-CK1α mutants were recruited to FAM83D(F283A)-GFP, however, it 
should be noted that even if these mutations leave CK1α with a small amount of residual 
catalytic output, that may be sufficient to induce partial phosphorylation when 
artificially forcing the constitutive interaction between these proteins. Alternatively, the 
interaction between FAM83D and CK1α may be required to present FAM83D to a  
priming kinase(s), prior to the final phosphorylation step(s) by CK1α. In agreement with 
a requirement for a priming kinase, under conditions where recombinant CK1α could 
phosphorylate purified FAM83G in vitro, it failed to phosphorylate recombinant 
FAM83D (Figure 4-17B). Interestingly, when wild-type CK1ε, which does not interact 
with FAM83D nor localise to the spindle, was delivered to FAM83D(F283A)-GFP by 
aGFP.16, it too rescued the FAM83D phospho-mobility shift (Figure 4.17C). Thus, the 
proximal catalytic activity of CK1 appears sufficient for the FAM83D phospho-shift, and 
this observation highlights the notion that subcellular localisation and substrate 
association are important determinants for CK1 targets in cells. Importantly, robust co-
localisation between FAM83D(F283A)-GFP and aGFP.16-CK1α on intact mitotic spindles 
was observed (Figure 4-17D), suggesting that the aGFP.16-CK1α is binding the 
FAM83D(F283A)-GFP target within cells, and not just in extracts.  
Through delivering CK1α to the mitotic spindle, it is likely that FAM83D acts to 
position CK1α for phosphorylation of mitotic CK1α substrates, including FAM83D itself. 
However, this hypothesis relies on CK1α being catalytically active when bound to 
FAM83D in mitosis. To examine the catalytic status of FAM83D-bound CK1α, I employed  
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Figure 4-18: FAM83D-bound CK1α is a catalytically-active kinase: A: Schematic 
depicting the IP kinase assay strategy used to test whether FAM83D-bound CK1a was 
catalytically active. B: FAM83D knockout (KO), FAM83DGFP/GFP knockin (KI), and 
FAM83DGFP/GFP (F283A) knockin (FA) U2OS cells were synchronised in mitosis (M) using 
STLC. Lysed extracts were subjected to anti-GFP IPs, followed by [γ-32P]-ATP kinase 
assays, using an optimised CK1 substrate peptide (CK1tide). Asynchronous (AS) cells 
were used as controls. Error bars, SEM; P<0.01; ANOVA (n=3). Input and IP samples were 
analysed by IB with the indicated antibodies. 
 
 
an immunoprecipitation-based in vitro kinase assay strategy, in order to isolate the 
FAM83D-CK1α complex, and subsequently measure phosphorylation of an optimised 
substrate peptide (CK1tide) in the presence of [γ-32P]-ATP (Figure 4-18A). Excitingly, 
when anti-GFP immunoprecipitates from FAM83D knockout, FAM83DGFP/GFP, and 
FAM83DGFP/GFP (F283A) U2OS cells were subjected to these kinase assays, only those from 
mitotic FAM83D-GFP extracts, which co-precipitated endogenous CK1α, displayed 
significant kinase activity towards CK1tide (Figure 4-18B), suggesting that FAM83D-





4.2.6: The HMMR-FAM83D-CK1α complex regulates spindle positioning: 
Throughout the course of these experiments, I have generated data supporting 
a model where the HMMR-FAM83D-CK1α complex localises to the mitotic spindle, and 
in doing so, acts to direct an active kinase to the spindle apparatus for, presumably, 
phosphorylation-mediated control of mitosis. Thus, I set out to identify where in the cell 
division pathway this protein complex may act. Separately, FAM83D, and CK1α have 
been implicated in mitotic resolution, and correct spindle/chromosome alignment 
(Dunsch et al., 2012, Gross, Simerly et al., 1997, Santamaria et al., 2008, Wang et al., 
2013). So, I sought to test whether FAM83D and CK1α act in the same pathway in 
mitosis. To achieve this, a collaboration was initiated with the Maxwell laboratory 
(University of British Columbia), who previously identified a role for the FAM83D-
interacting protein HMMR in spindle positioning.  
Compared to wild-type and FAM83DGFP/GFP U2OS cells, there was a significant 
delay in the metaphase-to-anaphase transition in FAM83D knockout and FAM83DGFP/GFP 
(F283A) cell lines (Figure 4-19A-C). When spindle orientation was analysed in these cells, 
spindles orientated at a fixed angle in knockout and FAM83DGFP/GFP (F283A) cells (Figure 4-
19D, yellow lines), consistent with the phenotype described following siRNA-mediated 
depletion of FAM83D (Dunsch et al., 2012). The position of the cell-division axis at 
anaphase, relative to its expected position aligned with the long cell axis in interphase, 
deviated significantly in FAM83D-/- and FAM83DGFP/GFP (F283A) cells, compared to wild-type 
and FAM83DGFP/GFP cells (Figure 4-20A&B). Excitingly, this phenotype in FAM83D-/- cells 
was rescued when FAM83D cDNA was restored at the endogenous FAM83D locus, with 
full rescue observed when restored FAM83D expression was comparable to that of wild-
type cells (rescue clone 6) and a partial rescue observed when restored FAM83D 
expression was lower than that of wild-type cells (rescue clone 11) (Figure 4-20A&B).  
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Figure 4-19: The metaphase-to-anaphase transition duration is increased following 
ablation of CK1α spindle recruitment: A: Representative images initiating at metaphase 
for the indicated mitotic U2OS cell lines stained with Hoechst, taken every 5 min as they 
progress through division. Mitotic stage was determined by chromosome condensation 
and is indicated by the coloured boxes. Scale bar; 20 μm. B: Graphical representation 
for the kinetics of transition from metaphase alignment (yellow) to anaphase (green), 
and cytokinesis (blue). 100 mitotic cells per genotype are plotted; n=2. C: Length of time 
needed to transition from metaphase to anaphase. Mean of 100 mitotic cells per 







Figure 4-20: Absence of spindle-localised CK1α causes spindle mispositioning: A: 
Representative bright field images for the mitotic U2OS cell lines, indicating the long axis 
during interphase (white line) preceding mitosis, and the division axis determined at 
anaphase (yellow line). DNA is stained with Hoechst. Scale bar; 20 μm. B: Percentage of 
oriented divisions for U2OS cells grown in subconfluent cultures. An oriented division 
axis was defined as being less than 30° removed from the long axis of the interphase 
cell. Mean of 50 cells per genotype are plotted, n=2. Error bars, SEM. ***, P< 0.0001; 
ANOVA. (credit: Zhengcheng He). 
 
 
In order to better study the process of spindle orientation in these cell lines, individual 
FAM83D-/-, FAM83DGFP/GFP or FAM83DGFP/GFP (F283A) U2OS cells were seeded onto L-
shaped fibronectin-coated micropatterns, which cause cells to position their spindle on 
a defined axis (Thery et al., 2005), and measured the angles of spindle orientation. 
Whereas wild-type and FAM83DGFP/GFP cells orientated their spindles along the defined, 
predicted axes, significant deviations in the predicted spindle orientation axes were 
observed in FAM83D-/- and FAM83DGFP/GFP (F283A) cells (Figure 4-21A), with near 80% 
unable to orientate their spindles correctly (Figure 4-21B). As seen with the previous 
spindle orientation experiments (Figure 4-20A&B), this phenotype in the FAM83D-/- cells 






Figure 4-21: Cells devoid of spindle-localised CK1α fail to orientate their spindles on L-
shaped micropatterns: A: Circular graphs, superimposed on L-shaped micropatterns, 
show the distribution of cell division angles measured at anaphase. Angles for 100 U2OS 
cells are plotted per cell line, n=2. Metaphase plate position is indicated (yellow line) 
and the percentages of division angles ± 15° from the expected axis (red line) are 
indicated. B: Percentage of metaphase U2OS cells that align chromosomes outside of 
the expected axis (angles ± 15°). Mean of 100 cells per genotype are plotted, n=2. Error 
bars, SEM. ***, P< 0.0001; ANOVA (credit: Zhengcheng He). 
 
 
During the process of analysing spindle positioning in these cell lines, a random 
orientation of the initial spindle position was observed, which is normally directed by 
the position of retraction fibers (Thery et al., 2007) and the assembly of subcortical actin 
(Fink et al., 2011, Kwon, Bagonis et al., 2015). Thus, actin dynamics were examined in 
these cells. To monitor actin dynamics during the process of spindle assembly and 
orientation, cells were transfected with actin-Red Fluorescent Protein (RFP) prior to 
seeding cells onto L-shaped fibronectin-coated micropatterns (Figure 4-22A). In wild-
type cells, subcortical actin  was polarised adjacent to the right angle of the L-shape 
following DNA condensation through to anaphase (Figure 4-22B). However, actin 
appeared to be randomly organised with respect to the micropattern in FAM83D-/- and 
FAM83DGFP/GFP (F283A) cells during the spindle-assembly process (Figure 4-22B). This 
observation in FAM83D-/- cells was rescued in FAM83D cDNA knockin clone 6, and  
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Figure 4-22: Cells devoid of spindle-localised CK1α present with disordered subcortical 
actin cytoskeletons: A: Representative images of RFP-actin localisation in mitotic U2OS 
cells grown on fibronectin-coated, L-shaped micropatterns, which is superimposed. 
Arrowheads indicate polarised cortical actin. Heatmap shows the intensity of RFP-actin 
localisation (Image J z-projection standard deviation) as the cell progresses from 
prophase to metaphase (12-24 min). Scale bar; 20 μm. B: Heatmap additive intensities 
of RFP-actin localisation in two representative mitotic U2OS cells for each cell line grown 
on fibronectin-coated, L-shaped micropatterns. Arrowheads indicate polarised cortical 
actin (credit: Zhengcheng He). 
 
 
partially in clone 11 (Figure 4-22B). FAM83DGFP/GFP cells organised their actin in a manner 
comparable to that seen in wild-type cells (Figure 4-22B). 
The targeted delivery of wild-type or kinase-dead (K46D) CK1a to FAM83D-GFP 
(F283A) in knockin cells, using the aGFP.16-CK1a strategy (Figure 4-16A), 
notwithstanding the potential caveats of overexpression, allowed us to explore the role 
of CK1a catalytic activity in metaphase length and spindle orientation. Delivery of both 
wild-type and kinase-dead aGFP.16-CK1a resulted in shortening of the metaphase delay 
observed in FAM83DGFP/GFP (F283A) cells (Figure 4-19A-C). However, the spindle orientation 







Figure 4-23: siRNA knockdown of CK1α phenocopies the effects of FAM83D knockout 
on spindle positioning: A: Immunoblot analysis of U2OS cell extracts 48 h 
after treatment with scrambled siRNA (siScramble) controls or siRNA targeting CK1a 
(siCK1a). B: Representative images of mitotic U2OS cells stained with 
Hoechst, beginning at metaphase and taken every 5 min as they progressed through 
division. Mitotic stage was determined by chromosome condensation and is indicated 
by the coloured boxes. Scale bar; 20 μm. C: Graphical representation of the kinetics of 
transition from metaphase alignment (yellow) to anaphase (green), and cytokinesis 
(blue), determined by the morphology of chromosomes and daughter cells, 
respectively. The kinetics of 100 mitotic cells per genotype are plotted as measured for 
50 cells per experiment from 2 independent experiments. D: Length of time needed to 
transition from metaphase to anaphase. Mean ± SEM is plotted for 2 independent 
experiments, which each measured 50 mitotic cells per genotype (n = 100 mitotic cells 
per genotype total). *** p< 0.0001, Student’s T-test. E: Representative images of mitotic 
U2OS cells stained with Hoechst and grown on L-shaped micropatterns previously 
coated with fibronectin. The cell division angle at anaphase is indicated (yellow line). 
Scale bar; 20 μm. F: Circular graphs, superimposed on a L-shaped micropattern, show 
the distribution of cell division angles measured at anaphase. Angles are plotted for 100 
U2OS cells per genotype measured from 2 independent experiments. The percentages 
of division angles ± 15° from the expected axis (red line) are indicated. G: Heatmap 
additive intensities of RFP-actin localisation in two representative mitotic U2OS cells for 
each genotype grown on fibronectin-coated, L-shaped micropatterns. 
Arrowheads indicate polarised cortical actin (credit: Zhengcheng He). 
 
 
only partially with the kinase-dead aGFP.16-CK1a, in both sub-confluent cultures (Figure 
4-20A&B) and L-shaped micropatterns (Figure 4-21A&B). Actin was correctly polarised 
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in FAM83DGFP/GFP (F283A) cells rescued with wild-type, but not with the kinase-dead 
aGFP.16-CK1a (Figure 4-22B). 
Similar spindle mis-positioning and actin cytoskeletal defects were observed 
when CK1a was knocked down using siRNA oligonucleotides (Figure 4-23), reinforcing 
the notion that FAM83D and CK1a act together within the same pathway in mitosis.  
During the course of performing these phenotypic assays, frequent plasma 
membrane blebbing on one of the daughter cells in FAM83D-/- and FAM83DGFP/GFP (F283A) 
cells was also observed, at the latter stages of mitosis. This phenomenon, known as 
asymmetric membrane elongation (AME), is a compensatory mechanism to ensure 
equal distribution of cell size following mitosis, when the spindle is misorientated 
(Kiyomitsu & Cheeseman, 2013). Live cell-microscopy confirmed blebbing in FAM83D-/- 
and FAM83DGFP/GFP (F283A) cells, but not in wild-type, or FAM83DGFP/GFP cells, or in both 
clones rescued through knockin of FAM83D cDNA into the endogenous FAM83D locus 
in the FAM83D-/- background (Figure 4-24A-B). Reduction of blebbing in FAM83DGFP/GFP 
(F283A) cells to levels seen in wild-type cells was observed when cells were rescued with 
wild-type aGFP.16-CK1a whereas an intermediate phenotype was observed with the 
kinase-dead aGFP.16-CK1a rescue (Figure 4-24B).  
Importantly, there was no difference in daughter cell size between all cell lines 
(Figure 4-24C), suggesting that the observed AME compensatory mechanism was 
functioning correctly.  
Taken together, these data indicate the FAM83D-CK1a interaction is critical for 
timely mitotic progression, including the processes of orienting both the mitotic spindle 




Figure 4-24: Asymmetric membrane elongation is prevalent in cells devoid of spindle-
localised CK1α: A: Representative bright field images initiating at metaphase for mitotic 
U2OS cells taken every 1 min as they progress through division. Asymmetric membrane 
elongation, or membrane blebbing, is indicated by red arrowheads and only occurred 
on one daughter cell. Scale bar; 20 μm. B: Percentage of mitotic cells that displayed 
membrane blebbing. Mean of 50 cells per genotype are plotted from 2 independent 
experiments. Error bars; SEM. * P< 0.005, ANOVA. C: Daughter cell size ratio following 
U2OS cell division remains unchanged. Mean of 50 cells per genotype are plotted from 




Correctly orientated cell division, primarily achieved through the proper 
positioning of the mitotic spindle, is crucial for both normal development, and 
maintenance of healthy tissues. (Fleming, Temchin et al., 2009, Kiyomitsu & Cheeseman, 
2012, Konno, Shioi et al., 2008, Lu & Johnston, 2013). By conclusively placing CK1a at 
the mitotic spindle, and demonstrating that spindle-localised CK1a appears to regulate 
spindle positioning and timely cell division, these data present strong evidence for CK1a 
as a new player in the phosphorylation-mediated control of mammalian mitosis. 
Interestingly, the mechanism by which FAM83D acts to bind and direct CK1a to mitotic 
spindles draws parallels with the way TPX2 recruits and regulates Aurora Kinase A during 
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mitosis (Bayliss et al., 2003, Chen et al., 2014). While interacting partners of FAM83D, 
including HMMR and DYNLL1, offer insights into how FAM83D localises to the mitotic 
spindle to recruit CK1a, the full extent of CK1a substrates that potentially mediate 
proper spindle positioning, to ensure error-free progression through mitosis, remain to 
be defined. Furthermore, exactly how the spindle-localised FAM83D-CK1a complex can 
appear to regulate the spatially-distinct actin network during mitosis remains to be 
determined. However, phosphorylation of CK1a substrates could trigger their 
translocation from the spindle to the actin network, or indeed anywhere within the cell, 
either directly or indirectly. Nonetheless, the findings that the FAM83D-CK1a complex 
acts at the mitotic spindle add to the evidence for intricate subcellular regulation of CK1 
isoforms by FAM83 proteins (Bozatzi et al., 2018, Fulcher et al., 2018, Kuga et al., 2016a, 
Kuga et al., 2013).  
Traditionally, when one thinks of mitotic kinases, CK1 isoforms do not get 
mentioned, with prominent names such as Cyclin-dependent kinases (CDKs), Aurora 
kinases, Polo-like kinase (PLKs) and Nima-related kinases (NEKs) stealing the cell division 
lime light (Nigg, 2001). However, given the reported participation of CK1 isoforms in 
such diverse biological processes (see section 1.2.4), it is perhaps not surprising that 
some studies have explored and reported on roles for CK1a in the cell-division cycle. 
From as early as 1992, CK1α has been reported to localise to the mitotic spindle 
apparatus (Brockman et al., 1992), and large-scale mitotic spindle proteomic studies 
have also identified CK1α as a spindle-localised protein (Sauer et al., 2005). More 
recently, anti-CK1α antibodies injected into the cytosol of developing mouse embryos 
was shown to result in either complete abolition of, or a significant delay in, progression 
to the first mitotic cleavage (Gross et al., 1997). Interestingly, CK1α morpholino injection 
in mouse oocytes resulted in meiotic chromosomal alignment and congression defects 
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(Wang et al., 2013). However, these studies lacked any mechanistic understanding into 
how CK1a regulated these processes. Interestingly, CK1 activity in C. elegans embryos 
was shown to regulate spindle positioning through regulating force generation at the 
cell cortex (Panbianco, Weinkove et al., 2008). However, FAM83D and the other FAM83 
proteins are not conserved in invertebrates, thus there will likely be some differences in 
the way CK1 regulates spindle positioning in this context. 
Beyond CK1α, the phosphorylation-mediated control of spindle positioning has 
been attributed to several other protein kinase families. Of note, the activity of CDKs, 
PLKs, and Aurora kinases have all been shown to be critically important in regulating 
spindle orientation (Chen et al., 2014, Connell et al., 2017, Enserink & Kolodner, 2010, 
Gallini, Carminati et al., 2016, Johnston, Hirono et al., 2009, Kotak, Afshar et al., 2016, 
Ly, Ahmad et al., 2014, Sana, Keshri et al., 2018, Tame et al., 2016). Both their 
recruitment to the mitotic spindle, and their activities once they are recruited there are 
tightly regulated (Bayliss et al., 2003, Chen et al., 2014, Enserink & Kolodner, 2010, 
Golsteyn et al., 1995). In the case of PLK1, the centrosomal PLK1 pool regulates spindle 
positioning through the PLK1-dependent spindle positioning pathway, and acts to strip 
Dynein/NuMA from the cortex when the spindle pole gets too close to the cortex 
(Kiyomitsu & Cheeseman, 2012). PLK1 itself is regulated downstream of CDK1 and 
Aurora A, illustrating some of the crosstalk evident between these mitotic kinases 
(Macurek et al., 2008). Thus, the concerted action of mitotic kinases likely functions 
within a tightly controlled phosphorylation-network to ensure the correct and efficient 
orientation of the mitotic spindle. Given the requirement for a priming phosphorylation 
event for many CK1 substrates, it is highly likely that such cross-talk also extends to 
mitotic CK1α substrates. Future efforts aimed at elucidating these mitotic CK1α 
substrates, and examining if they too are subject to co-regulation by other mitotic 
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kinases, will further decipher the intricate phospho-controlled network evident in the 
mammalian cell cycle, and help to establish which branches of the pathway would be 























5. An Affinity-directed PROtein Missile (AdPROM) system for 




Studying protein function at the endogenous level remains the gold standard in 
biomedical research. However, for many proteins, studying them at the endogenous 
level is not always feasible, and is dependent on numerous factors. Such factors can 
include the absence of a robust antibody that recognises the target protein of interest, 
or lack of detectable catalytic activity to assay. Furthermore, if the protein of interest is 
required for cell viability, genetic ablation experiments are often very challenging, if not 
impossible, to accomplish (Wang, Birsoy et al., 2015). As FAM83 proteins are a fairly 
novel, largely uncharacterised family of proteins, commercially-available tools to study 
them are somewhat scarce. Thus, in combination with generating specific antibodies for 
each FAM83 member, I sought to design and implement novel technologies to aid me 
in the investigation of FAM83 biology, and beyond. Here, I sought to develop a 
proteolytic methodology, to aid us in studying FAM83 function. 
The degradation of many proteins by the ubiquitin-proteasome system (UPS) is 
crucial for maintenance of cellular homeostasis, and plays a fundamental role in protein 
turnover (Adams, 2003, Budenholzer, Cheng et al., 2017, Tanaka, 2009). The UPS centres 
around the sequential action of E1 ubiquitin-activating enzymes, E2 ubiquitin-
conjugating enzymes, and E3 ubiquitin ligases which attach the small protein ubiquitin 
onto target proteins (Adams, 2003, Budenholzer et al., 2017, Nandi, Tahiliani et al., 
2006, Tanaka, 2009). Subsequently, additional ubiquitin molecules can be conjugated to 
the existing ubiquitin on the monoubiquitinated protein, creating a chain of ubiquitins 
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on the target protein, with distinct chain types being linked to specific biological 
processes (Akutsu, Dikic et al., 2016, Komander & Rape, 2012, Pickart & Eddins, 2004). 
For example, and of relevance here, ubiquitins linked in a lysine 48-linked manner mark 
proteins for degradation via the proteasome (Akutsu et al., 2016, Komander & Rape, 
2012, Pickart & Eddins, 2004). 
The human genome encodes two E1 enzymes, around 50 E2 enzymes, and over 
600 E3 ubiquitin ligases (Li, Bengtson et al., 2008, Wenzel, Stoll et al., 2011, Zhao, 
Bhuripanyo et al., 2012). The substrate specificity of the UPS is conferred through 
substrate-recognition elements within the E3 ligase complexes (Bulatov & Ciulli, 2015, 
Jackson, Eldridge et al., 2000). The Cullin RING (really interesting new gene) E3 ligases 
(CRLs) constitute the largest family of UPS-contributing E3 ligases. The CRL family is 
comprised of seven evolutionarily conserved members, designated CUL1, CUL2, CUL3, 
CUL4A, CUL4B, CUL5 and CUL7 (Bulatov & Ciulli, 2015, Zheng, Schulman et al., 2002). All 
cullins share similar structural and catalytic features, and are bound in a complex with 
selective adaptor and substrate-recognition subunits, as well as one RING E3 ligase 
protein, either RBX1 or RBX2 (Bulatov & Ciulli, 2015, Cardote, Gadd et al., 2017, Zhao & 
Sun, 2013, Zheng et al., 2002). CRLs are activated through the post-translational process 
of NEDDylation, which acts to covalently attach the small ubiquitin-like modifier NEDD8 
onto lysine residues within the Cullin backbone (Enchev, Schulman et al., 2015). 
NEDDylation, like ubiquitination, requires its own cognate E1, E2 and E3 enzymes, which 
sequentially function to activate and ligate the NEDD8 molecule onto the Cullin (Enchev 
et al., 2015). A selective inhibitor of the NEDD8-activating enzyme, MLN4924, inhibits 
the activation of CRLs in cells, and thereby blocks the ubiquitination of CRL substrates, 
thus preventing their degradation (Soucy, Smith et al., 2009). Upon binding to the 
cognate substrate receptor subunit, the CRL substrate is positioned in close proximity to 
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the RBX1/2 RING E3 ligase and its associated E2-ubiquitin conjugate. The optimally 
positioned substrate is then ubiquitinated by RBX1/2, priming it for proteolysis through 
the proteasome (Bulatov & Ciulli, 2015, Cardote et al., 2017, Duda, Scott et al., 2011, 
Zheng et al., 2002).  
In the case of CUL2, the proteins Elongin B and C serve as adaptor proteins, and 
the tumor suppressor protein Von Hippel-Lindau (VHL) acts as the substrate receptor 
(Cardote et al., 2017, Kamura, Maenaka et al., 2004, Yu, White et al., 2001). The best 
characterised CUL2 substrate is hypoxia-inducible factor 1 alpha (HIF1α). Under 
normoxic conditions, HIF1α is hydroxylated on proline residues by a class of enzymes 
termed prolyl hydroxylases. Hydroxyproline-modified HIF1α is recognised and bound by 
VHL, which subsequently recruits HIF1α to the CUL2-CRL complex for its ubiquitination, 
marking it for proteolysis (Figure 5-1) (Kamura et al., 2004, Yu et al., 2001). The VHL-BOX 
domain of VHL, comprised of residues T152-H191 of the human VHL protein, mediates 
the association between VHL and the elongin B/C adaptor proteins (Kamura et al., 2004). 
Other CRL complexes function in analogous ways, employing distinct adaptor and 
substrate receptor proteins for the ubiquitination of their substrates (Bosu & Kipreos, 
2008, Bulatov & Ciulli, 2015, Duda et al., 2011, Kamura et al., 2004, Zhao & Sun, 2013, 
Zheng et al., 2002).  
Molecular studies on CRLs have established the key mode of substrate 
degradation to be proximity-driven ubiquitination (Bosu & Kipreos, 2008, Bulatov & 
Ciulli, 2015). As such, the CRL-UPS has been successfully exploited, both as a research 
tool and for the development of therapeutics. For example, PROteolysis TArgeting 
ChimeraS (PROTACS) are an emerging class of small molecule that harbour a target 
protein recognition moiety on one end, with an E3 ligase recognition element on the 
other. In this capacity, upon PROTAC administration, PROTACs act to direct specific 
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target proteins to E3 ligase complexes to promote their proximity-dependent 
ubiquitination and subsequent proteolysis (Sakamoto, Kim et al., 2001, Zengerle, Chan 
et al., 2015). The successful application of some PROTACs, which encompass moieties 
that bind components of CRL systems such as VHL, demonstrate that CRL systems can 
be successfully exploited for target protein degradation, provided that the target 
protein can be effectively recruited to the CRL substrate receptors (Bulatov & Ciulli, 
2015, Sakamoto et al., 2001, Zengerle et al., 2015).  
Historically, the idea of targeted proteolysis was first demonstrated in 1994, 
when Dohmen and colleagues fused a temperature-sensitive dihydrofolate reductase 
enzyme harbouring an N-terminal arginine (Arg-DHFR) to both Ura3 and Cdc28 proteins 
in S. cerevisiae (Dohmen, Wu et al., 1994). Arg-DHFR is long-lived at 23°C, but is quickly 
degraded at 37°C. Importantly, this temperature-sensitive degron property of Arg-DHFR 
is conferred to proteins it is tagged to, thus, fusion of Arg-DHFR to Ura3 and Cdc28 
triggered their degradation when the yeast cells were cultured at 37°C (Dohmen et al., 
1994). As such, this system was named the heat-inducible degron. This system was later 
adapted in order to improve target protein degradation kinetics (Labib, Tercero et al., 
2000), and since then there has been great research interest aimed at generating 
targeted proteolysis methodologies that are compatible with higher eukaryotes. Most 
notably was the development of the auxin-inducible degron. Plant cell signalling relies 
on phytohormones such as auxin (AUX), and upon exposure to hormones of the auxin 
family such as indole-3-acetic acid (IAA), the AUX/IAA family of transcriptional repressor 
proteins are rapidly degraded (Nishimura, Fukagawa et al., 2009, Tan, Calderon-
Villalobos et al., 2007). Such degradation is achieved through a specific form of the SCF 
CRL E3 Ligase complex, containing the substrate receptor F-box Transport Inhibitor 
Response 1 (TIR1). Auxin hormones bind to TIR1, in order to promote the association 
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between the SCF-CRL complex and AUX/IAA transcriptional repressor proteins, and 
trigger AUX/IAA ubiquitination, priming them for proteolysis (Nishimura et al., 2009, Tan 
et al., 2007). Whilst other eukaryotes lack this auxin-inducible response, the SCF 
degradation pathway is conserved, implying that such auxin-inducible degradation 
could be transferred to other eukaryotic cells. The Kanemaki lab first demonstrated this 
possibility in chicken, mouse, yeast and human cells, and showed rapid, reversible 
degradation of essential POIs in these different cell lines (Nishimura et al., 2009). This 
was achieved through fusing an IAA17 degron sequence on to the POI, and 
simultaneously overexpressing TIR1 in the target cells. Rapid protein degradation was 
observed following IAA treatment (Nishimura et al., 2009). As it is generally believed 
that the auxin degradation pathway is only active in plants, any off-target effects 
resulting from auxin treatment are thought to be minimal. That said, IAA oxidation by 
eukaryotic peroxidases has been reported to be toxic at high doses (Folkes, Dennis et 
al., 1999), highlighting the need to test auxin sensitivity in the target cell line before 
using this system. One of the key limitations of the Auxin-inducible system is that it 
cannot be used to explore the effects of endogenous protein degradation, without first 
inserting the IAA degron sequence at the POI locus. This has not been such an 
impediment in yeast (Nishimura et al., 2009), however in higher eukaryotes this has 
been more challenging, owing to the much less efficient homologous recombination in 
these cells compared to that seen in yeast.  
Recent years have seen the advancement of gene editing technologies, such as 
CRISPR/Cas9 (Cong et al., 2013, Sander & Joung, 2014). This has made it relatively simple 
to achieve gene knockouts in somatic cells, provided that the gene of interest is not 
essential for cell survival or proliferation. It is estimated that there are over 1800 genes 
that are impossible to knockout with conventional CRISPR/Cas9 methods (Wang et al., 
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2015). Similarly, the CRISPR/Cas9 system has been successfully employed to knockin 
fluorescent reporter tags, such as green fluorescent protein (GFP), onto target genes. 
However, the success of genetic knockins rely on the knockin tag not impinging on target 
gene expression and/or function of the protein product. With such advances, the AID 
degron sequence was also successfully knocked into genes encoding cohesin and dynein 
in human colorectal cancer HCT116 cells (Natsume, Kiyomitsu et al., 2016). Following 
TIR1 overexpression, IAA-responsive degradation of cohesin and dynein were observed 
(Natsume et al., 2016). Whilst this auxin-inducible approach presents a powerful tool to 
achieve target protein degradation in cells, inserting a non-fluorescent AID degron tag 
homozygously onto the POI locus remains a challenge. This is not such a problem for 
fluorescent knockin tags, which allow rapid isolation of fluorescent-positive cell clones 
through fluorescence-activated cell sorting (FACS) (Rojas-Fernandez et al., 2015). Such 
fluorescent tags also allow for robust localisation, proteomic and biochemical studies, 
and additionally, present a tantalising target for the specific proteolysis of tagged 
proteins of interest. 
Concomitantly, recent years have also witnessed the rapid development and use 
of small, isolated variable domain fragments, derived from single chain antibodies, as 
seen in species such as camels and sharks (Fridy, Li et al., 2014, Kirchhofer, Helma et al., 
2010, Rothbauer, Zolghadr et al., 2008). A key advantage of these small polypeptides 
(hereafter referred to as nanobodies) is that their coding sequence can be easily 
packaged into plasmids for expression in multiple cellular systems. Once expressed, 
nanobodies retain their specificity and affinity for their protein targets. Many 
nanobodies have been generated against distinct targets, including fluorescent proteins 









Figure 5-1: Conceptual design of AdPROM: Schematic illustration of the CRL-mediated 
degradation of HIF1α (left-hand side), and  AdPROM-mediated degradation of GFP-
tagged targets (right-hand side). VHL; Von Hippel-Lindau protein, CUL2; Cullin 2, RBX1; 
RING-box protein 1, E2; E2 ubiquitin-conjugating enzyme, aGFP; anti-GFP nanobody.  
 
 
Here, I sought to combine the nanobody and CRISPR/Cas9 technologies to 
generate a method to degrade GFP-tagged knockin proteins of interest. An approach 
where one could express VHL conjugated to an anti-GFP (aGFP) nanobody within cells, 
and in doing so recruit the GFP-tagged knockin protein to the CUL2-CRL complex for its 
proteolysis, was envisaged (Figure 5-1). This approach was named the Affinity-directed 
PROtein Missile (AdPROM) system, and its development and characterisation will be 
explored in detail within this chapter.  
 
5.2: Results: 
5.2.1: AdPROM is effective for degradation of selective GFP-tagged knockin proteins: 
In order to test the effectiveness of the conceived AdPROM design, two different 
GFP knockin cell lines were infected with AdPROM retroviruses encoding either VHL-






























Figure 5-2: AdPROM is effective for degradation of GFP-VPS34 and PAWS1-GFP: A: 
Western blot analysis of extracts from PAWS1-GFP and GFP-VPS34 knockin U2OS and 
HEK 293 cells respectively, using the indicated antibodies (n=3). B: Cells described in A. 
were infected with control retroviruses (GFP) or retroviruses encoding aGFP-VHL or VHL-
aGFP. Cells were lysed and extracts (20 µg) were separated by SDS–PAGE, prior to 
immunoblotting (IB) with the indicated antibodies (n=3). C: PAWS1-GFP knockin U2OS 
cells were infected with retroviruses encoding GFP, aGFP, VHL, aGFP-VHL, or VHL-aGFP. 
Following lysis, extracts were subjected to SDS-PAGE and subsequent IB with the 
indicated antibodies (n=3). 
 
 
vector control. For this purpose, GFP-VPS34 HEK 293 and FAM83G-GFP (hereafter 
referred to as PAWS1-GFP) U2OS knockin cells were used, generated by Annika 
Hornberger and Polyxeni Bozatzi respectively (Figure 5-2A). Following infection and 
selection of AdPROM-expressing clones with the antibiotic puromycin, the abundance 
of GFP-VPS34 and PAWS1-GFP knockin proteins were evaluated by immunoblotting with  
antibodies against GFP, VPS34 and PAWS1. Whilst in control vector, and aGFP-VHL-
expressing cells, where the levels of both GFP-VPS34 and PAWS1-GFP remained 
unaltered, robust depletion of both GFP knockin proteins in cells expressing VHL-aGFP 
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Figure 5-3: Swapping aGFP for a distinct GFP nanobody does not hinder AdPROM-
mediated degradation: A: PAWS1-GFP knockin U2OS cells were infected with control 
retroviruses (GFP) or retroviruses encoding aGFP.16, VHL, or VHL-aGFP.16. Cells were 
lysed and extracts (20 µg) were separated by SDS–PAGE, prior to immunoblotting (IB) 
with the indicated antibodies (n=3). B: As in A, except that GFP-VPS34 knockin HEK 293 
cells were used (n=3). 
 
 
modified to possess a GFP fusion tag, no PAWS1 depletion was observed, suggesting 
that VHL-aGFP only targets GFP-tagged proteins for degradation (Figure 5-2B). Similar 
observations were made in U2OS cells in which the VPS34 gene is not edited to encode 
a GFP fusion protein (Figure 5-2B). Collectively, these data suggested that the 
conjugation of aGFP onto the C-terminus, but not the N-terminus, of VHL was essential 
for proteolysis. Consequently, the VHL-aGFP polypeptide was used as the effective 
orientation for the AdPROM system in subsequent experiments.  
In order to confirm that the individual VHL and aGFP components that constitute 
the AdPROM system did not drive the degradation of GFP-tagged proteins on their own, 











































VHL or aGFP. As expected, neither VHL nor aGFP when expressed individually caused a 
reduction in PAWS1-GFP protein levels (Figure 5-2C).  
Furthermore, to circumvent the possibility that VHL-aGFP was causing 
degradation through non-UPS mechanisms, the aGFP was replaced with an 
independently-derived, distinct camelid anti-GFP nanobody which recognises a different 
epitope on GFP (hereafter referred to as aGFP.16). The AdPROM system encompassing 
VHL-aGFP.16 also drove degradation of GFP-VPS34 and PAWS1-GFP when expressed in 
cells, whereas individual expression of VHL or aGFP.16 did not (Figure 5-3A&B). 
 
5.2.2: AdPROM exploits the CRL-UPS for targeted degradation of GFP-tagged knockin 
proteins: 
Next, I sought to confirm that the observed degradation of GFP-VPS34 and 
PAWS1-GFP was indeed being mediated by the predicted CUL2-CRL machinery. To test 
this, cells were treated with the pan-Cullin NEDDylation inhibitor MLN4924 (Soucy et al., 
2009), and the levels of the GFP-tagged knockin proteins were monitored. As expected, 
treatment of both U2OS and HEK 293 cells with MLN4924 resulted in robust inhibition 
of CUL2 NEDDylation, and concomitant stabilisation of its endogenous substrate HIF1α 
(Figure 5-4A). Under these conditions, in cells expressing VHL-aGFP, levels of both GFP-
VPS34 and PAWS1-GFP were partially restored with MLN4924 treatment, whereas no 
changes in their protein levels were detected in control cells (Figure 5-4A). Importantly, 
the expression of the VHL-aGFP AdPROM did not appear to stabilise HIF1α, suggesting 
that AdPROM does not interfere with substrate recognition by the endogenous CUL2-
CRL complex (Figure 5-4A). To test the involvement of the proteasome in AdPROM-
induced protein degradation, PAWS1-GFP knockin U2OS cells were treated with the 
proteasome inhibitor Bortezomib, and PAWS1-GFP levels were monitored by  
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Figure 5-4: AdPROM exploits the CRL-UPS for degradation of target proteins: A: GFP-
VPS34 HEK 293 and PAWS1-GFP U2OS knockin cell lines were infected with retroviruses 
encoding either control (GFP) or VHL-aGFP. Infected cells were then treated with either 
DMSO or the pan-Cullin NEDDylation inhibitor MLN4924 (1 µM) for 6 h, as indicated. 
Extracts (20 µg protein) were resolved by SDS–PAGE, and subjected to immunoblotting 
(IB) with the indicated antibodies (n=3). B: Control (GFP) or VHL-aGFP PAWS1-GFP U2OS 
cells described in A were treated with 10 µM Bortezomib for 0, 4, 10 or 24 h prior to 
lysis. Extracts (20 µg protein) were resolved by SDS–PAGE, and subjected to IB with the 




immunoblotting. Whereas no significant changes in PAWS1-GFP protein levels were 
detected in control cells treated with Bortezomib, stabilisation of PAWS1-GFP was 
observed in a time-dependent manner in VHL-aGFP expressing cells, following 
Bortezomib addition to the culture media (Figure 5-4B). Collectively, these data suggest 
that the AdPROM-mediated degradation of GFP-tagged knockin protein occurs through 
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5.2.3: Adapting the AdPROM system for inducible degradation of GFP-tagged knockin 
proteins: 
Having demonstrated utility of the AdPROM system in the constitutive degradation of 
GFP-tagged knockin proteins, I next sought to adapt AdPROM into an inducible 
proteolytic tool. For this purpose, the pRetroX Tet-On retroviral system was employed 
to clone VHL-aGFP.16, with the hope of achieving tetracycline (Tet)-inducible expression 
of the VHL-aGFP.16 AdPROM. Using this approach, in cells expressing either an empty 
vector or VHL-aGFP.16 under the control of the Tet-inducible promoter, no changes in 
GFP-VPS34 protein levels were observed in the absence of the Tet analogue doxycycline 
(Figure 5-5A). However, whereas no changes in GFP-VSP34 protein levels were detected 
in empty vector-expressing cells in response to doxycycline treatment, time-dependent 
degradation of GFP-VPS34 was observed in the VHL-aGFP.16-expressing cells, following 
induction with doxycycline (Figure 5-5A). Interestingly, a concomitant reduction in the 
levels of the VPS34-interacting protein UVRAG was evident, suggesting that AdPROM 
has the potential to target protein complexes for degradation (Figure 5-5A). 
Given the role VPS34 plays in the generation of phosphatidylinositol 3-
phosphate (PI3P) on endosomal membranes, in its capacity as a PI3P lipid kinase (Bago, 
Malik et al., 2014, Gillooly, Morrow et al., 2000), I sought to test if AdPROM-mediated 
GFP-VPS34 proteolysis would impact endogenous VPS34 biology. Endosomal PI3P acts 
to recruit proteins containing FYVE and PX domains, in order to mediate downstream 
signalling (Gillooly et al., 2000). To visualise endosomal PI3P, I made use of a recently-
developed AlexaFluor-488-conjugated probe attached to the PX domain of P40phox 
(Kanai, Liu et al., 2001, Malik, Macartney et al., 2018, Munson, Allen et al., 2015). A PI3P-
interaction-deficient PX domain mutant conjugated to AlexaFluor-594 served as a 
negative control in these assays, and allowed simultaneous visualisation of both the  
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Figure 5-5: Adapting AdPROM for Tet-inducible degradation of target proteins: A: GFP-
VPS34 HEK 293 knockin cells were first infected with the pRetroX-Tet-ON advanced 
vector (Clontech) and selected for the expression of the Tet-transactivator. Cells were 
then infected with either the pRetroX-Tight empty vector control or the pRetroX-Tight 
vector encoding VHL-aGFP.16. Cells were then treated with 2 µg/ml doxycycline for the 
indicated time points prior to lysis. Extracts (20 µg protein) were resolved by SDS–PAGE, 
and subjected to immunoblotting (IB) with the indicated antibodies (n=3). B: GFP-VPS34 
HEK 293 knockin cells expressing the pRetroX system described in A. were either left 
untreated, treated with doxycycline (2 µg/ml; 24 h), or with VPS34-IN1 (2.5 µM, 1 h). 
Cells were permeabilised in liquid nitrogen, and fixed in 3.7% (w/v) paraformaldehyde 
before staining with fluorescently-labelled selective PI3P binding (green) and interaction 
deficient (red) probes as described in the Material and methods section. DNA is stained 
with DAPI. Representative images from one field of view, representative of 2 




the wild-type and mutant PI3P probes in the same samples (Malik et al., 2018). Using 
these fluorescent probes, endosomal PI3P levels in response to GFP-VPS34 degradation 
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with the Tet-inducible VHL-aGFP.16 AdPROM were examined. Whereas no difference in 
cellular PI3P puncta was observed in response to doxycycline in empty vector-expressing 
cells, there was a substantial reduction in PI3P puncta in VHL-aGFP.16-expressing cells 
following GFP-VPS34 degradation (Figure 5-5B). This reduction in PI3P puncta was 
similar to that seen in response to VPS34 inhibition with the VPS34 kinase inhibitor 
VPS34-IN1 (Bago et al., 2014)  (Figure 5-5B). Under identical conditions, no PI3P puncta 
were detected with the mutant probe, suggesting that the puncta that were assayed 
were indeed PI3P (Figure 5-5B). Thus, AdPROM-induced degradation of GFP-VPS34 
appears to impact the cellular function of VPS34, which is at least comparable to its 
chemical inhibition using small molecule inhibitors.  
 
5.2.4: Adapting AdPROM for degradation of unmodified target proteins in cells: 
As mentioned above, knocking in fluorescent tags onto target proteins can 
potentially affect their stability and/or cellular function(s). To combat these potential 
limitations, I sought to expand the AdPROM system and explore whether unmodified, 
native proteins could be targeted for degradation. To test this, I made use of a nanobody 
raised against the inflammasome protein ASC (Schmidt, Lu et al., 2016) (Figure 5-6A), 
and fused it onto the C terminus of VHL. A FLAG tag was introduced at the N-terminus 
of VHL to facilitate easier visualisation.  
Following successful expression of FLAG-VHL-aASC in cells, through retroviral 
infections, the protein levels of ASC in ASC-expressing K-562 cells were monitored. 
Control retroviruses encoding unfused FLAG-aASC or VHL were also included. Whereas 
no detectable decrease in ASC abundance was observed in cells treated with control 
retroviruses, a substantial reduction in the protein levels of ASC was observed in VHL-
aASC-expressing cells (Figure 5-6B). In order to demonstrate the affinity of the aASC  
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Figure 5-6: The AdPROM system is adaptable for degradation of endogenous ASC: A: 
Domain structure of ASC with the N-terminal Pyrin domain (PYD) and C-terminal Caspase 
recruitment domain (CARD) indicated. The aASC nanobody recognises the CARD domain 
of human ASC. B: Uninfected human K-562 cells (WT) or cells infected with retroviruses 
encoding VHL, FLAG-aASC or FLAG-VHL-aASC were lysed, and extracts (20 µg protein) 
were resolved by SDS-PAGE. Separated proteins were subjected to immunoblotting (IB) 
with the indicated antibodies (n=3). C: Extracts (1 mg protein) from the cells described 
in B. were subjected to immunoprecipitation (IP) with anti-FLAG M2 resin. The resulting 
IP, and Input and flow-through (flow) samples (20 µg protein) were resolved by SDS-
PAGE and subjected to IB with the indicated antibodies (n=3). D: As in B. except that 
murine J774 monocyte cells were used (n=3). E: As in C. except that murine J774 
monocytes from D. were used (n=3). 
 
 
nanobody for the human ASC protein, anti-FLAG immunoprecipitations were 
performed. In FLAG-aASC-expressing K-562 cells, ASC was robustly immunoprecipitated 
and depleted from flow-through extracts (Figure 5-6C). As ASC was degraded by VHL-
aASC, immunoprecipitations from FLAG-VHL-aASC-expressing cells did not 
immunoprecipitate ASC, as expected (Figure 5-6C). As the aASC nanobody was reported 























































































































































experiments in murine J774 monocytes. Consistently, no degradation of murine ASC was 
detected in FLAG-VHL-aASC-expressing cells (Figure 5-6D), and FLAG-aASC 
immunoprecipitations failed to coimmunoprecipitate the murine ASC protein (Figure 5-
6E). Collectively, these data highlight the versatility of the AdPROM system, and 
showcase successful adaptation of AdPROM for degradation of endogenous, 
unmodified human ASC protein. 
Nanobodies are just one class of high-affinity polypeptide binder that have been 
developed in recent years. Whereas nanobodies rely on immunisation of single chain 
antibody-producing animals, such as camels, in order to obtain functional high-affinity 
binders, a number of synthetic approaches have successfully yielded specific 
polypeptide binders as well. One such method exploits the backbone of the human 10th 
fibronectin type III domain, where varying combinations of residues within the variable  
regions are screened for their ability to bind the target antigen (Sha, Gencer et al., 2013). 
Resulting polypeptide binders are referred to as monobodies, and there have been a 
few high-affinity monobodies developed for specific targets (Sha et al., 2013, Wojcik, 
Hantschel et al., 2010, Wojcik, Lamontanara et al., 2016). To examine if monobodies 
were also compatible with the AdPROM system, I chose two distinct monobodies that 
recognise the protein tyrosine phosphatase SHP2 (also known as PTPN11). SHP2 
possesses two SH2 domains at its N-terminus, termed N-SH2 and C-SH2 respectively, 
with N-SH2 being slightly more N-terminal than C-SH2 (Sha et al., 2013). The 
monobodies chosen to test within the AdPROM system bind to either the N-SH2 and C-
SH2 domains of SHP2, and are designated aNSa1 and aCS3 respectively (Sha et al., 




Figure 5-7: AdPROM is adaptable for degradation of endogenous SHP2 using 
monobodies instead of nanobodies: A: Domain structure of SHP2. N-SH2; N-terminal 
SH2 domain. C-SH2; C-terminal SH2 domain. PTP; protein tyrosine phosphatase domain. 
The monobodies aNSa1 and aCS3 recognise the N-SH2 and C-SH2 domains of SHP2 
respectively. B: U2OS cells were infected with retroviruses encoding VHL, FLAG-NSa1, 
FLAG-aCS3, FLAG-VHL-aNSa1 or FLAG-VHL-aCS3, or left uninfected (WT). Cell extracts 
(20 µg protein) were resolved by SDS-PAGE and subjected to immunoblotting (IB) with 
the indicated antibodies (n=3). C-E: as in B. except that  MDA-MB-468 mammary gland 
adenocarcinoma (C), A549 pulmonary adenocarcinoma (D) and MDA-MB-231 breast 
cancer (E) cells were used (n=3). 
 
 
FLAG-VHL-aNSa1 and FLAG-VHL-aCS3 were packaged into mammalian-
expression pBABED retroviral vectors, and retroviruses were produced. Following 
successful infection of U2OS osteosarcoma cells, the levels of SHP2 were evaluated by 
immunoblotting. Control retroviral infections encoding FLAG-aNSa1, FLAG-aCS3, or VHL 
were performed in parallel. The endogenous SHP2 levels were unaltered and 









































































































































Figure 5-8: AdPROM employs the CRL-UPS for SHP2 degradation: A: Uninfected U2OS 
cells (wild type) or cells infected with retroviruses encoding FLAG-aCS3 or FLAG-VHL-
aCS3 were treated with MLN4924 (1 µM) for 0, 6 or 24 h. Cells were lysed and extracts 
(20 µg protein) were resolved by SDS-PAGE and subjected to immunoblotting (IB) with 
the indicated antibodies. HIF1α serves as a positive control for MLN4924 treatment 
(n=3). B: U2OS cells treated with or without MLN4924 (1 µM) for 24 h were lysed and 
extracts (1 mg protein) were subjected to immunoprecipitation (IP) with anti-FLAG M2 
resin. Following elution, both the IPs and Input extracts (20 µg protein) were resolved 
by SDS-PAGE, and subjected to IB with the indicated antibodies (n=3). 
 
 
FLAG-aCS3 controls (Figure 5-7B). In contrast, compared to these cells, a substantial 
reduction in SHP2 protein levels was observed in cells expressing FLAG-VHL-aNSa1, and 
an even greater reduction in cells expressing FLAG-VHL-aCS3 (Figure 5-7B). Similar 
results in SHP2 degradation were detected in MDA-MB-468 mammary gland 
adenocarcinoma (Figure 5-7C), A549 pulmonary adenocarcinoma (Figure 5-7D), and 
MDA-MB-231 breast cancer cells (Figure 5-7E), suggesting that the observations on 
SHP2 protein abundance are not due to cell type-specific mechanisms.  
Next, in order to confirm that VHL-bound monobodies also mediate degradation 
through the predicted CUL2-CRL machinery, FLAG-VHL-aCS3-expressing cells were 




































Uninfected and control FLAG-aCS3 cells were also treated. In uninfected cells, or in cells 
expressing FLAG-aCS3, MLN4924 treatment had no effect on SHP2 protein levels (Figure 
5-8A). In stark contrast, MLN4924 treatment rescued the degradation of SHP2 in FLAG-
VHL-aCS3-expressing cells (Figure 5-8A). Consistent with previous observations, 
expression of the SHP2 AdPROM system did not appear to stabilise the endogenous VHL 
substrate HIF1α, suggesting the monobody version of AdPROM does not impact hypoxia 
signalling either (Figure 5-8A). To demonstrate the affinity of the aCS3 and aNSa1 
monobodies for the SHP2 protein, anti-FLAG immunoprecipitations were performed in 
aCS3 cells, with or without prior treatment with MLN4924 for 24 h. In FLAG-aCS3-
expressing cells, SHP2 was robustly immunoprecipitated, irrespective of MLN4924 
treatment (Figure 5-8B). As SHP2 was degraded by VHL-aCS3, anti-FLAG 
immunoprecipitations from FLAG-VHL-aCS3-expressing cells did not co-
immunoprecipitate SHP2 in the absence of MLN4924 treatment, whereas some SHP2 
could be detected in the eluates following treatment with MLN4924 (Figure 5-8B).  
Collectively, these data highlight that both nanobodies and monobodies 
recognising endogenous target proteins can be successfully employed as effective 
affinity probes within the AdPROM system, provided they can bind their intended 
targets within cells. Furthermore, the AdPROM-mediated degradation of endogenous 
SHP2 appears to be mediated by the intended CUL2-CRL machinery. 
 
5.2.5: Comparing the proteolytic AdPROM with an RNA interference approach, for the 
depletion of SHP2: 
In order to evaluate the degradation rate of AdPROM targets, the VHL-aCS3 
sequence was packaged into the Tet-inducible pRetroX Tet-On system described above 




Figure 5-9: Comparing proteolytic AdPROM with siRNA for the depletion of SHP2: A: 
MDA-MB-468 cells were infected with retroviruses encoding the pRetroX-Tet-On 
transactivator and either pRetroX-Tight empty vector (empty) or pRetroX-Tight-VHL-
aCS3 (VHL-aCS3). Infected cells were treated with doxycycline (2 µg/ml) for the indicated 
time points prior to lysis. Cell extracts (20 µg protein) were separated by SDS-PAGE, and 
subjected to immunoblotting (IB) with the indicated antibodies (n=3). B: MDA-MB-468 
cells were transfected with non-targeting control siRNAs (siN.T.) or siRNAs targeting 
SHP2 (siSHP2) and lysed at the indicated time points after transfection. Cell extracts (20 




Tight plasmid was introduced as a control. Treatment of VHL-aCS3 cells, but not the 
empty vector cells, with doxycycline induced a time-dependent reduction in SHP2 
protein levels, which coincided with expression of the VHL-aCS3 AdPROM (Figure 5-9A). 
Under these conditions, SHP2 levels appeared to be substantially reduced after 8 h, and 
almost completely reduced after 24 h, treatment with doxycycline (Figure 5-9A); 
suggesting that AdPROM system induces degradation fairly rapidly after its successful 
expression.  
Next, to evaluate how AdPROM-mediated SHP2 proteolysis compares with 
conventional siRNA-induced depletion, MDA-MB-468 cells were transfected with either 

























were lysed 8, 24 and 48 h after transfection. Whereas control siRNAs had no effect on 
SHP2 protein levels at all time points tested, siRNAs against SHP2 induced SHP2 
depletion only at 48 h post-transfection (Figure 5-9B). These results suggest that RNA 
interference approaches, which rely on native protein turnover rates, are not as efficient 
at depleting SHP2 compared with the AdPROM system, which degrades proteins 
independently of their half-life duration. 
 
5.2.6: Leveraging AdPROM technology to study FAM83D: 
I previously showed that CK1α fails to localise to the mitotic spindle in FAM83D 
knockout cells. To further ascertain whether CK1α-recruitment to the spindle apparatus 
was dependent on FAM83D, I sought to use AdPROM to efficiently degrade FAM83D-
GFP in FAM83DGFP/GFP U2OS cells (Figure 5-10A).  Whereas the control VHL, or aGFP.16 
retroviruses had no effect on FAM83D-GFP protein levels compared to control 
uninfected cells (Figure 5-10B), robust FAM83D-GFP degradation was observed in cells 
expressing VHL-aGFP.16 (Figure 5-10B), suggesting that AdPROM-mediated proteolysis 
was compatible with FAM83D-GFP. 
Next, the spindle localisation of CK1α was examined in these cells. Robust co-
fluorescence was observed between FAM83D-GFP and CK1α staining in uninfected, VHL, 
or aGFP.16-expressing cells (Figure 5-10C). However, when FAM83D-GFP was degraded 
in VHL-aGFP.16-expressing cells, I observed concurrent absence of CK1α on the spindle 
apparatus (Figure 5-10C), consistent with the model that FAM83D recruits CK1α to the 




Figure 5-10: AdPROM-mediated degradation of FAM83D-GFP: A: Schematic illustration 
of the AdPROM-mediated degradation of FAM83D-GFP. VHL; Von Hippel-Lindau 
protein, CUL2; Cullin 2, RBX1; RING-box protein 1, E2; E2 ubiquitin-conjugating enzyme, 
aGFP.16; anti-GFP.16 nanobody. B: FAM83DGFP/GFP knockin U2OS cells were infected 
with retroviruses encoding either VHL, aGFP.16, or VHL-aGFP.16. Uninfected cells were 
used as a control. Cells were lysed and subjected to immunoblotting (IB) with the 
indicated antibodies (n=3). C: The cell lines described in B. were subjected to anti-CK1a 
immunofluorescence and GFP fluorescence microscopy. DNA is stained with DAPI. Scale 
bars; 20 µM (n=2).  
 
 
As a proof of principle, I wondered if an anti-mCherry nanobody (LAM2) could 
also be tethered to VHL, to facilitate degradation of endogenous mCherry-tagged CK1α 
in FAM83DGFP/GFP / mCherry/mCherryCSNK1A1 U2OS cells (Figure 5-11A). The expression of the 
VHL-LAM2 AdPROM resulted in robust mCherry-CK1α degradation, without affecting 
FAM83D-GFP levels (Figure 5-11B).  
As a whole, as corroborating data can be obtained through both genetic ablation 
of FAM83D, and targeted proteolysis of FAM83D-GFP, these results suggest that 
AdPROM will be a useful tool for examining the biology of FAM83-CK1 interactions in 









Figure 5-11: AdPROM-mediated degradation of mCherry-CK1α: A: Schematic 
illustration of the AdPROM-mediated degradation of mCherry-CK1α. VHL; Von Hippel-
Lindau protein, CUL2; Cullin 2, RBX1; RING-box protein 1, E2; E2 ubiquitin-conjugating 
enzyme, LAM2; llama anti-mCherry nanobody 2. B: FAM83DGFP/GFP / 
mCherry/mCherryCSNK1A1 knockin U2OS cells were infected with retroviruses encoding VHL-
aGFP.16. Uninfected cells were used as a control. Cells were lysed and subjected to 




Efficient and specific targeted proteolysis of endogenous cellular proteins is 
desirable in both basic research, and in potential therapeutic approaches. Here I 
describe an effective proteolytic AdPROM system that recruits target proteins to the 
CUL2-CRL complex for the subsequent ubiquitination and degradation of the target 
protein via the proteasome. I showcase that two distinct types of high-affinity binding 
proteins, namely nanobodies and monobodies, act as effective affinity probes for the 
AdPROM system. Importantly, the AdPROM system does not appear to impact 
endogenous hypoxia signalling, which is regulated by the VHL-CUL2 complex. 
Whilst the current pool of available nanobodies, monobodies, and similar high-
affinity polypeptide binders is limited, the multiple, diverse, potential uses of these 






































That said, even in the absence of individual protein-targeting binders, binders 
recognising epitope tags such as the GFP nanobody described here, can be effectively 
employed, assuming that the fusion of the epitope tag onto the target protein does not 
impact protein function/stability.  
In some cases, VHL may not be the ideal substrate receptor to tether the high-
affinity binder to. Indeed, the precise tolerances of the CUL2-CRL complex for VHL-
recruited substrates, in terms of their protein mass and composition, have not yet been 
established. Thus, it is prudent to develop an array of varied E3 ligase components that 
are compatible with the AdPROM system, that will allow for the targeted proteolysis of 
target proteins in cases where VHL AdPROMs do not function optimally.  
In order to improve the AdPROM system, the ability to control AdPROM 
expression in an inducible manner is desirable. Whilst we have demonstrated the 
efficacy of a Tet-inducible AdPROM, such transcriptional inducible systems are not ideal 
as they require both transcription and translation of the AdPROM polypeptide before 
target protein degradation is observed, which can take many hours. Thus, the 
development of a rapid inducible AdPROM system is an important next step, and will 
facilitate studies into the effects of POI degradation at key, short-lived cellular events. 
That said, with increasing pharmaceutical interest in PROTACs (Bulatov & Ciulli, 2015, 
Sakamoto et al., 2001, Zengerle et al., 2015), technologies such as the constitutive 
AdPROM system should be able to rapidly inform if a putative PROTAC target can be 
degraded by the intended E3 ligase complex, prior to expensive and laborious 





6. Conclusions and Future Perspectives: 
 
The CK1 family of Ser/Thr protein kinases have been implicated in many cellular 
processes, from Wnt signalling to the DNA damage response (Knippschild et al., 2005a, 
Schittek & Sinnberg, 2014, Venerando et al., 2014) (see section 1.2.4). Despite such a 
wide plethora of apparent functions, regulatory mechanisms responsible for 
coordinating these constitutively-active enzymes remain elusive. Here, the FAM83 
family of proteins are presented as interactors of selective CK1 family isoforms, with the 
data-driven suggestion that FAM83-CK1 interactions act to localise CK1 isoforms to 
distinct cellular sites. In this capacity, FAM83 members may act to position CK1 isoforms 
in close proximity to their substrates within the cellular compartments in which each 
FAM83 protein resides. Alternatively, the FAM83 members may act as signalosome 
assembly platforms, and act to bridge the gap between CK1 isoforms and their 
substrates. Indeed, the diverse sets of interactors reported for each FAM83 member 
would suggest that non-CK1 interacting partners of FAM83 proteins are in abundance 
(Bozatzi et al., 2018, Cummins et al., 2018, Dunsch et al., 2012, Kuga et al., 2016a, 
Santamaria et al., 2008, Vogt et al., 2014). In this vein, each FAM83-interacting protein 
should be considered as a putative CK1 substrate, and be tested experimentally.  
An additional regulatory mechanism prevalent for some kinases such as Aurora 
A and CDKs is direct allosteric activation through binding interacting partners (Bayliss et 
al., 2003, Ito, 2000). Whilst direct allosteric activation of CK1α by FAM83G in vitro was 
ruled out in this thesis, the potential contribution of allosteric activation will need to be 
further explored for the other FAM83 members. With the notion that FAM83 proteins 
can act to streamline CK1 signal transduction by recruiting selective CK1 isoforms to 
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distinct locations in mind, charting the FAM83-dependent CK1 substrate landscape, 
through phosphoproteomic approaches, will be an important next step. 
In the case of the mitotic FAM83D-CK1α interaction, deciphering the CK1α 
substrate(s) responsible for coordinating precise spindle positioning will provide 
mechanistic insights into this regulatory pathway. Research into the phosphorylation-
mediated control of spindle positioning has focussed primarily on three main kinase 
families, namely CDKs, AURKs, and PLKs. However, the extent of phosphorylation 
reported over a cell division cycle is unlikely to be explained by these kinase families 
alone, thereby suggesting roles for other kinases in mitosis. Interestingly, a recent 
phosphoproteomic screen found that near 50% of all cell cycle phosphopeptides 
conformed to the predicted CK1 consensus motif (Ly et al., 2017). Thus, the influence 
that CK1α exerts on the regulation of the cell division cycle may be far-reaching. The 
FAM83D-CK1α interaction is the first FAM83-CK1 interaction identified to be dependent 
on cell cycle stage, and indeed, to require a stimulus in general. For the less robust 
FAM83-CK1 interactions, elucidating their biological niche may illuminate further 
stimuli-dependent FAM83-CK1 associations.  
Recently, the FAM83D-interacting protein HMMR, which is responsible for 
recruiting FAM83D and by extension CK1α to spindle microtubules, was found to 
regulate the PLK1-dependent spindle positioning pathway (Connell et al., 2017). PLK1 is 
a Ser/Thr protein kinase that possesses a polo-box domain, thought to be important in 
mediating PLK1 localisation (Combes, Alharbi et al., 2017, Garcia-Alvarez, de Carcer et 
al., 2007). The polo-box domain binds to phospho-epitopes on docking proteins, thereby 
localising PLK1 to spindle poles and kinetochores (Combes et al., 2017, Garcia-Alvarez 
et al., 2007, Park et al., 2010). Spindle pole-localised PLK1 is thought to regulate the 
activity of dynein complexes at the cortex, to create a balanced equilibrium of pulling 
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forces acting to position the spindle (Kiyomitsu & Cheeseman, 2012). In short, when a 
spindle pole gets too close to the cortex, PLK1 activity acts to strip dynein motor 
complexes from that near-cortex, resulting in greater pulling forces from the opposite 
cortex, and reestablishment of a centralised spindle (Kiyomitsu & Cheeseman, 2012). 
Cells lacking HMMR were found to have reduced PLK1 activity at spindle poles, and could 
not strip cortical dynein complexes effectively, resulting in aberrant spindle positioning 
(Connell et al., 2017). Given that cells lacking HMMR also lack FAM83D-CK1α on mitotic 
spindles, any defects resulting from HMMR depletion could be explained by non-
delivery of CK1α to the spindle apparatus. Indeed, FAM83D knockout and FAM83DGFP/GFP 
(F283A) cells, as well as siCK1α-depleted cells, also present with spindle positioning 
defects. Thus, future efforts aimed at testing the tantalising hypothesis that CK1α also 
acts in the PLK1-dependent spindle positioning pathway may provide mechanistic 
insights into how CK1α regulates spindle orientation at the molecular level.  
The HMMR-FAM83D-CK1α complex could be envisaged to regulate  PLK1 activity 
by at least two mechanisms. Firstly, CK1α may act to activate PLK1 in a direct or indirect 
manner, although the upstream PLK1 kinase is generally believed to be Aurora A 
(Macurek et al., 2008). Secondly, and more likely, CK1α may act to phosphorylate a 
docking protein at the spindle pole to generate a phospho-epitope to facilitate polo-box 
domain binding, and allow PLK1 recruitment. Any FAM83D-centred phosphoproteomic 
screens should thus be examined for putative spindle-pole (and/or kinetochore) 
localised proteins, and tested for their ability to bind PLK1 following their 
phosphorylation by CK1α. However, it should be noted that HMMR is also reported to 
localise the TPX2-Aurora A complex to mitotic spindles (BlancoKuchenbaecker et al., 
2015, Chen et al., 2014), so defects resulting from HMMR depletion are likely more 
severe than those resulting from FAM83D ablation alone.  
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Ultimately, cancer cells grown in culture do not care which direction they divide. 
However, in development, the precise control of spindle orientation is critical for tissue 
establishment, and for the asymmetric distribution of cell fate determining factors 
(Bergstralh et al., 2017, Lu & Johnston, 2013, Siller & Doe, 2009). Thus, to truly 
appreciate the physiological role of the HMMR-FAM83D-CK1α complex, and any 
accompanying defects following perturbation of this pathway, animal models are a 
logical next step. Whilst CSNK1A1 is an essential gene, FAM83D and HMMR are not 
(Wang et al., 2015). Indeed, HMMR knockout mice present with neurodevelopmental 
defects, likely arising from spindle misorientation (Connell et al., 2017). Thus, ablation 
of FAM83D and/or HMMR in mice, or other animal models, would be predicted to 
facilitate the evaluation of CK1α in developmental cell divisions, without affecting the 
essential non-mitotic CK1α functions. 
Many CK1 substrates appear to be degraded following their phosphorylation 
(Del Valle-Perez et al., 2011, Eide, Woolf et al., 2005, Gao et al., 2002, Huart et al., 2009, 
Xu, Lee et al., 2010). Given the dynamic nature of cell division, the cellular landscape 
must be quickly changed in order to facilitate mitotic exit and entry into interphase. 
Central to this notion is the proteolytic degradation of mitotic proteins following 
completion of their mitotic roles (Ang & Wade Harper, 2005, Chang et al., 2003, Koepp, 
2014). Thus, it is feasible that CK1α-mediated phosphorylation of mitotic substrates 
simply acts to prime them for proteolysis by creating a phospho-degron signal. Indeed, 
in the case of FAM83D, which exhibits mitotic phosphorylation dependent on its 
interaction with CK1α, it seems to be the phosho-FAM83D species that is degraded 
following mitotic exit. Thus, examining any putative mitotic CK1 substrates on the basis 
that they may be degraded following their phosphorylation might be insightful. This will 
be particularly important when designing phosphoproteomic experiments, as 
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proteasomal inhibition may need to be employed in order to efficiently capture CK1-
dependent phosphopeptides. Perhaps comparison of the proteomes and 
phosphoproteomes between wild-type and FAM83D knockout or FAM83DGFP/GFP (F283A) 
cells would address this question. Comparing the proteomes/phosphoproteomes 
between FAM83D knockout and FAM83DGFP/GFP (F283A) cells would additionally allow 
distinction between general FAM83D-dependent events (knockout cells) and FAM83D-
dependent CK1α events (F283A cells).   
The contribution of FAM83D to disease, if any, remains poorly defined. That said, 
FAM83D has been reported to promote the progression of certain cancers, namely 
those of ovarian, gastric, breast, colorectal, lung and hepatocellular origin (Huang et al., 
2017, Liao, Liu et al., 2015, Lin, Chen et al., 2016, Perez-Pena et al., 2017, Shi et al., 2016, 
Wang, Han et al., 2015a, Yan, Yao et al., 2017, Zhang, Yu et al., 2019, Zhu, Diao et al., 
2019). Whether this is merely an association, or if FAM83D truly is a driver of 
proliferation in these cancers, needs to be further investigated. Furthermore, whether 
this putative carcinogenic role requires the association of FAM83D with CK1α needs to 
be explored. Interestingly, lenalidomide-induced degradation of CK1a was recently 
shown to be effective in the treatment of pre-leukemic human myelodysplastic 
syndrome (MDS) (Stahl & Zeidan, 2017). In contrast, other studies have demonstrated 
that CK1 inhibitors stabilise  b-Catenin and activate Wnt signalling, which promotes cell 
proliferation (MacDonald et al., 2009, Schittek & Sinnberg, 2014, Teo & Kahn, 2010). The 
findings presented here would suggest that the anti-proliferative effects of CK1a 
inhibitors might be occurring, at least in part, through the inhibition of the mitotic 
FAM83D-CK1a pool. 
Given the participation of CK1 family kinases in such diverse signalling pathways, 
and the seemingly antagonistic roles within the same signalling pathway at different 
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stages of signal transduction (Del Valle-Perez et al., 2011, Knippschild et al., 2005a, 
Schittek & Sinnberg, 2014) (see section 1.2.4), pan-cellular inhibition of CK1 isoforms is 
likely not going to be effective, from both basic research and therapeutic perspectives. 
Teasing out specific CK1 functions using inhibitors will thus be very challenging, as would 
untangling CK1 processes following their knockdown with RNA interference approaches. 
A more attractive means of facilitating functional characterisation of CK1 isoforms may 
be to disrupt their interaction with FAM83 proteins, or other regulatory binding 
partners. In the case of CK1α in mitosis, both the ablation of FAM83D and the disruption 
of the FAM83D-CK1α interaction removed CK1α from mitotic spindles, yet presumably 
did not disrupt the other, non-mitotic roles of CK1α. Furthermore, knockout of FAM83G 
resulted in disruption of canonical Wnt signalling (Bozatzi et al., 2018), but, again, 
presumably did not impact the non-Wnt functions of CK1α. Whilst this model needs to 
be tested more comprehensively, abolition of FAM83-CK1 interactions may provide a 
novel means to study the biology of specific CK1 isoforms.  
The identification of the biological niche(s) of the other FAM83-CK1 interactions 
is an important next step, in order to further test the working hypothesis that FAM83 
proteins serve to direct CK1 isoforms to distinct cellular sites. Perhaps through creating 
a screen containing many different stimuli, involving growth factors and cellular 
stresses, the affinities of the other FAM83-CK1 interactions can be assessed in order to 
probe the biological pathways they might participate in. Indeed, as CK1 kinases have 
been extensively linked to DNA damage responses, the identification of a FAM83-CK1 
pair involved in DNA damage signalling would be an interesting finding. Furthermore, 
many of the reported signalling pathways regulated by CK1 are principally important 
during development. Thus, in order to decipher any FAM83-CK1 pairs contributing to 
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these processes, such as the Hippo and Hedgehog pathways, a more physiological 
developmental model may need to be employed. 
From a therapeutic standpoint, CK1 kinases have long been deemed 
undruggable. This is largely due to the vast array of cellular processes they seem to 
control. Furthermore, due to the highly homologous kinase domains between isoforms 
(Knippschild et al., 2005a, Schittek & Sinnberg, 2014) (Figure 1-2), off-target effects 
pertaining to related CK1 members and additional protein kinases have been a strong 
cause for concern. Perhaps targeted proteolysis of FAM83 members, using PROTAC 
technology for example, would be a viable strategy to shut down specific CK1 functions 
in disease. In line with this idea, AdPROM-mediated proteolytic degradation of FAM83D 
also removed CK1α from mitotic spindles, suggesting such proteolytic approaches would 
be effective.  
In summary, the identification that FAM83 proteins act as regulatory subunits of 
CK1 isoforms adds to the evidence for the intricate control of CK1 kinases in cells. Using 
the FAM83D-CK1α interaction as an example, the model whereby FAM83 proteins act 
to recruit CK1 isoforms to distinct cellular sites so that they can elicit their functions was 
tested. Future efforts aimed at elucidating FAM83-dependent CK1 substrates is an 
important next step and, in combination with delineating the biology of the other non-
characterised FAM83-CK1 interactions, will hopefully provide deeper insights into 
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The following ImageJ macro was developed by Graeme Ball in order to measure mean CK1α staining 
intensity on mitotic spindles. 
 
// Spindle stain quantification macro 
// - measure stain in spindle region bounded by DAPI ring exterior 
// - measure stain outside DAPI ring region to estimate background 
// - for each nucleus identified, report ratio spindle/background 
// 
// for Luke Fulcher, 2018 
// 
// Copyright Graeme Ball 2018, Dundee Imaging Facility 
// License: Creative Commons CC-BY-NC-SA 
// 
// parameters 
chDAPI = 3;  // channel number for DAPI 
chCK1a = 1;  // channel for CK1alpha stain 
minSizeSpindle = 8000;  // minimum number of pixels in a spindle region 
Dialog.create("Measure_spindle_ratio"); 
Dialog.addNumber("DAPI channel", chDAPI); 
Dialog.addNumber("CK1a channel", chCK1a); 
Dialog.show(); 
chDAPI = Dialog.getNumber(); 
chCK1a = Dialog.getNumber(); 
roiManager("reset"); 
roiManager("UseNames", "true"); 
roiManager("Show All with labels"); 
run("Set Measurements...", "area mean standard min integrated display redirect=None decimal=3"); 
setOption("BlackBackground", true); 
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// find spindle regions 
Stack.setDisplayMode("grayscale"); 
Stack.setChannel(chDAPI); 
run("Duplicate...", " "); 
run("Convert to Mask", "method=Otsu background=Dark calculate black"); 
run("Fill Holes"); 
run("Analyze Particles...", "size=" + minSizeSpindle + "-Infinity exclude add"); 
close(); 
// create CK1a whole-cell mask with separated cells 
Stack.setChannel(chCK1a); 
run("Duplicate...", " "); 
setAutoThreshold("Triangle dark"); 
run("Convert to Mask"); 
run("Fill Holes"); 
run("Median...", "radius=15");  // clean up rough edges 
run("Make Binary"); 
run("Watershed"); 
// for each spindle ROI, attempt to find containing cell ROI and create cytoplasm ring ROI 
nNuclei = roiManager("count"); 
setThreshold(1, 255); 
for (i = 0; i < nNuclei; i++) { 
 roiManager("select", i); 
 roiManager("rename", "spindle" + i); 
 getSelectionBounds(x, y, w, h); 
 x = round(x + w/2); 
 y = round(y + h/2); 
 doWand(x, y); 
 roiManager("add");  // cytoplasm region centred on this spindle 
 newCellIndex = roiManager("count") - 1; 
 indices = newArray(i, newCellIndex); 
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 roiManager("select", indices); 
 roiManager("XOR"); 
 roiManager("add"); 
 newCytoIndex = roiManager("count") - 1; 
 roiManager("select", newCytoIndex); 
 roiManager("rename", "cytoplasm" + i); 
 roiManager("select", newCellIndex); 
 roiManager("delete"); 
} 
close(); // close CK1a whole-cell mask 
// make measurements using paired ROIs and write to Results table 
run("Clear Results"); 
Stack.setChannel(chCK1a); 
for (i = 0; i < nNuclei; i++) { 
 row = nResults; 
 setResult("cellID", row, i); 
 roiManager("select", i); 
 getRawStatistics(nPixels, spMean, min, max, std); 
 setResult("spindleMean", row, spMean); 
 setResult("spindleTotal", row, (spMean * nPixels)); 
 roiManager("select", i + nNuclei);  // corresponding cytoplasm ROI 
 getRawStatistics(nPixels, cyMean, min, max, std); 
 setResult("cytoMean", row, cyMean); 
 setResult("ratioS/C", row, (spMean/cyMean)); 
} 
//run("From ROI Manager"); 
 
